



(86) **Date de dépôt PCT/PCT Filing Date:** 2013/03/11
(87) **Date publication PCT/PCT Publication Date:** 2013/09/19
(85) **Entrée phase nationale/National Entry:** 2014/09/12
(86) **N° demande PCT/PCT Application No.:** US 2013/030208
(87) **N° publication PCT/PCT Publication No.:** 2013/138237
(30) **Priorité/Priority:** 2012/03/12 (US61/609,723)

(51) **Cl.Int./Int.Cl. C12Q 1/68** (2006.01),
A61K 31/704 (2006.01), **A61P 35/02** (2006.01),
C40B 30/00 (2006.01), **G01N 33/48** (2006.01)
(71) **Demandeur/Applicant:**
MEMORIAL SLOAN-KETTERING CANCER CENTER,
US
(72) **Inventeurs/Inventors:**
LEVINE, ROSS L., US;
ABDEL-WAHEB, OMAR, US;
PATEL, JAY P., US;
GONEN, MITHAT, US
(74) **Agent:** GOWLING LAFLEUR HENDERSON LLP

(54) **Titre : METHODES ET COMPOSITIONS POUR LE DIAGNOSTIC, LE PRONOSTIC ET LE TRAITEMENT DE LA LEUCEMIE
MYELOIDE AIGUE**
(54) **Title: METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF ACUTE MYELOID
LEUKEMIA**

Cytogenetic Classification	Mutations		Overall Risk
Inv(16)/t(16;16) t(8;21)	Any		Favorable
Normal Karyotype or Intermediate-Risk Cytogenetic Lesions	FLT3-ITD negative	NPM1 and IDH1/2 mutant	Intermediate
	FLT3-ITD negative	ASXL1, MLL-PTD, PHF6, and TET2 wildtype	
	FLT3-ITD negative or positive	CEBPA mutant	
	FLT3-ITD positive	MLL-PTD, TET2, and DNMT3A wildtype, and trisomy 8 negative	
	FLT3-ITD negative	TET2, MLL-PTD, ASXL1 or PHF6 mutant	Unfavorable
	FLT3-ITD positive	TET2, MLL-PTD, DNMT3A mutant or trisomy 8	
Unfavorable			

FIG. 3a

(57) **Abrégé/Abstract:**

Methods useful in the diagnosis, prognosis, treatment and management of acute myeloid leukemia are disclosed. One method entails predicting survival of a patient with acute myeloid leukemia, said method comprising: analyzing a genetic sample isolated from the patient for the presence of cytogenetic abnormalities and a mutation in at least one of FLT3, NPM1, DNMT3A, NRAS, CEBPA, TET2, WTI, IDH1, IDH2, KIT, RUNX1, MLL-PTD, ASXL1, PHF6, KRAS, PTEN, P53, HRAS, and EZH2.



(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/US2013/030208

(22) International Filing Date:
11 March 2013 (11.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/609,723 12 March 2012 (12.03.2012) US

(71) Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER [US/US]; 1275 York Avenue, New York, New York 10065 (US).

(72) Inventors: LEVINE, Ross L.; 504 East 63rd Street, Apt. 22P, New York, NY 10065 (US). ABDEL-WAHEB, Omar; 430 E. 63rd Street, Apt. 7K, New York, NY 10065 (US). PATEL, Jay P.; 220 Lakeland Avenue, Apt. J5, Sayville, NY 11782 (US). GONEN, Mithat; 1161 York Avenue, 8-J, New York, NY 10065 (US).

(74) Agent: FALATI, Shahrokh; Heslin Rothenberg Farley & Mesiti P.C., 5 Columbia Circle, Albany, New York 12203 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA

Cytogenetic Classification	Mutations		Overall Risk
inv(16)/t(16;16) t(8;21)	Any		Favorable
Normal Karyotype or Intermediate-Risk Cytogenetic Lesions	FLT3-ITD negative	NPM1 and IDH1/2 mutant	Intermediate
	FLT3-ITD negative	ASXL1, MLL-PTD, PHF6, and TET2 wildtype	
	FLT3-ITD negative or positive	CEBPA mutant	
	FLT3-ITD positive	MLL-PTD, TET2, and DNMT3A wildtype, and trisomy 8 negative	Unfavorable
	FLT3-ITD negative	TET2, MLL-PTD, ASXL1 or PHF6 mutant	
	FLT3-ITD positive	TET2, MLL-PTD, DNMT3A mutant or trisomy 8	
Unfavorable			

FIG. 3a

(57) Abstract: Methods useful in the diagnosis, prognosis, treatment and management of acute myeloid leukemia are disclosed. One method entails predicting survival of a patient with acute myeloid leukemia, said method comprising: analyzing a genetic sample isolated from the patient for the presence of cytogenetic abnormalities and a mutation in at least one of FLT3, NPM1, DNMT3A, NRAS, CEBPA, TET2, WTI, IDH1, IDH2, KIT, RUNX1, MLL-PTD, ASXL1, PHF6, KRAS, PTEN, P53, HRAS, and EZH2.

METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA

[001] CROSS REFERENCE TO RELATED APPLICATION

[002] This application claims priority to U.S. provisional patent application no. 61/609,723 filed March 12, 2012. The entire content of each prior application is hereby incorporated by reference.

[003] SEQUENCE LISTING

[004] The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on March 7, 2013, is named 3314.002AWO_SL.txt and is 75,356 bytes in size.

[005] FEDERALLY-SPONSORED RESEARCH OR DEVELOPMENT

[006] This invention was made with Government support under contract U54CA143798-01 awarded by the National Cancer Institute Physical Sciences Oncology Center. The U.S. Government has certain rights in this invention.

[007] FIELD OF INVENTION

[008] The invention described herein relates to methods useful in the diagnosis, treatment and management of cancers. The field of the present invention is molecular biology, genetics, oncology, clinical diagnostics, bioinformatics. In particular, the field of the present invention relates to the diagnosis, prognosis and treatment of blood cancer.

[009] BACKGROUND OF THE INVENTION

[0010] The following description of the background of the invention is provided simply as an aid in understanding the invention and is not admitted to describe or constitute prior art to the invention.

[0011] After cardiovascular disease, cancer is the leading cause of death in the developed world. In the United States alone, over one million people are diagnosed with cancer each year, and over 500,000 people die each year as a result of it. It is estimated that 1 in 3 Americans will develop cancer during their lifetime, and one in five will die from cancer. Further, it is predicted that cancer may surpass cardiovascular diseases as the number one cause of death within 5 years. As such, considerable efforts are directed at improving treatment and diagnosis of this disease.

[0012] Most cancer patients are not killed by their primary tumor. They succumb instead to metastases: multiple widespread tumor colonies established by malignant cells that detach themselves from the original tumor and travel through the body, often to distant sites. In the case of blood cancers, there are four types depending upon the origin of the affected cells and the course of the disease. The latter criterion classifies the types into either acute or chronic. The former criterion further divides the types as lymphoblastic or lymphocytic leukemias and myeloid or myelogenous leukemias. These malignancies have varying prognoses, depending on the patient and the specifics of the condition.

[0013] Blood primarily consists of red blood cells (RBC), white blood cells (WBC) and platelets. The red blood cells' function is to carry oxygen to the body, the white blood cells protect our body, and platelets help clot the blood after injury. Irrespective of the types of the disease, any abnormality in these cell types leads to blood cancer. The main

categories of blood cancer include Acute Lymphocytic or Lymphoblastic Leukemias (ALL), Chronic Lymphocytic or Lymphoblastic Leukemias (CLL), Acute Myelogenous or Myeloid Leukemias (AML), and Chronic Myelogenous or Myeloid Leukemias (CML).

[0014] In the case of leukemia, the bone marrow and the blood itself are attacked, such that the cancer interferes with the body's ability to make blood. In the patient, this most commonly manifests itself in the form of fatigue, anemia, weakness, and bone pain. It is diagnosed with a blood test in which specific types of blood cells are counted. Treatment for leukemia usually includes chemotherapy and radiation to kill the cancer, and measures like stem cell transplants are sometimes required. As outlined above, there are several different types of leukemia, with myeloid leukemia being usually subdivided into two groups: Acute Myeloid Leukemia (AML) and Chronic Myeloid Leukemia (CML).

[0015] AML is characterized by an increase in the number of myeloid cells in the marrow and an arrest in their maturation, frequently resulting in hematopoietic insufficiency. In the United States, the annual incidence of AML is approximately 2.4 per 100,000 and it increases progressively with age to a peak of 12.6 per 100,000 adults 65 years of age or older. Despite improved therapeutic approaches, prognosis of AML is very poor around the globe. Even in the United States, the five-year survival rate among patients who are less than 65 years of age is less than 40%. During approximately the last decade this value was 15. Similarly, the prognosis of CML is also very poor in spite of advancement of clinical medicine.

[0016] Acute myeloid leukemia (AML) is a heterogeneous disorder that includes many entities with diverse genetic abnormalities and clinical features. The pathogenesis has only been fully delineated for relatively few types of leukemia. Patients with intermediate

and poor risk cytogenetics represent the majority of AML; chemotherapy based regimens fail to cure most of these patients, and stem cell transplantation is frequently the treatment choice. Since allogeneic stem cell transplantation is not an option for many patients with high risk leukemia, there is a need to improve our understanding of the biology of these leukemias and to develop improved therapies.

[0017] Since not enough is known of the etiology, cell physiology and molecular genetics of acute myeloid leukemia, the development of effective new agents and novel treatment and/or prognostic methods against myeloid leukemia, and in particular acute myeloid leukemia, is a major focal point today in translational oncology research. However, there are inherent difficulties in the diagnosis and treatment of cancer including, among other things, the existence of many different subgroups of cancer and the concomitant variation in appropriate treatment strategies to maximize the likelihood of positive patient outcome.

[0018] One relatively new approach is to investigate the genetic profile of cancer, an effort aimed at identifying perturbations in genes that lead to the malignant phenotype. These gene profiles, including gene expression and mutations, provide valuable information about biological processes in normal and disease cells. However, cancers differ widely in their genetic “signature,” leading to difficulty in diagnosis and treatment, as well as in the development of effective therapeutics.

[0019] Increasingly, genetic signatures are being identified and exploited as tools for disease detection as well as for prognosis and prospective assessment of therapeutic success. Genetic profiling of cancers, including leukemias, may provide a more effective approach to cancer management and/or treatment. In the context of the present invention, specific genes and gene products, and groups of genes and their gene products, involved in

progression of myeloblasts into a malignant phenotype is still largely unknown. As such, there is a great need in the art to better understand the genetic profile of acute myeloid leukemia, in an effort to provide improved therapeutics, and tools for the treatment, therapy and diagnosis of acute myeloid leukemia and other cancers of the blood. There is a great need for improved methods for diagnosing acute myeloid leukemia and for determining the prognosis of patients afflicted by this disease.

[0020] SUMMARY OF THE INVENTION

[0021] One aspect of the present disclosure is a method of predicting survival of a patient with acute myeloid leukemia, said method comprising: analyzing a genetic sample isolated from the patient for the presence of cytogenetic abnormalities and a mutation in at least one of *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL-PTD*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* genes; and (i) predicting poor survival of the patient if a mutation is present in at least one of *FLT3*, *MLL-PTD*, *ASXL1* and *PHF6* genes, or (ii) predicting favorable survival of the patient if a mutation is present in *IDH2R140* and/or a mutation is present in *CEBPA*. In one embodiment, the method further comprises, predicting intermediate survival of the patient with cytogenetically-defined intermediate risk AML if : (i) no mutation is present in any of *FLT3-ITD*, *TET2*, *MLL-PTD*, *DNMT3A*, *ASXL1* or *PHF6* genes, (ii) a mutation in *CEBPA* is present in the presence of a *FLT3-ITD* mutation, or (iii) a mutation is present in *FLT3-ITD* but trisomy 8 is absent. In another embodiment, the method further comprises predicting unfavorable survival of the patient if (i) a mutation in *TET2*, *ASXL1*, or *PHF6* or an *MLL-PTD* is present in a patient without the *FLT3-ITD* mutation, or (ii) the patient has a *FLT3-ITD* mutation and a mutation in *TET2*, *DNMT3A*, *MLL-PTD* or trisomy 8.

[0022] Unless context demands otherwise, in this and any other aspect of the invention, the mutation may be any one of those described in the Table below entitled “Specific somatic mutations identified in the sequencing of 18 genes in AML patients, and the nature of these mutations”.

[0023] In one embodiment, the sample is DNA and it is extracted from bone marrow or blood from the patient. The extraction may be historical, and in all embodiments herein the sample may be utilized in the invention as a previously provided sample i.e. the extraction or isolation is not part of the method *per se*. In a related embodiment, the genetic sample is DNA isolated from mononuclear cells (MNC) from the patient. In one embodiment, poor or unfavorable survival of the patient is survival of less than or equal to about 10 months. In another embodiment, intermediate survival the patient is survival of about 18 months to about 30 months. In another embodiment, favorable survival of the patient is survival of about 32 months or more.

[0024] In one aspect, the present disclosure is a method of predicting survival of a patient with acute myeloid leukemia, said method comprising, assaying a genetic sample from the patient's blood or bone marrow for the presence of a mutation in at least one of genes *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL-PTD*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* in said sample; and predicting a poor survival of the patient if a mutation is present in at least one of genes *FLT3-ITD*, *MLL-PTD*, *ASXL1*, *PHF6*; or predicting a favorable survival of the patient if a mutation is present in *CEBPA* or a mutation is present in *IDH2* at R140. In one embodiment, the patient is characterized as intermediate-risk on the basis of cytogenetic analysis.

[0025] In one embodiment, amongst patients with cytogenetically-defined intermediate-risk acute myeloid leukemia who have *FLT3*-ITD mutation, at least one of the following: trisomy 8 or a mutation in *TET2*, *DNMT3A*, or the *MLL*-PTD are associated with an adverse outcome and poor overall survival of the patient. In another embodiment, amongst patients with cytogenetically-defined intermediate-risk acute myeloid leukemia who have a mutation in *FLT3*-ITD gene, a mutation in *CEBPA* gene is associated with improved outcome and overall survival of the patient. In one embodiment, in a cytogenetically-defined intermediate risk AML patient with both *IDH1*/*IDH2* and *NPM1* mutations, the overall survival is improved compared to *NPM1*-mutant patients wild-type for both *IDH1* and *IDH2*. In one embodiment, amongst patients acute myeloid leukemia, *IDH2*R140 mutations are associated with improved overall survival. Poor or unfavorable survival (adverse risk) of the patient, in one example, is survival of less than or equal to about 10 months. Favorable survival of the patient, in one example, is survival of about 32 months or more.

[0026] One aspect of the present disclosure is a method of predicting survival of a patient with acute myeloid leukemia, said method comprising assaying a genetic sample from the patient's blood or bone marrow for the presence of a mutation in genes *ASXL1* and *WT1*; and determining the patient has or will develop primary refractory acute myeloid leukemia if mutated *ASXL1* and *WT1* genes are detected.

[0027] Another aspect of the present disclosure is a method of determining responsiveness of a patient with acute myeloid leukemia to high dose therapy, said method comprising analyzing a genetic sample isolated from the patient for the presence of a mutation in genes *DNMT3A*, and *NPM1*, and for the presence of a *MLL* translocation; and (i) identifying the patient as one who will respond to high dose therapy if a mutation in

DNMT3A or *NPM1* or an *MLL* translocation are present, or (ii) identifying the patient as one who will not respond to high dose therapy in the absence of mutations in *DNMT3A* or *NPM1* or an *MLL* translocation.

[0028] In one embodiment, the therapy comprises the administration of anthracycline. In one example, the anthracycline is selected from the group consisting of Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, and Adriamycin. In a particular example, the anthracycline is Daunorubicin. In one embodiment, the high dose administration is Daunorubicin administered at 60mg per square meter of body-surface area (60mg/m²), or higher, daily for three days. In a particular embodiment, the high dose administration is Daunorubicin administered at about 90mg per square meter of body-surface area (90mg/m²), daily for three days. In one embodiment, the high dose daunorubicin is administered at about 70mg/m² to about 140mg/m². In a particular embodiment, the high dose daunorubicin is administered at about 70mg/m² to about 120mg/m². In a related embodiment, this high dose administration is given each day for three days, that is for example a total of about 300mg/m² over the three days (3x100mg/m²). In another example, this high dose is administered daily for 2-6 days. In other clinical situations, an intermediate daunorubicin dose is administered. In one embodiment, the intermediate dose daunorubicin is administered at about 60mg/m². In one embodiment, the intermediate dose daunorubicin is administered at about 30mg/m² to about 70mg/m². Additionally, the related anthracycline idarubicin, in one embodiment, is administered at from about 4mg/m² to about 25mg/m². In one embodiment, the high dose idarubicin is administered at about 10mg/m² to 20mg/m². In one embodiment, the intermediate dose idarubicin is administered at about 6mg/m² to about 10mg/m². In a

particular embodiment, idarubicin is administered at a dose of about 8 mg/m² daily for five days. In another example, this intermediate dose is administered daily for 2-10 days.

[0029] In one aspect, the present disclosure is a method of predicting whether a patient suffering from acute myeloid leukemia will respond better to high dose chemotherapy than to standard dose chemotherapy, the method comprising: obtaining a DNA sample obtained from the patient's blood or bone marrow; determining the mutational status of genes *DNMT3A* and *NPM1*, and the presence of a *MLL* translocation; and predicting that the subject will be more responsive to high dose chemotherapy than standard dose chemotherapy where the sample is positive for a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation, or predicting that the subject will be non-responsive to high dose chemotherapy compared to standard dose chemotherapy where the sample is wild type with no mutations in *DNMT3a* or *NPM1* genes and no translocation in *MLL*.

[0030] One aspect of the present disclosure is a method of screening a patient with acute myeloid leukemia for responsiveness to treatment with high dose of Daunorubicin or a pharmaceutically acceptable salt, solvate, or hydrate thereof, comprising: obtaining a genetic sample comprising an acute myeloid leukemic cell from said individual; and assaying the sample and detecting the presence of a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation; and correlating a finding of a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation, as compared to wild type controls where there is no mutation, with said acute myeloid leukemia patient being more sensitive to high dose treatment with Daunorubicin or a pharmaceutically acceptable salt, solvate, or hydrate thereof. In one embodiment, the method further comprises predicting the patient is at a lower risk of relapse of acute myeloid leukemia following chemotherapy if a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation is detected.

[0031] Another aspect of the present disclosure is a method of determining whether a human has an increased genetic risk for developing or developing a relapse of acute myeloid leukemia, comprising, analyzing a genetic sample isolated from the human's blood or bone marrow for the presence of a mutation in at least one gene from *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL-PTD*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2*; and determining the individual with cytogenetically-defined intermediate risk AML has an increased genetic risk for developing or developing a relapse of acute myeloid leukemia, relative to a control human with no such gene mutations in said genes, when: (i) a mutation in at least one of *TET2*, *MLL-PTD*, *ASXL1* and *PHF6* genes is detected when the patient has no *FLT3*-ITD mutation, or (ii) a mutation in at least one of *TET2*, *MLL-PTD*, and *DNMT3A* genes or trisomy 8 is detected when the patient has a *FLT3*-ITD mutation.

[0032] In one aspect, the present disclosure is a method for preparing a personalized genomics profile for a patient with acute myeloid leukemia, comprising: subjecting mononuclear cells extracted from a bone marrow aspirate or blood sample from the patient to gene mutational analysis; assaying the sample and detecting the presence of a cytogenetic abnormality and one or more mutations in a gene selected from the group consisting of *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL-PTD*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* in said cells; and generating a report of the data obtained by the gene mutation analysis, wherein the report comprises a prediction of the likelihood of survival of the patient or a response to therapy.

[0033] In one aspect, the disclosure is a kit for determining treatment of a patient with AML, the kit comprising means for detecting a mutation in at least one gene selected from the group consisting of *ASXL1*, *DNMT3A*, *NPM1*, *PHF6*, *WT1*, *TP53*, *EZH2*, *CEBPA*,

TET2, *RUNX1*, *PTEN*, *FLT3*, *HRAS*, *KRAS*, *NRAS*, *KIT*, *IDH1*, and *IDH2*; and instructions for recommended treatment based on the presence of a mutation in one or more of said genes. In one example, the instructions for recommended treatment for the patient based on the presence of a *DNMT3A* or *NPM1* mutation or *MLL* translocation indicate high-dose daunorubicin as the recommended treatment.

[0034] One aspect of the present disclosure is a method of treating, preventing or managing acute myeloid leukemia in a patient, comprising, analyzing a genetic sample isolated from the patient for the presence of a mutation in genes *DNMT3A*, and *NPM1*, and for the presence of a *MLL* translocation; identifying the patient as one who will respond to high dose chemotherapy better than standard dose chemotherapy if a mutation in *DNMT3A* or *NPM1* or a *MLL* translocation are present; and administering high dose therapy to the patient. The patient, in one example, is characterized as intermediate-risk on the basis of cytogenetic analysis. In one example, the therapy comprises the administration of anthracycline. In a related embodiment, administering high dose therapy comprises administering one or more high dose anthracycline antibiotics selected from the group consisting of Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, and Adriamycin.

[0035] One aspect of the present disclosure is directed to a method of predicting survival of a patient with acute myeloid leukemia, comprising: (a) analyzing a sample isolated from the patient for the presence of (i) a mutation in at least one of *FLT3*, *MLL-PTD*, *ASXL1*, and *PHF6* genes, plus optionally one or more of *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* genes; or (ii) a mutation in *IDH2* and/or *CEBPA* genes, plus optionally one or more of *FLT3*, *MLL-PTD*, *ASXL1*, *PHF6*, *NPM1*, *DNMT3A*, *NRAS*, *TET2*, *WT1*, *IDH1*, *KIT*,

RUNX1, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* genes; and (b) (i) predicting poor survival of the patient if a mutation is present in at least one of *FLT3*, *MLL-PTD*, *ASXL1* and *PHF6* genes, or (ii) predicting favorable survival of the patient if a mutation is present in *IDH2R140* and/or a mutation is present in *CEBPA*. The method further comprises analyzing the sample for the presence of cytogenetic abnormalities. The method further comprises predicting favorable survival of the patient if the following mutation is present: *IDH2R140Q*.

[0036] Other aspects of the present disclosure include the chemotherapeutics for use in the methods described herein, or use of those in the preparation of a medicament when used in the methods described herein.

[0037] **BRIEF DESCRIPTION OF THE DRAWINGS**

[0038] **Figure 1** shows the mutational complexity of AML. Circos diagram depicting relative frequency and pairwise co-occurrence of mutations in *de novo* AML patients enrolled in the ECOG protocol E1900 (Panel A). The arc length corresponds to the frequency mutations in the first gene and the ribbon width corresponds to the percentage of patients that also have a mutation in the second gene. Pairwise co-occurrence of mutations is denoted only once, beginning with the first gene in the clockwise direction. Since only pairwise mutations are encoded for clarity, the arc length was adjusted to maintain the relative size of the arc and the correct proportion of patients with a single mutant allele is represented by the empty space within each mutational subset. Panel A also contains the mutational frequency in the test cohort. Panels B and C show the mutational events in *DNMT3A* and *FLT3* mutant patients respectively.

[0039] **Figure 2** shows multivariate risk classification of intermediate-risk AML. Kaplan-Meier estimates of overall survival (OS) are shown for the risk stratification of intermediate-risk AML (p-values represent a comparison of all curves). For *FLT3*-ITD negative, intermediate-risk AML (Panel A) there are three genotypes: poor defined by mutant *TET2* or *ASXL1* or *PHF6* or *MLL*-PTD, good defined by mutant *IDH1* or *IDH2* and mutant *NPM1*, and intermediate defined by all other genotypes. For *FLT3*-ITD positive, intermediate-risk AML (Panel B), there is the mutant *CEBPA* genotype, poor defined by mutant *TET2* or *DNMT3A* or *MLL*-PTD or trisomy 8, and all other genotypes.

[0040] **Figure 3** shows revised AML risk stratification based on integrated genetic analysis. Figure 3A shows a revised risk stratification based on integrated cytogenetic and mutational analysis. Final overall risk groups are on the right. Figure 3B shows the impact of integrated mutational analysis on risk stratification in the test cohort of AML patients (p-values represent a comparison of all curves). The black curves show the patients in the cytogenetic risk groups that remained unchanged. The green curve shows patients that were reclassified from intermediate-risk to favorable-risk. The red curve shows patients that were reclassified from intermediate-risk to unfavorable-risk. Figure 3C confirms the reproducibility of the genetic prognostic schema in an independent cohort of 104 samples from the E1900 trial (p-values represent a comparison of all curves).

[0041] **Figure 4** shows the molecular determinants of response to high-dose Daunorubicin induction chemotherapy. Kaplan-Meier estimates of OS in the entire cohort according to *DNMT3A* mutational status (Panel A) and *DNMT3A* status in patients receiving high-dose or standard-dose daunorubicin (Panel B). OS in patients according to treatment arm is shown in patients with *DNMT3A* or *NPM1* mutations or *MLL*

translocations (Panel C) and patients lacking *DNMT3A* or *NPM1* mutations or *MLL* translocations (Panel D).

[0042] **Figure 5** shows comprehensive mutational profiling improves risk-stratification and clinical management of patients with acute myeloid leukemia (AML). Use of mutational profiling delineates subsets of cytogenetically defined intermediate-risk patients with markedly different prognoses and reallocates a substantial proportion of patients to favorable or unfavorable-risk categories (A). In addition, mutational profiling identifies genetically defined subsets of AML patients with improved outcome with high-dose anthracycline induction chemotherapy (B).

[0043] **Figure 6** shows Circos diagrams for each gene.

[0044] **Figure 7** shows Circos diagrams for all genes and some relevant cytogenetic abnormalities in patients within cytogenetically-defined favorable-risk (Panel A), intermediate-risk (Panel B), and unfavorable-risk (Panel C) subgroups. The percentage of patients in each cytogenetic risk category with > 2 mutations is displayed in Panel D. The proportion of intermediate risk patients with 2 or more somatic mutations was significantly higher than of patients in the other 2 cytogenetic subgroups

[0045] **Figure 8** is a Circos diagram, showing the mutual exclusivity of *IDH1*, *IDH2*, *TET2*, and *WT1* mutations.

[0046] **Figure 9** shows Kaplan-Meier estimates of OS according to mutational status: data are shown for OS in the entire cohort according to the mutational status of *PHF6* (Panel A) and *ASXL1* (Panel B).

[0047] **Figure 10** shows Kaplan-Meier survival estimates shown for *IDH2* (Panel A), *IDH2* R140 (Panel B), *IDH1* (Panel C) and the *IDH2* R172 allele (Panel D) in the entire cohort. Panel E shows both *IDH2* alleles while Panel F shows all three *IDH* alleles (pvalue represents comparison of all curves). These data show that the *IDH2* R140 allele is the only *IDH* allele to have prognostic relevance in the entire cohort.

[0048] **Figure 11** shows Kaplan-Meier estimates of OS in patients from the test cohort with core-binding factor alterations with mutations in *KIT* versus those wildtype for *KIT*. *KIT* mutations were not associated with a difference in OS when patients with any corebinding factor alteration (i.e. patients with t(8;21), inv(16), or t(16;16)) were studied (A). In contrast, *KIT* mutations were associated with a significant decrease in OS in patients bearing t(8;21) specifically (B). *KIT* mutations were not associated with adverse OS in patients with inv(16) or t(16;16) (C).

[0049] **Figure 12** shows Kaplan-Meier survival estimates for *TET2* in cytogenetically defined intermediate-risk patients in the cohort.

[0050] **Figure 13** shows Kaplan-Meier survival estimates for *NPM1*-mutant patients with cytogenetically-defined intermediate-risk in the cohort. Only those with concomitant *IDH* mutations have improved survival.

[0051] **Figure 14** shows the risk classification schema for *FLT3*-ITD wildtype (A) and mutant (B) intermediate-risk AML shown in Figure 3 is shown here for normal-karyotype patients only.

[0052] **Figure 15** shows that the mutational prognostic schema predicts outcome regardless of post-remission therapy with no transplantation (A), autologous

transplantation (B), and allogeneic transplantation (C) (p-value represents comparison of all curves). Note, curves represent overall risk categories integrating cytogenetic and mutational analysis (as shown in final column in Figure 3A).

[0053] Figure 16 shows Kaplan-Meier estimates of OS in the entire cohort according to *DNMT3A* mutational status (Panel A and B), *MLL* translocation status (Panel C and D) or *NPM1* mutational status in patients receiving high-dose or standard-dose daunorubicin (Panels E and F). OS in patients according to treatment arm is shown in *DNMT3A* mutant (Panel A) and wild-type (Panel B) patients. Panel C shows OS in *MLL* translocated patients receiving high-dose or standard-dose daunorubicin while Panel D shows OS in non-*MLL* translocated patients depending on daunorubicin dose. OS in patients according to treatment arm is shown in *NPM1* mutant (Panel E) and wild-type (Panel F) patients as well.

[0054] Table 1 shows baseline characteristics of the samples in the test, validation, and entire cohort from the ECOG E1900 trial.

[0055] Table 2 shows genomic DNA primer sequences utilized for comprehensive genetic analysis. All primer sequences are displayed with M13F2/M13R2 tags.

[0056] Table 3 shows P-values for the test of proportional hazards for all mutations identified in the test cohort.

[0057] Table 4 shows mutational frequency of genes sequenced in patients in the overall ECOG E1900 cohort and within each cytogenetic risk group.

[0058] Table 5 shows co-occurrences of somatic mutations and cytogenetic abnormalities in the test cohort of 398 AML patients with *de novo* AML from the ECOG E1900 trial.

[0059] Table 6 shows pairwise correlations between all genetic abnormalities.

[0060] Table 7 shows frequently co-occurring genetic abnormalities.

[0061] Table 8 shows mutually exclusive genetic abnormalities.

[0062] Table 9 shows univariate analysis of the effects of mutations in individual genes on overall survival in the ECOG E1900 cohort.

[0063] Table 10 shows univariate analysis of mutations in individual genes on intermediate-risk group in the ECOG E1900 cohort.

[0064] Table 11 shows a revised AML risk stratification based on integrated genetic analysis with frequency and number of patients in each genetic risk category displayed.

[0065] Table 12 shows that genetic prognostic schema is independent of treatment-related mortality and chemotherapy resistance in the test cohort and the entire cohort of the analyzed ECOG E1900 patients.

[0066] Table 13 shows differential response to high-dose versus standard-dose daunorubicin induction chemotherapy based on genotype of AML patients.

[0067] **DETAILED DESCRIPTION OF THE INVENTION**

[0068] To facilitate understanding of the invention, the following definitions are provided. It is to be understood that, in general, terms not otherwise defined are to be

given their meaning or meanings as generally accepted in the art. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

[0069] In practicing the present invention, many conventional techniques in molecular biology are used. These techniques are described in greater detail in, for example, Molecular Cloning: a Laboratory Manual 3rd edition, J.F. Sambrook and D.W. Russell, ed. Cold Spring Harbor Laboratory Press 2001 and DNA Microarrays: A Molecular Cloning Manual. D. Bowtell and J. Sambrook, eds. Cold Spring Harbor Laboratory Press 2002. Additionally, standard protocols, known to and used by those of skill in the art in mutational analysis of mammalian cells, including manufacturers' instruction manuals for preparation of samples and use of microarray platforms are hereby incorporated by reference.

[0070] In the description that follows, a number of terms are used extensively. The following definitions are provided to facilitate understanding of the invention. Unless otherwise specified, "a," "an," "the," and "at least one" are used interchangeably and mean one or more than one.

[0071] The terms "cancer", "cancerous", or "malignant" refer to or describe the physiological condition in mammals that is typically characterized by unregulated growth of tumor cells. Examples of a blood cancer include but are not limited to acute myeloid leukemia.

[0072] The term "diagnose" as used herein refers to the act or process of identifying or determining a disease or condition in a mammal or the cause of a disease or condition by the evaluation of the signs and symptoms of the disease or disorder. Usually, a diagnosis

of a disease or disorder is based on the evaluation of one or more factors and/or symptoms that are indicative of the disease. That is, a diagnosis can be made based on the presence, absence or amount of a factor which is indicative of presence or absence of the disease or condition. Each factor or symptom that is considered to be indicative for the diagnosis of a particular disease does not need be exclusively related to said particular disease; i.e. there may be differential diagnoses that can be inferred from a diagnostic factor or symptom. Likewise, there may be instances where a factor or symptom that is indicative of a particular disease is present in an individual that does not have the particular disease.

[0073] “Expression profile” as used herein may mean a genomic expression profile. Profiles may be generated by any convenient means for determining a level of a nucleic acid sequence e.g. quantitative hybridization of microRNA, labeled microRNA, amplified microRNA, cRNA, etc., quantitative PCR, ELISA for quantitation, and the like, and allow the analysis of differential gene expression between two samples. A subject or patient tumor sample, e.g., cells or collections thereof, e.g., tissues, is assayed. Samples are collected by any convenient method, as known in the art.

[0074] “Gene” as used herein may be a natural (e.g., genomic) gene comprising transcriptional and/or translational regulatory sequences and/or a coding region and/or non- translated sequences (e.g., introns, 5'- and 3' -untranslated sequences). The coding region of a gene may be a nucleotide sequence coding for an amino acid sequence or a functional RNA, such as tRNA, rRNA, catalytic RNA, siRNA, miRNA or antisense RNA. The term “gene” has its meaning as understood in the art. However, it will be appreciated by those of ordinary skill in the art that the term “gene” has a variety of meanings in the art, some of which include gene regulatory sequences (e.g., promoters, enhancers, etc.) and/or intron sequences, and others of which are limited to coding sequences. It will

further be appreciated that definitions of “gene” include references to nucleic acids that do not encode proteins but rather encode functional RNA molecules such as tRNAs. For the purpose of clarity we note that, as used in the present application, the term “gene” generally refers to a portion of a nucleic acid that encodes a protein; the term may optionally encompass regulatory sequences. This definition is not intended to exclude application of the term “gene” to non-protein coding expression units but rather to clarify that, in most cases, the term as used in this document refers to a protein coding nucleic acid.

[0075] “Mammal” for purposes of treatment or therapy refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, *etc.* Preferably, the mammal is human.

[0076] “Microarray” refers to an ordered arrangement of hybridizable array elements, preferably polynucleotide probes, on a substrate.

[0077] Therapeutic agents for practicing a method of the present invention include, but are not limited to, inhibitors of the expression or activity of genes identified and disclosed herein, or protein translation thereof. An “inhibitor” is any substance which retards or prevents a chemical or physiological reaction or response. Common inhibitors include but are not limited to antisense molecules, antibodies, and antagonists.

[0078] The term “poor” as used herein may be used interchangeably with “unfavorable.” The term “good” as used herein may be referred to as “favorable.” The term “poor responder” as used herein refers to an individual whose cancer grows during or shortly thereafter standard therapy, for example radiation-chemotherapy, or who experiences a clinically evident decline attributable to the cancer. The term “respond to therapy” as used

herein refers to an individual whose tumor or cancer either remains stable or becomes smaller / reduced during or shortly thereafter standard therapy, for example radiation-chemotherapy.

[0079] “Probes” may be derived from naturally occurring or recombinant single- or double-stranded nucleic acids or may be chemically synthesized. They are useful in detecting the presence of identical or similar sequences. Such probes may be labeled with reporter molecules using nick translation, Klenow fill-in reaction, PCR or other methods well known in the art. Nucleic acid probes may be used in southern, northern or *in situ* hybridizations to determine whether DNA or RNA encoding a certain protein is present in a cell type, tissue, or organ.

[0080] “Prognosis” as used herein refers to a forecast as to the probable outcome of cancer, including the prospect of recovery from the cancer. As used herein the terms prognostic information and predictive information are used interchangeably to refer to any information that may be used to foretell any aspect of the course of a disease or condition either in the absence or presence of treatment. Such information may include, but is not limited to, the average life expectancy of a patient, the likelihood that a patient will survive for a given amount of time (e.g., 6 months, 1 year, 5 years, etc.), the likelihood that a patient will be cured of a disease, the likelihood that a patient's disease will respond to a particular therapy (wherein response may be defined in any of a variety of ways). Prognostic and predictive information are included within the broad category of diagnostic information.

[0081] The term “prognosis” as used herein refers to a prediction of the probable course and outcome of a clinical condition or disease. A prognosis of a patient is usually made

by evaluating factors or symptoms of a disease that are indicative of a favorable or unfavorable course or outcome of the disease. The phrase “determining the prognosis” as used herein refers to the process by which the skilled artisan can predict the course or outcome of a condition in a patient. The term “prognosis” does not refer to the ability to predict the course or outcome of a condition with 100% accuracy. Instead, the skilled artisan will understand that the term “prognosis” refers to an increased probability that a certain course or outcome will occur; that is, that a course or outcome is more likely to occur in a patient exhibiting a given condition, when compared to those individuals not exhibiting the condition. A prognosis may be expressed as the amount of time a patient can be expected to survive. Alternatively, a prognosis may refer to the likelihood that the disease goes into remission or to the amount of time the disease can be expected to remain in remission. Prognosis can be expressed in various ways; for example prognosis can be expressed as a percent chance that a patient will survive after one year, five years, ten years or the like. Alternatively prognosis may be expressed as the number of months, on average, that a patient can expect to survive as a result of a condition or disease. The prognosis of a patient may be considered as an expression of relativism, with many factors effecting the ultimate outcome. For example, for patients with certain conditions, prognosis can be appropriately expressed as the likelihood that a condition may be treatable or curable, or the likelihood that a disease will go into remission, whereas for patients with more severe conditions prognosis may be more appropriately expressed as likelihood of survival for a specified period of time.

[0082] The terms “favorable prognosis” and “positive prognosis,” or “unfavorable prognosis” and “negative prognosis” as used herein are relative terms for the prediction of the probable course and/or likely outcome of a condition or a disease. A favorable or

positive prognosis predicts a better outcome for a condition than an unfavorable or negative or adverse prognosis. In a general sense a “favorable prognosis” is an outcome that is relatively better than many other possible prognoses that could be associated with a particular condition, whereas an “unfavorable prognosis” predicts an outcome that is relatively worse than many other possible prognoses that could be associated with a particular condition. Typical examples of a favorable or positive prognosis include a better than average cure rate, a lower propensity for metastasis, a longer than expected life expectancy, differentiation of a benign process from a cancerous process, and the like. For example, if a prognosis is that a patient has a 50% probability of being cured of a particular cancer after treatment, while the average patient with the same cancer has only a 25% probability of being cured, then that patient exhibits a positive prognosis. A positive prognosis may be diagnosis of a benign tumor if it is distinguished over a cancerous tumor.

[0083] The term “relapse” or “recurrence” as used in the context of cancer in the present application refers to the return of signs and symptoms of cancer after a period of remission or improvement.

[0084] As used herein a “response” to treatment may refer to any beneficial alteration in a subject's condition that occurs as a result of treatment. Such alteration may include stabilization of the condition (e.g., prevention of deterioration that would have taken place in the absence of the treatment), amelioration of symptoms of the condition, improvement in the prospects for cure of the condition. One may refer to a subject's response or to a tumor's response. In general these concepts are used interchangeably herein.

[0085] “Treatment” or “therapy” refer to both therapeutic treatment and prophylactic or preventative measures. The term “therapeutically effective amount” refers to an amount of a drug effective to treat a disease or disorder in a mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (*i.e.*, slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (*i.e.*, slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/ or relieve to some extent one or more of the symptoms associated with the disorder.

[0086] For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 2-5, the numbers 3 and 4 are contemplated in addition to 2 and 5, and for the range 2.0-3.0, the number 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 and 3.0 are explicitly contemplated. As used herein, the term “about” X or “approximately” X refers to +/-10% of the stated value of X.

[0087] Inherent difficulties in the diagnosis and treatment of cancer include among other things, the existence of many different subgroups of cancer and the concomitant variation in appropriate treatment strategies to maximize the likelihood of positive patient outcome. Current methods of cancer treatment are relatively non-selective. Typically, surgery is used to remove diseased tissue; radiotherapy is used to shrink solid tumors; and chemotherapy is used to kill rapidly dividing cells.

[0088] In the case of blood cancers, it is worthy to begin by noting that blood primarily consists of red blood cells (RBC), white blood cells (WBC) and platelets. Red blood cells carry oxygen to the body, the white blood cells police and protect the body, and platelets

help clot the blood when there is injury. Abnormalities in these cell types can lead to blood cancer. The main categories of blood cancer are Acute Lymphocytic or Lymphoblastic Leukemias (ALL), Chronic Lymphocytic or Lymphoblastic Leukemias (CLL), Acute Myelogenous or Myeloid Leukemias (AML), and Chronic Myelogenous or Myeloid Leukemias (CML).

[0089] Both leukemia and lymphoma are hematologic malignancies (cancers) of the blood and bone marrow. In the case of leukemia, the cancer is characterized by abnormal proliferation of leukocytes and is one of the four major types of cancer. The cancer interferes with the body's ability to make blood, and the cancer attacks the bone marrow and the blood itself, causing fatigue, anemia, weakness, and bone pain. Leukemia is diagnosed with a blood test in which specific types of blood cells are counted; it accounts for about 29,000 adults and 2,000 children diagnosed each year in the United States. Treatment for leukemia typically includes chemotherapy and radiation to kill the cancer, and may involve bone marrow transplantation in some cases.

[0090] Leukemias are classified according to the type of leukocyte most prominently involved. Acute leukemias are predominantly undifferentiated cell populations and chronic leukemias have more mature cell forms. The acute leukemias are divided into lymphoblastic (ALL) and non-lymphoblastic (ANLL) types, with ALL being predominantly a childhood disease while ANLL, also known as acute myeloid leukemia (AML), being a more common acute leukemia among adults.

[0091] AML is characterized by an increase in the number of myeloid cells in the marrow and an arrest in their maturation, frequently resulting in hematopoietic insufficiency. In the United States, the annual incidence of AML is approximately 2.4 per 100,000 and it

increases progressively with age to a peak of 12.6 per 100,000 adults 65 years of age or older. Despite improved therapeutic approaches, prognosis of AML is very poor around the globe. Even in the United States, five-year survival rate among patients who are less than 65 years of age is less than 40%.

[0092] Acute myeloid leukemia (AML) is a heterogeneous disorder that includes many entities with diverse genetic abnormalities and clinical features. The pathogenesis is known for relatively few types of leukemia. Patients with intermediate and poor risk cytogenetics represent the majority of AML; chemotherapy based regimens fail to cure most of these patients and stem cell transplantation is frequently the treatment choice. Since allogeneic stem cell transplantation is not an option for many patients with high risk leukemia, there is a need to improve our understanding of the biology of these leukemias and to develop improved therapies. Despite considerable advances, not enough is known of the etiology, cell physiology and molecular genetics of acute myeloid leukemia. As such, the development of effective new agents and novel treatment and/or prognostic methods against myeloid leukemia, and in particular acute myeloid leukemia, remains a focal point today in translational oncology research.

[0093] Significant progress has been made in understanding risk factors, including genetic factors, that may contribute to AML, but the relevance of these factors to clinical outcome remains unclear. In addition, the expression level and antibody staining pattern of several proteins have been shown to be predictive of outcome and of the likelihood of response to therapy. However, the clinical outcome of individual patients remains uncertain, and the ability to predict which patients are likely to benefit from a particular type of therapy (e.g., a certain drug or class of drug) remains elusive.

[0094] In the present disclosure, leukemic samples from patients with diagnosed AML were obtained. Bone marrow or peripheral blood samples were collected, prepared by Ficoll-Hypaque (Nygaard) gradient centrifugation. Cytogenetic analyses of the samples were performed at presentation, as previously described (Bloomfield; Leukemia 1992; 6:65-67. 21). The criteria used to describe a cytogenetic clone and karyotype followed the recommendations of the International System for Human Cytogenetic Nomenclature. DNA was extracted from diagnostic bone marrow aspirate samples or peripheral blood samples using method described previously (Zuo et al. Mod Pathol. 2009; 22, 1023-1031).

[0095] The present disclosure is based on mutational analysis of 18 genes in 398 patients with AML younger than 60 years of age randomized to receive induction therapy including high-dose or standard dose daunorubicin. Prognostic findings were further validated in an independent set of 104 patients.

[0096] The inventors of the instant application have identified ≥ 1 somatic alteration in 97.3% of patients. These Applicants discovered (1) that *FLT3*-ITD ($p=0.001$), *MLL*-PTD ($p=0.009$), *ASXL1* ($p=0.05$), and *PHF6* ($p=0.006$) mutations are associated with reduced overall survival ("OS"); and (2) that *CEBPA* ($p=0.05$) and *IDH2R140Q* ($p=0.01$) mutations were associated with improved OS.

[0097] Accordingly, in one aspect of the present disclosure is a method of predicting survival of a patient with acute myeloid leukemia, said method comprising: analyzing a genetic sample isolated from the patient for the presence of cytogenetic abnormalities and a mutation in at least one of *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL*-PTD, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* genes; and (i) predicting poor survival of the patient if a mutation is present in at least one

of *FLT3*, *MLL-PTD*, *ASXL1* and *PHF6* genes, or (ii) predicting favorable survival of the patient if a mutation is present in *IDH2R140* (e.g. *IDH2R140Q*) and/or a mutation is present in *CEBPA*. In one embodiment, the method further comprises, predicting intermediate survival of the patient with cytogenetically-defined intermediate risk AML if: (i) no mutation is present in any of *FLT3-ITD*, *TET2*, *MLL-PTD*, *DNMT3A*, *ASXL1* or *PHF6* genes, (ii) a mutation in *CEBPA* is and the *FLT3-ITD* is present, or (iii) a mutation is present in *FLT3-ITD* but trisomy 8 is absent. In another embodiment, the method further comprises predicting unfavorable survival of the patient if (i) a mutation in *TET2*, *ASXL1*, or *PHF6* or an *MLL-PTD* is present in a patient without the *FLT3-ITD* mutation, or (ii) the patient has a *FLT3-ITD* mutation and a mutation in *TET2*, *DNMT3A*, *MLL-PTD* or trisomy 8.

[0098] The genetic sample may be obtained from a bone marrow aspirate or the patient's blood. Once the sample is obtained, in one example, the mononuclear cells are isolated according to known techniques including Ficoll separation and their DNA is extracted. In a particular embodiment, poor survival or adverse risk of the patient is survival of less than or equal to about 10 months. Whereas, in one embodiment, intermediate survival the patient is survival of about 18 months to about 30 months. In another embodiment, favorable survival of the patient is survival of about 32 months or more.

[0099] In another aspect, the present disclosure teaches a method of predicting survival of a patient with acute myeloid leukemia, said method comprising, assaying a genetic sample from the patient's blood or bone marrow for the presence of a mutation in at least one of genes *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL-PTD*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* in said sample;

and predicting a poor survival of the patient if a mutation is present in at least one of genes *FLT3*-ITD, *MLL*-PTD, *ASXL1*, *PHF6*; or predicting a favorable survival of the patient if a mutation is present in *CEBPA* or a mutation is present in *IDH2* at R140. In one embodiment, the patient is characterized as intermediate-risk on the basis of cytogenetic analysis.

[00100] In one embodiment, amongst patients with cytogenetically-defined intermediate-risk acute myeloid leukemia who have *FLT3*-ITD mutation, at least one of the following: trisomy 8 or a mutation in *TET2*, *DNMT3A*, or the *MLL*-PTD are associated with an adverse outcome and poor overall survival of the patient. In another embodiment, amongst patients with cytogenetically-defined intermediate-risk acute myeloid leukemia who have a mutation in *FLT3*-ITD gene, a mutation in *CEBPA* gene is associated with improved outcome and overall survival of the patient. In one embodiment, in a cytogenetically-defined intermediate risk AML patient with both *IDH1*/*IDH2* and *NPM1* mutations, the overall survival is improved compared to *NPM1*-mutant patients wild-type for both *IDH1* and *IDH2*. In one embodiment, amongst patients with acute myeloid leukemia, *IDH2*R140 mutations are associated with improved overall survival. Poor or unfavorable survival (adverse risk) of the patient, in one example, is survival of less than or equal to about 10 months. Favorable survival of the patient, in one example, is survival of about 32 months or more.

[00101] In one embodiment, the favorable impact of *NPM1* mutations was restricted to patients with co-occurring *IDH1*/*IDH2* and *NPM1* mutations. Further, Applicants identified genetic predictors of outcome that improved risk stratification in AML independent of age, WBC count, induction dose, and post-remission therapy and validated their significance in an independent cohort. Applicants discovered that high-dose

daunorubicin improved survival in patients with *DNMT3A* or *NPM1* mutations or *MLL* translocations ($p=0.001$) relative to treatment with standard dose daunorubicin, but not in patients wild-type for these alterations ($p=0.67$).

[00102] These data provide clinical implications of genetic alterations in AML by delineating mutations that predict outcome in AML and improve AML risk stratification. Applicants have herein discovered and demonstrated the utility of mutational profiling to improve prognostic and therapeutic decisions in AML, and in particular, have shown that *DNMT3A* or *NPM1* mutations or *MLL* translocations predict for improved outcome with high-dose induction chemotherapy.

[00103] Previous studies have highlighted the clinical and biologic heterogeneity of acute myeloid leukemia (AML). However, a relatively small number of cytogenetic and molecular lesions have sufficient relevance to influence clinical practice. The prognostic relevance of cytogenetic abnormalities has led to the widespread adoption of risk stratification into three cytogenetically-defined risk groups with significant differences in OS. Although progress has been made in defining prognostic markers for AML, a significant proportion of patients lack a specific abnormality of prognostic significance. Additionally, there is significant heterogeneity in outcome for individual patients in each risk group.

[00104] Recent studies have identified a number of recurrent somatic mutations in patients with AML, however, to date, whether mutational profiling of a larger set of genes would improve prognostication in AML has not been investigated in a clinical trial cohort. Here, Applicants conceived that integrated mutational analysis of all known molecular alterations occurring in >5% of AML patients would allow for the identification of novel

molecular markers of outcome in AML and allow for the identification of molecularly defined subsets of patients who benefit from dose-intensified induction chemotherapy.

[00105] High-Throughput Mutational Profiling in AML: Comprehensive Genetic Analysis

[00106] Clinical studies have demonstrated that acute myeloid leukemia (AML) is heterogeneous with respect to presentation and to clinical outcome, and studies have shown that cytogenetics can be used to improve prognostication and to guide therapeutic decisions. More recently, genetic studies have improved our understanding of the genetic basis of AML. Applicants recognized genetic lesions represent prognostic markers which can be used to risk stratify AML patients and guide therapeutic decisions. However, although a number of gene mutations occur at significant frequency in AML, their prognostic value is not known in large phase III clinical trial cohorts.

[00107] Applicants report for the first time in a uniformly treated clinical cohort, the mutational status of all genes known to be significantly (>5%) mutated in AML as well as the effect of mutations in these genes on outcome and response to therapy. Applicants used a high throughput re-sequencing platform to perform full length resequencing of the coding regions of *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL-PTD*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* in pre-treatment genomic DNA from 398 patients with *de novo* AML enrolled in the ECOG E1900 Study.

[00108] Including both mutations and cytogenetic abnormalities, Applicants were able to identify a clonal alteration in 91.2% of all patients in the E1900 cohort; 42% had 1 somatic alteration, 36.4% had 2 alterations, 11.3% had 3 alterations and 1.5% had 4 alterations.

Mutational data from each patient was correlated with overall survival, disease-free survival, and with treatment assignment (standard dose or high dose daunorubicin). Applicants discovered somatic mutations in *FLT3* (37% total; 30% ITD, 7% TKD), *DNMT3A* (23%), *NPM1* (14%), *CEBPA* (10%), *TET2* (10%), *NRAS* (10%), *WT1* (10%), *KIT* (9%), *IDH2* (8%), *IDH1* (6%), *RUNX1* (6%), *ASXL1* (4%), *PHF6* (3%), *KRAS* (2.5%), *TP53* (2%), *PTEN* (1.5%); the only genes without mutations in Applicants' screen were *HRAS* and *EZH2*.

[00109] Applicants next used correlation analysis to assess whether mutations were positively or negatively correlated (Figure 1). In addition to identified mutational correlations (*FLT3* and *NPM1*, *KIT* and core binding factor leukemia), Applicants found that *FLT3* and *ASXL1* mutations were mutually exclusive in this large cohort ($p = 0.0008$). Further, Applicants found that *IDH1/IDH2* mutations were mutually exclusive of both *TET2* ($p = 0.02$), and *WT1* ($p = 0.01$) mutations, suggesting these mutations have overlapping roles in AML pathogenesis.

[00110] Applicants next set out to investigate if any mutations were associated with lack of response to chemotherapy; notably mutations in *ASXL1* ($p = 0.0002$) and *WT1* ($p = 0.03$) were enriched in patients with primary refractory-AML. Integration of mutational data with outcome in the ECOG E1900 trial revealed significant effects that mutations in *FLT3* ($p = 0.0005$), *ASXL1* ($p = 0.005$), and *PHF6* ($p = 0.02$) were associated with reduced overall survival. In addition, Applicants found that mutations in *CEBPA* ($p = 0.04$) and in *IDH2* ($p = 0.003$) were associated with improved overall survival; the favorable impact of *IDH1* mutations on outcome was exclusively seen in patients with *IDH2R140* mutations.

[00111] This data represents a comprehensive mutational analysis of 18 genes in a uniformly-treated *de novo* AML cohort, which allowed Applicants to delineate the mutational frequency of this gene set in *de novo* AML, the pattern of mutational cooperativity in AML and the clinical effects of gene mutations on survival and response to therapy in AML. In one embodiment, Applicants identified mutations in *ASXL1* and *WT1* as being significantly enriched in patients who failed to respond to standard induction chemotherapy in AML. This data provides important clinical implications of genetic alterations in AML and provides insight into the multistep pathogenesis of adult AML. In one embodiment, the acute myeloid leukemia is selected from newly diagnosed, relapsed or refractory acute myeloid leukemia.

[00112] Accordingly, one aspect of the present disclosure is a method of predicting survival of a patient with acute myeloid leukemia, said method comprising assaying a genetic sample from the patient's blood or bone marrow for the presence of a mutation in genes *ASXL1* and *WT1*; and determining the patient has or will develop primary refractory acute myeloid leukemia if mutated *ASXL1* and *WT1* genes are detected. The sample can be a bone marrow aspirate or the patient's blood. Further, in one embodiment, the mononuclear cells are isolated for use in the assay.

[00113] Applicants have developed a mutational classifier which can be used to predict risk of relapse in adults with acute myeloid leukemia by combining standard analysis of cytogenetics with full length sequencing of *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL-PTD*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2*. The teachings of the instant application allow for the development of an integrated mutation classifier which can more accurately predict outcome and relapse risk than currently available techniques. In one embodiment, poor survival is survival of

less than or equal to about ten months. In another embodiment, intermediate survival of the patient is survival of about 18 months to about 30 months. In a related embodiment, favorable survival of the patient is survival of about 32 months or more.

[00114] In one embodiment, in patients with *FLT3*-ITD wild-type intermediate-risk acute myeloid leukemia, *TET2*, *ASXL1*, *PHF6*, and *MLL*-PTD gene mutations were independently shown to be associated with adverse outcome and poor overall survival of the patient. In another embodiment, in patients with *FLT3*-ITD mutant intermediate-risk acute myeloid leukemia, *CEBPA* gene mutations were associated with improved outcome and overall survival of the patient. In yet another embodiment, in cytogenetically-defined intermediate risk AML patients with *FLT3*-ITD mutant intermediate-risk acute myeloid leukemia, trisomy 8 and *TET2*, *DNMT3A*, and *MLL*-PTD mutations were associated with an adverse outcome and poor overall survival of the patient. In one embodiment, cytogenetically-defined intermediate risk AML patients with both *IDH1*/*IDH2* and *NPM1* mutations have an improved overall survival compared to *NPM1*-mutant patients wild-type for both *IDH1* and *IDH2*. In a related embodiment, *IDH2* R140Q mutations are associated with improved overall survival in the overall cohort of AML patients.

[00115] One aspect of the present disclosure is directed to a method of predicting survival of a patient with acute myeloid leukemia, comprising: (a) analyzing a sample isolated from the patient for the presence of (i) a mutation in at least one of *FLT3*, *MLL*-PTD, *ASXL1*, and *PHF6* genes, plus optionally one or more of *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* genes; or (ii) a mutation in *IDH2* and/or *CEBPA* genes, plus optionally one or more of *FLT3*, *MLL*-PTD, *ASXL1*, *PHF6*, *NPM1*, *DNMT3A*, *NRAS*, *TET2*, *WT1*, *IDH1*, *KIT*, *RUNX1*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* genes; and (b) (i) predicting poor survival

of the patient if a mutation is present in at least one of *FLT3*, *MLL-PTD*, *ASXL1* and *PHF6* genes, or (ii) predicting favorable survival of the patient if a mutation is present in *IDH2R140* and/or a mutation is present in *CEBPA*. The method may further comprise analyzing the sample for the presence of cytogenetic abnormalities. The method may further comprise predicting favorable survival of the patient if the following mutation is present: IDH2R140Q.

[00116] Furthermore, Applicants have discovered that *DNMT3A* mutations, *NPM1* mutations or *MLL* fusions predict for improved outcome with high dose chemotherapy, which includes dose-intensified induction therapy. The teachings of the instant application provide for accurate risk stratification of AML patients and the ability to decide which patients need more aggressive therapy given high risk, and identification of low risk patients less in need of intensive post remission therapy. Moreover, it is possible to identify genotypically defined subsets of patients who would benefit from induction with dose-intensified anthracyclines, for example, daunorubicin. The present disclosure provides for more accurate assessment in risk classification. Presently, there is no effective way to determine which patients suffering from AML benefit from high dose daunorubicin. In one embodiment, the present disclosure provides for a novel classifier as well as a predictor of response.

[00117] Accordingly, one aspect of the present disclosure is a method of determining responsiveness of a patient with acute myeloid leukemia to high dose therapy, said method comprising analyzing a genetic sample isolated from the patient for the presence of a mutation in genes *DNMT3A*, and *NPM1*, and for the presence of a *MLL* translocation; and (i) identifying the patient as one who will respond to high dose therapy if a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation are present, or (ii) identifying the patient as

one who will not respond to high dose therapy in the absence of mutations in *DNMT3A* or *NPM1* or an *MLL* translocation. In one embodiment, the sample is DNA extracted from bone marrow or blood from the patient. The genetic sample may be DNA isolated from mononuclear cells (MNC) from blood or bone marrow of the patient. In one embodiment, the therapy comprises the administration of anthracycline. Examples of anthracyclines include Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, and Adriamycin. In a particular example, the anthracycline is Daunorubicin.

[00118] The method may be used to predict a patient's response to therapy before beginning therapy, during therapy, or after therapy is completed. For example, by predicting a patient's response to therapy before beginning therapy, the information may be used in determining the best therapy option for the patient.

[00119] One embodiment of the present invention is directed to methods to screen a patient for the prognosis for acute myeloid leukemia. The invention may provide information concerning the survival rate of a patient, the predicted life span of the patient, and/or the predicted likelihood of survival for the patient. In one embodiment, poor survival is referred generally as survival of about 10 months or less, and good prognosis or long-term survival is considered to be more than about 36 months or longer. In one embodiment, poor survival is considered as about one to 16 months, whereas good, favorable or long-term survival is considered to be range of about 30 to 42 months, more than about 46 months, or more than about 60 months. In one embodiment, good survival is considered to be about 30 months or longer.

[00120] In any aspect of the invention, unless context demands otherwise, the following combinations of genes and/or cytogenetic defects may be analyzed or assayed: FLT3 and

CEBPA; FLT3 and trisomy 8; FLT3 and TET2; FLT3 and DNMT3A; FLT3 and MLL; FLT3, MLL, ASXL1 and PHF6, optionally with TET2 or DNMT3A; IDH2 and CEBPA; IDH1, IDH2 and NPM1; IDH2, ASXL1 and WT1; DNMT3A, NPM1 and MLL. Any of these combinations may be combined with any one or more other genes shown in the Table entitled 'Genes analyzed for somatic mutations in genomic DNA of patients with AML and their clinical associations'. Optionally at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or 19 genes are analyzed or assayed, which genes are listed in said table.

[00121] The present invention is also directed to a method for determining if an individual will respond to one or more therapies for acute myeloid leukemia. The therapy may be of any kind, but in specific embodiments it comprises chemotherapy, such as one or more anthracycline antibiotic agents. In one embodiment, the chemotherapy comprises the antimetabolite cytarabine in combination with an anthracycline.

[00122] In certain embodiments of the invention the therapy is chemotherapy, immunotherapy, antibody-based therapy, radiation therapy, or supportive therapy (essentially any implemented for leukemia). In a particular embodiment, the therapy comprises the administration of a chemotherapeutic agent comprising anthracycline antibiotics. Examples of such anthracycline antibiotics include, but are not limited to, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, and Adriamycin. In some embodiments, the chemotherapy is Gleevac or idarubicin and ara-C. In a particular embodiment, daunorubicin is used.

[00123] Often, diagnostic assays are directed by a medical practitioner treating a patient, the diagnostic assays are performed by a technician who reports the results of the assay to

the medical practitioner, and the medical practitioner uses the values from the assays as criteria for diagnosing the patient. Accordingly, the component steps of the method of the present invention may be performed by more than one person.

[00124] Prognosis may be a prediction of the likelihood that a patient will survive for a particular period of time, or said prognosis is a prediction of how long a patient may live, or the prognosis is the likelihood that a patient will recover from a disease or disorder. There are many ways that prognosis can be expressed. For example prognosis can be expressed in terms of complete remission rates (CR), overall survival (OS) which is the amount of time from entry to death, disease-free survival (DFS) which is the amount of time from CR to relapse or death. In one embodiment, favorable likelihood of survival, or overall survival, of the patient includes survival of the patient for about eighteen months or more.

[00125] A prognosis is often determined by examining one or more prognostic factors or indicators. These are markers, the presence or amount of which in a patient (or a sample obtained from the patient) signal a probability that a given course or outcome will occur. The skilled artisan will understand that associating a prognostic indicator with a predisposition to an adverse outcome may involve statistical analysis. Additionally, a change in factor concentration from a baseline level may be reflective of a patient prognosis, and the degree of change in marker level may be related to the severity of adverse events. Statistical significance is often determined by comparing two or more populations, and determining a confidence interval and/or a p value. See, e.g., Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York, 1983. In one embodiment, confidence intervals of the invention are 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9% and 99.99%, while preferred p values are 0.1, 0.05, 0.025, 0.02, 0.01, 0.005,

0.001, and 0.0001. Exemplary statistical tests for associating a prognostic indicator with a predisposition to an adverse outcome are described.

[00126] One approach to the study of cancer is genetic profiling, an effort aimed at identifying perturbations in gene expression and/or mutation that lead to the malignant phenotype. These gene expression profiles and mutational status provide valuable information about biological processes in normal and disease cells. However, cancers differ widely in their genetic signature, leading to difficulty in diagnosis and treatment, as well as in the development of effective therapeutics. Increasingly, gene mutations are being identified and exploited as tools for disease detection as well as for prognosis and prospective assessment of therapeutic success.

[00127] The inventors of the instant application hypothesized that genetic profiling of acute myeloid leukemia would provide a more effective approach to cancer management and/or treatment. The inventors have herein identified that mutations of a panel of genes lead to the malignant phenotype.

[00128] The present inventors have used a molecular approach to the problem and have identified a set of gene mutations in acute myeloid leukemia correlates significantly with overall survival. Accordingly, the present invention relates to gene mutation profiles useful in assessing prognosis and/or predicting the recurrence of acute myeloid leukemia. In one aspect, the present invention relates to a set of genes, the mutation of which in bone marrow or blood cells, in particular mononuclear cells, of a patient correlates with the likelihood of poor survival. The present invention relates to the prognosis and/or therapy response outcome of a patient with acute myeloid leukemia. The present invention

provides several genes, the mutation of which, alone or in combination, has prognostic value, specifically with respect to survival.

[00129] In one example, the disclosure is a method of determining whether a human has an increased genetic risk for developing or developing a relapse of acute myeloid leukemia, comprising, analyzing a genetic sample isolated from the human's blood or bone marrow for the presence of a mutation in at least one gene from *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL-PTD*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2*; and determining the individual with cytogenetically-defined intermediate risk AML has an increased genetic risk for developing or developing a relapse of acute myeloid leukemia, relative to a control human with no such gene mutations in said genes, when: (i) a mutation in at least one of *TET2*, *MLL-PTD*, *ASXL1* and *PHF6* genes is detected when the patient has no *FLT3*-ITD mutation, or (ii) a mutation in at least one of *TET2*, *MLL-PTD*, and *DNMT3A* genes or trisomy 8 is detected when the patient has a *FLT3*-ITD mutation.

[00130] To date, no test exists that predicts outcome in acute myeloid leukemia, where one can stratify AML patients into good versus poor responders, and in particular, identify patients who would respond better to high dose chemotherapy. As a consequence, some individuals may be overtreated, in that they unnecessarily receive treatment that has minimal effect. Alternatively, some individuals may be undertreated, in that additional agents added to standard therapy may improve outcome for these patients who would be refractory to standard treatment alone. As such, it is desirable to prospectively distinguish responders from non-responders to standard therapy prior to the initiation of therapy in order to optimize therapy for individual patients.

[00131] Accordingly, one aspect of the present disclosure is a method of predicting whether a patient suffering from acute myeloid leukemia will respond better to high dose chemotherapy than to standard dose chemotherapy, the method comprising, obtaining a DNA sample obtained from the patient's blood or bone marrow; determining the mutational status of genes *DNMT3A* and *NPM1*, and the presence of a *MLL* translocation; and predicting that the subject will be more responsive to high dose chemotherapy than standard dose chemotherapy where the sample is positive for a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation, or predicting that the subject will be non-responsive to high dose chemotherapy compared to standard dose chemotherapy where the sample is wild type with no mutations in *DNMT3A* or *NPM1* genes and no translocation in *MLL*.

[00132] In one embodiment, the invention provides a clinical test that is useful to predict outcome in acute myeloid leukemia. The mutational status and/or expression of one or more specific genes is measured in the sample. Individuals are stratified into those who are likely to respond well to therapy vs. those who will not. The information from the results of the test is used to help determine the best therapy for the patient in need of therapy. Patients are stratified into those who are likely to have a poor prognosis vs. those who will have a good prognosis with standard therapy. A health care provider uses the results of the test to help determine the course of action, for example the best therapy, for the patient in need of therapy.

[00133] Because certain markers from a patient relate to the prognosis of a patient in a continuous fashion, the determination of prognosis can be performed using statistical analyses to relate the determined marker status to the prognosis of the patient. A skilled artisan is capable of designing appropriate statistical methods. For example the methods of the present invention may employ the chi-squared test, the Kaplan-Meier method, the

log-rank test, multivariate logistic regression analysis, Cox's proportional-hazard model and the like in determining the prognosis. Computers and computer software programs may be used in organizing data and performing statistical analyses.

[00134] In one embodiment, a test is provided whereby a sample, for example a bone marrow or blood sample, is profiled for a gene set and, from the mutation profile results, an estimate of the likelihood of response to standard acute myeloid leukemia therapy is determined. In another embodiment, the invention concerns a method of predicting the prognosis and/or likelihood of response to standard and/or high dose chemotherapy, following treatment, in an individual with acute myeloid leukemia, comprising determining the mutational status of one or more genes, in particular one to *DNMT3A* or *NPM1* genes, or a *MLL* translocation, in a genetic sample obtained from the patient, normalized against a control gene or genes. A total value is computed for each individual from the mutational status of the individual genes in this gene set.

[00135] The present invention relates to the diagnosis, prognosis and treatment of blood cancer, including predicting the response to therapy and stratifying patients for therapy. The present disclosure teaches the mutational frequency, prognostic significance, and therapeutic relevance of integrated mutation profiling in 398 patients from the ECOG E1900 phase III clinical trial and validates these data in an independent cohort of 104 patients from the same trial. Previous studies have suggested that mutational analysis of *CEBPA*, *NPM1*, and *FLT3-ITD* can be used to risk stratify intermediate-risk AML patients. By performing comprehensive mutational analysis on a large cohort of patients treated on a single clinical trial, Applicants demonstrate that more extensive mutational analysis can better discriminate AML patients into relevant prognostic groups (**Figure 3**). For example, *FLT3-ITD*-negative *NPM1/IDH* mutant patients represent a favorable risk

AML subset defined by a specific mutational genotype, whereas *FLT3*-ITD-negative *NPM1*-mutant patients without concurrent *IDH* mutations had a much less favorable outcome, particularly in patients with concurrent poor-risk mutations.

[00136] Furthermore, Applicants discovered that *TET2*, *ASXL1*, *MLL*-PTD, *PHF6*, and *DNMT3A* mutations can be used to define patients with adverse outcome in cytogenetically-defined intermediate-risk AML patients without the *FLT3*-ITD. Taken together, these data demonstrate that mutational analysis of a larger set of genetic alterations can be used to discriminate AML patients into more precise subsets with favorable, intermediate, or unfavorable risk with marked differences in overall outcome. This approach can be used to define an additional set of patients with mutationally defined favorable outcome with induction and consolidation therapy alone, and a set of patients with mutationally defined unfavorable risk who are candidates for allogeneic stem cell transplantation or clinical trials given their poor outcome with standard AML therapy (Figure 5A).

[00137] The two recent randomized trials examining the benefits of anthracycline dose-intensification in AML demonstrated that more intensive induction chemotherapy improves outcomes in AML. (Fernandez et al., N Engl J Med, 2009, 361, 1249-59; Lowenberg et al., N Engl J Med, 2009, 361, 1235-48). Notably, re-evaluation of the original E1900 trial using our 502 patient cohort revealed that there was an even distribution of patients within each genetic risk category in both treatment arms of the original trial ($p=0.41$, Pearson's Chi-squared test). However, the initial reports of these studies did not identify whether dose-intensified induction therapy improved outcomes in different AML subgroups.

[00138] Applicants have discovered that anthracycline dose-intensification markedly improves outcomes in patients with mutations in *DNMT3A* or *NPM1* or *MLL* translocations, suggesting mutational profiling can be used to determine which patients benefit from dose-intensive induction therapy (**Figure 5B**).

[00139] Applicants also discovered mutational combinations that commonly occur in AML patients and those that rarely, if ever, co-occur consistent with the existence of additional mutational complementation groups. For example, the observation that *TET2* and *IDH* mutations are mutually exclusive in this AML cohort led to functional studies linking *IDH* mutations and loss-of-function *TET2* mutations in a shared mechanism of hematopoietic transformation.

[00140] As is true in the case of many treatment regimens, some patients respond to treatment with chemotherapy, for example an anthracycline antibiotic, daunorubicin, and others do not. Prescribing the treatment to a patient who is unlikely to respond to it is not desirable. Thus, it would be useful to know how a patient could be expected to respond to such treatment before a drug is administered so that non-responders would not be unnecessarily treated and so that those with the best chance of benefiting from the drug are properly treated and monitored. Further, of those who respond to treatment, there may be varying degrees of response. Treatment with therapeutics other than anthracycline or treatment with therapeutics in addition to the anthracycline daunorubicin may be beneficial for those patients who would not respond to a particular chemotherapy or in whom response to the particular chemotherapy, e.g. daunorubicin, or a similar anthracycline antibiotic, alone is less than desired.

[00141] The present disclosure demonstrates the ability of integrated mutational profiling of a clinical trial cohort to advance our understanding of AML biology, improve current prognostic models, and inform therapeutic decisions. In particular, these data indicate that more detailed genetic analysis can lead to improved risk stratification and identification of patients who benefit from more intensive induction chemotherapy.

[00142] In a specific aspect, the present disclosure is a method of screening a patient with acute myeloid leukemia for responsiveness to treatment with high dose of Daunorubicin or a pharmaceutically acceptable salt, solvate, or hydrate thereof, comprising: obtaining a genetic sample comprising an acute myeloid leukemic cell from said individual; and assaying the sample and detecting the presence of a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation; and correlating a finding of a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation, as compared to wild type controls where there is no mutation, with said acute myeloid leukemia patient being more sensitive to high dose treatment with Daunorubicin or a pharmaceutically acceptable salt, solvate, or hydrate thereof. In one embodiment, the method further comprises predicting the patient is at a lower risk of relapse of acute myeloid leukemia following chemotherapy if a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation is detected. In one embodiment, the method further comprises predicting the patient is at a lower risk of relapse of acute myeloid leukemia following chemotherapy if either *DNMT3A* or *NPM1* mutations or an *MLL* translocation are detected.

[00143] Stratification of patient populations to predict therapeutic response is becoming increasingly valuable in the clinical management of cancer patients. For example, companion diagnostics are required for the stratification of patients being treated with targeted therapies such as trastuzumab (Herceptin, Genentech) in metastatic breast cancer,

and cetuximab (Erbix, Merck) in colorectal cancer. Predictive biomarkers are also being utilized for imatinib (Gleevec, Novartis) in gastrointestinal stromal tumors, and for gefitinib (Iressa, Astra-Zeneca) in lung cancer. Currently there is no method available to predict response to an anthracycline antibiotic in acute myeloid leukemia. To identify genes that are associated with greater sensitivity to an anthracycline antibiotic, and in particular to daunorubicine, Applicants assayed for the presence of mutations in certain genes as described above.

Genes analyzed for somatic mutations in genomic DNA of patients with AML and their clinical associations, as presently disclosed

GENE	CLINICAL ASSOCIATION IN AML
FLT3	Internal tandem duplications or mutations in the tyrosine kinase domain of the receptor tyrosine kinase <i>FLT3</i> are important for predicting survival in the overall cohort of AML patients as well as those with cytogenetically-defined intermediate-risk AML.
DNMT3A	Mutations in <i>DNMT3A</i> were relevant for (a) predicting for adverse overall survival in the presence of the <i>FLT3</i> -ITD in patients with cytogenetically-defined intermediate-risk AML and (b) predicting for responsiveness to high-dose induction chemotherapy with daunorubicin and cytarabine.
NPM1	Mutations in <i>NPM1</i> were relevant for (a) predicting for improved overall survival when they co-occurred with <i>IDH1/2</i> mutations in cytogenetically-defined intermediate-risk AML and (b) predicting for responsiveness to high-dose induction chemotherapy with daunorubicin and cytarabine.
NRAS	Activating mutations in <i>NRAS</i> were seen in 10% of AML patients studied here.

CEBPA	Mutations in <i>CEBPA</i> were relevant for (a) predicting for improved overall survival in the overall cohort of AML patients regardless of cytogenetic risk (b) predicting for intermediate overall risk in patients with cytogenetically-defined intermediate-risk AML and the presence of the <i>FLT3</i> ITD.
TET2	Mutations in <i>TET2</i> were relevant for predicting for worsened overall risk in patients with cytogenetically-defined intermediate-risk AML regardless of the presence of the <i>FLT3</i> ITD.
WT1	Mutations in <i>WT1</i> were present in 8% of AML patients here overall but were enriched amongst patients who were refractory to initial induction chemotherapy.
IDH2	Mutations in <i>IDH2</i> were relevant for (a) predicting for improved overall survival in the overall cohort of AML patients regardless of cytogenetic risk specifically when mutations were present at Arginine 140; (b) predicting for favorable overall risk in patients with cytogenetically-defined intermediate-risk AML and no <i>FLT3</i> ITD when accompanied by an <i>NPM1</i> mutation .
IDH1	Mutations in <i>IDH1</i> were relevant for predicting for favorable overall risk in patients with cytogenetically-defined intermediate-risk AML and no <i>FLT3</i> ITD when accompanied by an <i>NPM1</i> mutation.
KIT	Mutations in <i>KIT</i> were seen in 6% of AML patients overall but were enriched in patients with core-binding factor translocations. In the presence of a mutation in <i>KIT</i> , patients with t(8;16) had an worsened overall survival compared to t(8;16) AML patients who were <i>KIT</i> wildtype.
RUNX1	Mutations in <i>RUNX1</i> were present in 5% of AML patients here.
MLL	Partial tandem duplications in <i>MLL</i> were relevant for (a) predicting for improved overall survival in patients receiving high-dose induction chemotherapy and (b) predicting for adverse overall survival in patients with cytogenetically-defined intermediate-risk AML regardless of mutations in <i>FLT3</i> .

ASXL1	Mutations in <i>ASXL1</i> were relevant for (a) predicting for adverse overall survival in the entire cohort of AML patients (b) predicting for adverse overall survival in cytogenetically-defined intermediate-risk AML patients who did not have the <i>FLT3</i> ITD and (c) were enriched amongst patients who failed to respond to initial induction chemotherapy.
PHF6	Mutations in <i>ASXL1</i> were relevant for (a) predicting for adverse overall survival in the entire cohort of AML patients and (b) predicting for adverse overall survival in cytogenetically-defined intermediate-risk AML patients who did not have the <i>FLT3</i> ITD.
KRAS	Mutations in <i>KRAS</i> were present in 2% of AML patients studied here.
PTEN	Mutations in <i>PTEN</i> were present in 2% of AML patients studied here.
TP53	Mutations in <i>TP53</i> were present in 2% of AML patients studied here.
HRAS	Mutations in <i>HRAS</i> were found in none of the AML patients studied here.
EZH2	Mutations in <i>EZH2</i> were found in none of the AML patients studied here.

Specific somatic mutations identified in the sequencing of 18 genes in AML patients, and the nature of these mutations

GENE	NATURE AND TYPE OF SOMATIC MUTATIONS IDENTIFIED
FLT3	Numerous somatic internal tandem duplications in <i>FLT3</i> were identified. These have been shown to result in constitutive activation of <i>FLT3</i> signaling and are listed below. In addition, mutations in the tyrosine

	kinase domain of <i>FLT3</i> were also identified and also shown to result in hyperactive signaling of <i>FLT3</i>. The specific internal tandem duplication mutations identified were as followed, though any in-frame insertion of nucleotides in the juxtamembrane domain of <i>FLT3</i> is scored as an internal tandem duplication. <i>FLT3</i> p.Q580_V581ins12; <i>FLT3</i> p.D586_N587ins15; <i>FLT3</i> p.F590_Y591ins14; <i>FLT3</i> p.Y591_V592ins23; <i>FLT3</i> p.D593_F594ins12; <i>FLT3</i> p.F594_R595ins14; <i>FLT3</i> p.R595_E596ins12; <i>FLT3</i> p.Y597_E598ins17; <i>FLT3</i> p.E598_Y599ins14; <i>FLT3</i> p.Y599_D600ins14; <i>FLT3</i> p.D600_L601ins21; <i>FLT3</i> p.K602_W603ins14; <i>FLT3</i> p.E604_F605ins15; <i>FLT3</i> p.L610_E611ins11; <i>FLT3</i> p.F612_G613ins30 Tyrosine kinase domain mutations identified: <i>FLT3</i> D835Y; <i>FLT3</i> D835E; <i>FLT3</i> D835H; <i>FLT3</i> D835V
DNMT3A	Mutations in <i>DNMT3A</i> were found as (1) out-of-frame insertion/deletions predicted to result in loss-of-function of the protein, (2) somatic nonsense mutations also predicted to result in loss-of-function of the protein, and (3) somatic missense mutations. Any out-of-frame insertion/deletion or somatic nonsense mutation would be scored as a mutation in the algorithm. Insertions/Deletions: FS at amino acid (AA) 296; FS at AA 458; FS at AA 492; FS at AA 537; FS at AA 571; FS at AA 592; FS at AA 639; FS at AA 695; FS at AA 706; FS at AA 731; FS at AA 765; FS at AA 772; FS at AA 804; FS at AA 902. Nonsense mutations: <i>DNMT3A</i> W581C; <i>DNMT3A</i> W581R; <i>DNMT3A</i> Y660X; <i>DNMT3A</i> Q696X; <i>DNMT3A</i> W753X; <i>DNMT3A</i> Q816X; <i>DNMT3A</i> Q886X; <i>DNMT3A</i> S892X. Missense mutations: <i>DNMT3A</i> E30A; <i>DNMT3A</i> P76Q; <i>DNMT3A</i> S105N; <i>DNMT3A</i> L125V; <i>DNMT3A</i> W297S; <i>DNMT3A</i> G298W; <i>DNMT3A</i> V328F; <i>DNMT3A</i> G511E; <i>DNMT3A</i> C537Y; <i>DNMT3A</i> W581C; <i>DNMT3A</i> W581R; <i>DNMT3A</i> R635W; <i>DNMT3A</i> V636L; <i>DNMT3A</i> S663P; <i>DNMT3A</i> E664K; <i>DNMT3A</i> R676W; <i>DNMT3A</i> I681T; <i>DNMT3A</i> G699S; <i>DNMT3A</i> S714C; <i>DNMT3A</i> V716I; <i>DNMT3A</i> T727A; <i>DNMT3A</i> F734L; <i>DNMT3A</i> T862N; <i>DNMT3A</i> R882C; <i>DNMT3A</i> R882H; <i>DNMT3A</i> R882S;

NPM1	Insertion/deletion mutations in <i>NPM1</i> which disrupt the N-terminal nucleolar localization signal of nucleophosmin and generate a nuclear export signal in its place were identified. <i>NPM1</i> p.W288fs*12; <i>NPM1</i> p.W288fs*16; <i>NPM1</i> p.W290fs*8; <i>NPM1</i> p.W290fs*10; <i>NPM1</i> p.W290_K292>CFSK
NRAS	Activating mutations in <i>NRAS</i> were identified. <i>NRas</i> G12A; <i>NRas</i> G12D; <i>NRas</i> G12S; <i>NRas</i> G13D; <i>NRas</i> G13R; <i>NRas</i> Q61R; <i>NRas</i> Q61E; <i>NRas</i> Q61H; <i>NRas</i> Q61K; <i>NRas</i> Q61R; <i>NRas</i> Q64D
CEBPA	Mutations in <i>CEBPA</i> were identified as (1) out-of-frame insertions/deletions (2) nonsense mutations and (3) somatic missense mutations. All of these mutations have been previously identified as somatic mutations and were shown to either result in a predicted shorter protein product with altered function or to affect dimerization of CEBPA. Insertions/deletions: <i>CEBPA</i> FS at AA 13; <i>CEBPA</i> FS at AA 15; <i>CEBPA</i> FS at AA 20; <i>CEBPA</i> FS at AA 28; <i>CEBPA</i> FS at AA 35; <i>CEBPA</i> FS at AA 50; <i>CEBPA</i> FS at AA 93; <i>CEBPA</i> FS at AA 190; <i>CEBPA</i> FS at AA 195; <i>CEBPA</i> FS at AA 197; <i>CEBPA</i> FS at AA301; <i>CEBPA</i> FS at AA 303; <i>CEBPA</i> FS at AA 305; <i>CEBPA</i> FS at AA 308; <i>CEBPA</i> FS at AA 309; <i>CEBPA</i> FS at AA 311; <i>CEBPA</i> FS at AA 312; <i>CEBPA</i> FS at AA 313; <i>CEBPA</i> FS at AA 315. Nonsense mutations: <i>CEBPA</i> K275X; <i>CEBPA</i> E329X Somatic missense mutations: <i>CEBPA</i> R291C; <i>CEBPA</i> R300H; <i>CEBPA</i> L335R; <i>CEBPA</i> R339P.
TET2	Mutations in <i>TET2</i> were found as out-of-frame insertions/deletions predicted to result in loss of functional protein, nonsense mutations also predicted to result in loss of functional protein, and somatic missense mutations. Any out-of-frame insertion/deletion or somatic nonsense mutation would be scored as a mutation in our algorithm. Insertions/deletions: <i>TET2</i> FS at AA 270; <i>TET2</i> FS at AA 586; <i>TET2</i> FS at AA 912; <i>TET2</i> FS at AA 921; <i>TET2</i> FS at AA 958; <i>TET2</i> FS at AA 966; <i>TET2</i> FS at AA

	1034; <i>TET2</i> FS at AA 1114; <i>TET2</i> FS at AA 1118; <i>TET2</i> FS at AA 1299; <i>TET2</i> FS at AA 1322; <i>TET2</i> FS at AA 1395; <i>TET2</i> FS at AA 1439; <i>TET2</i> FS at AA1448; <i>TET2</i> FS at AA 1893; <i>TET2</i> FS at AA1960. Nonsense mutations: <i>TET2</i> S327X; <i>TET2</i> K433X; <i>TET2</i> R544X; <i>TET2</i> R550X; <i>TET2</i> Q622X; <i>TET2</i> Q891X; <i>TET2</i> Q916X; <i>TET2</i> W1003X; <i>TET2</i> E1405X; <i>TET2</i> S1486X; <i>TET2</i> Q1524X; <i>TET2</i> Y1902X Missense mutations: <i>TET2</i> P426L; <i>TET2</i> E452A; <i>TET2</i> F868L; <i>TET2</i> Q1021R; <i>TET2</i> Q1084P; <i>TET2</i> E1141K; <i>TET2</i> H1219Y; <i>TET2</i> N1260K; <i>TET2</i> R1261C; <i>TET2</i> G1283D; <i>TET2</i> W1292R; <i>TET2</i> R1365H; <i>TET2</i> G1369V; <i>TET2</i> R1572W; <i>TET2</i> H1817N; <i>TET2</i> E1851K; <i>TET2</i> I1873T; <i>TET2</i> R1896M; <i>TET2</i> S1898F; <i>TET2</i> P1962L
WT1	Mutations in <i>WT1</i> were identified as out-of-frame insertion/deletions as well as somatic nonsense mutations all of which are predicted to disrupt function of <i>WT1</i>. Somatic missense mutations were also identified. Insertions/Deletions: <i>WT1</i> FS at AA 95; <i>WT1</i> FS at AA 123; <i>WT1</i> FS at AA 303; <i>WT1</i> FS at AA 368; <i>WT1</i> FS at AA 369; <i>WT1</i> FS at AA 370; <i>WT1</i> FS at AA 371; <i>WT1</i> FS at AA 377; <i>WT1</i> FS at AA 380; <i>WT1</i> FS at AA 381; <i>WT1</i> FS at AA 390; <i>WT1</i> FS at AA 395; <i>WT1</i> FS at AA 409; <i>WT1</i> FS at AA 420; <i>WT1</i> FS at AA 471. Nonsense mutations: <i>WT1</i> E302X; <i>WT1</i> C350X; <i>WT1</i> S381X; <i>WT1</i> K459X Missense mutations: <i>WT1</i> G60R; <i>WT1</i> M250T; <i>WT1</i> C350R; <i>WT1</i> T337R.
IDH2	Gain-of-function point mutations in <i>IDH2</i> were found. <i>IDH2</i> R140Q, <i>IDH2</i> R172K
IDH1	Gain-of-function point mutations in <i>IDH1</i> were found. <i>IDH1</i> R132C, <i>IDH1</i> R132G, <i>IDH1</i> R132H, <i>IDH1</i> R132S.

KIT	Somatic missense mutations in <i>KIT</i> which result in hyperactivation of <i>KIT</i> signaling were identified. These are found as missense mutations at amino acid 816 or in-frame deletions in exon 8. In-frame deletions: <i>KIT</i> FS at AA 418; <i>KIT</i> FS at AA 530. Somatic missense mutations: <i>KIT</i> D816Y; <i>KIT</i> D816V.
RUNX1	Mutations in <i>RUNX1</i> were found as somatic out-of-frame insertion/deletion mutations and nonsense mutations which are all predicted to result in loss-of-function. Somatic missense mutations were also found. Any out-of-frame insertion/deletion or somatic nonsense mutation would be scored as a mutation in the algorithm. Somatic insertions/deletions: <i>RUNX1</i> FS at AA 135.; <i>RUNX1</i> FS at AA 147; <i>RUNX1</i> FS at AA 183; <i>RUNX1</i> FS at AA 185; <i>RUNX1</i> FS at AA 220; <i>RUNX1</i> FS at AA 236; <i>RUNX1</i> FS at AA 321; <i>RUNX1</i> FS at AA 340; <i>RUNX1</i> FS at AA 415. Somatic nonsense mutations: <i>RUNX1</i> Y140X; <i>RUNX1</i> R204X; <i>RUNX1</i> Q272X; <i>RUNX1</i> E316X; <i>RUNX1</i> Y414X. Somatic missense mutations: <i>RUNX1</i> E8Q; <i>RUNX1</i> G24A; <i>RUNX1</i> V31A; <i>RUNX1</i> L56S; <i>RUNX1</i> W106C; <i>RUNX1</i> F158S; <i>RUNX1</i> D160A; <i>RUNX1</i> D160E; <i>RUNX1</i> R166G; <i>RUNX1</i> S167T; <i>RUNX1</i> G168E; <i>RUNX1</i> D198N; <i>RUNX1</i> R232W.
MLL	Somatic insertions which result in partial tandem duplications in <i>MLL</i> were identified.
ASXL1	Mutations in <i>ASXL1</i> were found as somatic out-of-frame insertion/deletion mutations and nonsense mutations which are all predicted to result in loss-of-function. Somatic missense mutations were also found. Any out-of-frame insertion/deletion or somatic nonsense mutation would be scored as a mutation in the algorithm. <i>ASXL1</i> FS at AA 590; <i>ASXL1</i> FS at AA 630; <i>ASXL1</i> FS at AA 633; <i>ASXL1</i> FS at AA 634; <i>ASXL1</i> FS at AA 640; <i>ASXL1</i> FS at AA 685; <i>ASXL1</i> FS at AA 890.

	Somatic nonsense mutations: <i>ASXL1</i> C594X; <i>ASXL1</i> R693X; <i>ASXL1</i> R1068X Somatic missense mutations: <i>ASXL1</i> E348Q; <i>ASXL1</i> M1050V.
PHF6	Somatic out-of-frame insertion/deletion mutations, missense mutations, and nonsense mutations were seen in <i>PHF6</i>, all of which are predicted to result in a loss-of-function. Any out-of-frame insertion/deletion or somatic nonsense mutation would be scored as a mutation in the algorithm. Insertion/deletions: <i>PHF6</i> FS at AA 176. Nonsense mutations: <i>PHF6</i> R274X; <i>PHF6</i> G291X; <i>PHF6</i> Y301X. Somatic missense mutations: <i>PHF6</i> I115K; <i>PHF6</i> I314T; <i>PHF6</i> H329L; <i>PHF6</i> L362P.
KRAS	Activating mutations in <i>KRAS</i> were seen. <i>KRas</i> G12D; <i>KRas</i> G12S; <i>KRas</i> G12V; <i>KRas</i> G13D; <i>KRas</i> I36M; <i>KRas</i> Q61H.
PTEN	Somatic missense mutations in <i>PTEN</i> were identified which result in loss-of-function of <i>PTEN</i>. Any out-of-frame insertion/deletion or somatic nonsense mutation would be scored as a mutation in the algorithm. <i>PTEN</i> H75L; <i>PTEN</i> N82Y; <i>PTEN</i> R142W; <i>PTEN</i> R308H; <i>PTEN</i> P339S; <i>PTEN</i> S380C; <i>PTEN</i> D386G
TP53	Mutations in <i>TP53</i> were found as somatic out-of-frame insertion/deletions, nonsense mutations, and missense mutations all of which are predicted to result in loss of TP53 function. Any out-of-frame insertion/deletion or somatic nonsense mutation would be scored as a mutation in our algorithm. Insertion/Deletions: <i>TP53</i> FS at AA 30; <i>TP53</i> FS at AA 31; <i>TP53</i> FS at AA 45; <i>TP53</i> FS at AA 93; <i>TP53</i> FS at AA 337.

	Nonsense mutations: <i>TP53</i> R213X Misense mutations: <i>TP53</i> S20L; <i>TP53</i> F54L; <i>TP53</i> H193R; <i>TP53</i> R196Q; <i>TP53</i> C242Y; <i>TP53</i> R267Q; <i>TP53</i> R273H; <i>TP53</i> T284P; <i>TP53</i> G356R.
--	---

[00144] Based on the present studies, a revised risk stratification for AML patients was devised. First, patients with internal tandem duplications in *FLT3*, partial tandem duplications in *MLL*, or mutations in *ASXL1* or *PHF6* are considered to have adverse overall survival regardless of cytogenetic characteristics. In contrast, patients with mutations in *IDH2* at R140 or mutations in *CEBPA* are predicted to have favorable overall risk. For patients who do not have any of the above molecular alterations, cytogenetic status is then considered in order to determine overall risk. Cytogenetic status is defined in this prediction algorithm based on the study by Slovak, M et al. Blood 2000;96:4075-83. In this cytogenetic classification, patients with cytogenetic alterations denoted as predicting for favorable cytogenetic risk (*t*(8;21), *inv*(16), or *t*(16;16)) or adverse cytogenetic risk (*del*(5q)/25, 27/*del*(7q), *abn* 3q, 9q, 11q, 20q, 21q, 17p, *t*(6;9), *t*(9;22) and complex karyotypes (≥ 3 unrelated *abn*)) are predicted to have an overall favorable risk or an overall adverse risk respectively. Patients which do not have any of the aforementioned favorable or adverse cytogenetic alterations, are then considered to have cytogenetically defined intermediate-risk AML. Such patients with cytogenetically defined intermediate-risk AML are further subdivided based on the presence or absence of the *FLT3ITD* mutation to determine overall risk. Patients with cytogenetically-defined intermediate risk AML and no *FLT3ITD* mutation are expected to have (1) a favorable overall risk if they

have mutations in both *NPM1* and *IDH1/2*, (2) an unfavorable overall risk if they have mutations in any one of *TET2*, *ASXL1*, *PHF6*, or have the *MLL*-PTD mutation, (3) an intermediate overall risk if they have no mutations in *TET2*, *ASXL1*, *PHF6*, and no *MLL*-PTD mutation and no *NPM1* mutation in the presence of an *IDH1* or *IDH2* mutation. In contrast, patients with cytogenetically-defined intermediate risk AML and the presence of the *FLT3ITD* mutation are expected to have (1) an intermediate overall risk if they have a *CEBPA* mutation as well, (2) an unfavorable overall risk if they have a mutation in *TET2* or *DNMT3A*, or have the *MLL*-PTD mutation or trisomy 8, (3) an intermediate overall risk if they have no mutations in *TET2*, *DNMT3A*, and no *MLL*-PTD mutation and no trisomy 8. In addition to the above algorithm which serves to predict overall risk at the time of diagnosis of AML patients, the present study also identified molecular predictors for response to high-dose induction chemotherapy for AML. In this part of the study, patients with mutations in any one of *DNMT3A* or *NPM1* or an *MLL*-translocation/rearrangement were found to have an improved overall survival after induction chemotherapy compared with patients with no mutations in *DNMT3A* or *NPM1* and no *MLL*-translocation/rearrangement.

[00145] In one embodiment, expression of nucleic acid markers is used to select clinical treatment paradigms for acute myeloid leukemia. Treatment options, as described herein, may include but are not limited to chemotherapy, radiotherapy, adjuvant therapy, or any combination of the aforementioned methods. Aspects of treatment that may vary include, but are not limited to: dosages, timing of administration, or duration of therapy; and may or may not be combined with other treatments, which may also vary in dosage, timing, or duration.

[00146] One of ordinary skill in the medical arts may determine an appropriate treatment paradigm based on evaluation of differential mutational profile of one or more nucleic acid targets identified. In one embodiment, cancers that express markers that are indicative of acute myeloid leukemia and poor prognosis may be treated with more aggressive therapies, as taught above. In another embodiment, where the gene mutations that are indicative of being a poor responder to one or more therapies may be treated with one or more alternative therapies.

[00147] In one embodiment, the sample is obtained from blood by phlebotomy or by any suitable means in the art, for example, by fine needle aspirated cells, e.g. cells from the bone marrow. The sample may comprise one or more mononuclear cells. A sample size required for analysis may range from 1, 100, 500, 1000, 5000, 10,000, to 50,000, 10,000,000 or more cells. The appropriate sample size may be determined based on the cellular composition and condition of the sample and the standard preparative steps for this determination and subsequent isolation of the nucleic acid and/or protein for use in the invention are well known to one of ordinary skill in the art.

[00148] Without limiting the scope of the present invention, any number of techniques known in the art can be employed for profiling of acute myeloid leukemia. In one embodiment, the determining step(s) comprises use of a detection assay including, but not limited to, sequencing assays, polymerase chain reaction assays, hybridization assays, hybridization assay employing a probe complementary to a mutation, fluorescent in situ hybridization (FISH), nucleic acid array assays, bead array assays, primer extension assays, enzyme mismatch cleavage assays, branched hybridization assays, NASBA assays, molecular beacon assays, cycling probe assays, ligase chain reaction assays, invasive cleavage structure assays, ARMS assays, and sandwich hybridization assays. In some

embodiments, the detecting step is carried out using cell lysates. In some embodiments, the methods may comprise detecting a second nucleic acid target. In one embodiment, the second nucleic acid target is RNA. In one embodiment, the determining step comprises polymerase chain reaction, microarray analysis, immunoassay, or a combination thereof.

[00149] In one embodiment of the presently claimed method, mutations in one or more of the *FLT3*-ITD, *DNMT3A*, *NPM1*, *IDH1*, *TET2*, *KIT*, *MLL*-PTD, *ASXL1*, *WT1*, *PHF6*, *CEBPA*, *IDH2* genes provides information about survival and/or response to therapy, wherein mutations in one or more of said genes is associated with a change in overall survival. One embodiment of the present invention further comprises detecting the mutational status of one or more genes selected from the group consisting of *TET2*, *ASXL1*, *DNMT3A*, *PHF6*, *WT1*, *TP53*, *EZH2*, *RUNX1*, *PTEN*, *FLT3*, *CEBPA*, *MLL*, *HRAS*, *KRAS*, *NRAS*, *KIT*, *IDH1*, and *IDH2*.

[00150] Identification of predictors that precisely distinguish individuals who will and will not experience a durable response to standard acute myeloid leukemia therapy is needed. The inventors of the present application identified a need for a consensus gene profile that is reproducibly associated with patient outcome for acute myeloid leukemia. In particular, the inventors of the present application have discovered certain mutations of genes in patients with acute myeloid leukemia correlate with poor survival and patient outcome. In one embodiment, the method is screening an individual for acute myeloid leukemia prognosis. In another embodiment, the method is screening an individual for response to acute myeloid leukemia therapy.

[00151] In one embodiment, the coding regions of one or more of the genes from the group consisting of *TET2*, *ASXL1*, *DNMT3A*, *PHF6*, *WT1*, *TP53*, *EZH2*, *NPM1*, *CEBPA*,

RUNX1, and *PTEN*, and coding exons of one or more of the genes from the group consisting of *FLT3*, *HRAS*, *KRAS*, *NRAS*, *KIT*, *IDH1*, and *IDH2* were assayed to detect the presence of mutations. In a particular embodiment, the mutational status of one or more of the *FLT3-ITD*, *MLL-PTD*, *ASXL1*, *PHF6*, *DNMT3A*, *IDH2*, and *NPM1* genes provides information about survival and/or response to therapy. The acute myeloid leukemia can be newly diagnosed, relapsed or refractory acute myeloid leukemia.

[00152] One embodiment of the present invention is directed to a kit for determining treatment of a patient with AML, the kit comprising means for detecting a mutation in at least one gene selected from the group consisting of *ASXL1*, *DNMT3A*, *NPM 1*, *PHF6*, *WT1*, *TP53*, *EZH2*, *CEBPA*, *TET2*, *RUNX1*, *PTEN*, *FLT3*, *HRAS*, *KRAS*, *NRAS*, *KIT*, *IDH1*, and *IDH2*; and instructions for recommended treatment based on the presence of a mutation in one or more of said genes. In one example, the instructions for recommended treatment for the patient based on the presence of a *DNMT3A* or *NPM1* mutation or *MLL* translocation indicate high-dose daunorubicin as the recommended treatment.

[00153] Kits of the invention may comprise any suitable reagents to practice at least part of a method of the invention, and the kit and reagents are housed in one or more suitable containers. For example, the kit may comprise an apparatus for obtaining a sample from an individual, such as a needle, syringe, and/or scalpel. The kit may include other reagents, for example, reagents suitable for polymerase chain reaction, such as nucleotides, thermophilic polymerase, buffer, and/or salt. The kit may comprise a substrate comprising polynucleotides, such as a microarray, wherein the microarray comprises one or more of the genes *ASXL1*, *DNMT3A*, *PHF6*, *NPM1*, *CEBPA*, *TET2*, *WT1*, *TP53*, *EZH2*, *RUNX1*, *PTEN*, *FLT3*, *HRAS*, *KRAS*, *NRAS*, *KIT*, *IDH1*, and *IDH2*.

[00154] In another embodiment, an array comprises polynucleotides hybridizing to at least 2, or at least 3, or at least 5, or at least 8, or at least 11, or at least 18 of the genes: *TET2*, *ASXL1*, *DNMT3A*, *PHF6*, *WT1*, *TP53*, *EZH2*, *RUNX1*, *PTEN*, *FLT3*, *HRAS*, *KRAS*, *NRAS*, *NPM1*, *CEPA*, *KIT*, *IDH1*, and *IDH2*. In one embodiment, the arrays comprise polynucleotides hybridizing to all of the listed genes.

[00155] As noted, the drugs of the instant invention can be therapeutics directed to gene therapy or antisense therapy. Oligonucleotides with sequences complementary to an mRNA sequence can be introduced into cells to block the translation of the mRNA, thus blocking the function of the gene encoding the mRNA. The use of oligonucleotides to block gene expression is described, for example, in, Strachan and Read, Human Molecular Genetics, 1996. These antisense molecules may be DNA, stable derivatives of DNA such as phosphorothioates or methylphosphonates, RNA, stable derivatives of RNA such as 2'-O-alkylRNA, or other antisense oligonucleotide mimetics. Antisense molecules may be introduced into cells by microinjection, liposome encapsulation or by expression from vectors harboring the antisense sequence.

[00156] One aspect of the present disclosure is a method of treating, preventing or managing acute myeloid leukemia in a patient, comprising, analyzing a genetic sample isolated from the patient for the presence of a mutation in genes *DNMT3A*, and *NPM1*, and for the presence of a *MLL* translocation; identifying the patient as one who will respond to high dose chemotherapy better than standard dose chemotherapy if a mutation in *DNMT3A* or *NPM1* or a *MLL* translocation are present; and administering high dose therapy to the patient. The patient, in one example, is characterized as intermediate-risk on the basis of cytogenetic analysis. In one example, the therapy comprises the administration of anthracycline. In a related embodiment, administering high dose therapy

comprises administering one or more high dose anthracycline antibiotics selected from the group consisting of Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, and Adriamycin. In one embodiment, Daunorubicin, Idarubicin and/or Mitoxantrone is used.

[00157] In one embodiment, the high dose administration is Daunorubicin administered at 60mg per square meter of body-surface area (60mg/m²), or higher, daily for three days.

In a particular embodiment, the high dose administration is Daunorubicin administered at about 90mg per square meter of body-surface area (90mg/m²), daily for three days. In one embodiment, the high dose daunorubicin is administered at about 70mg/m² to about 140mg/m². In a particular embodiment, the high dose daunorubicin is administered at about 70mg/m² to about 120mg/m². In a related embodiment, this high dose administration is given each day for three days, that is for example a total of about 300mg/m² over the three days (3x100mg/m²). In another example, this high dose is administered daily for 2-6 days. In other clinical situations, an intermediate daunorubicin dose is administered. In one embodiment, the intermediate dose daunorubicin is administered at about 60mg/m². In one embodiment, the intermediate dose daunorubicin is administered at about 30mg/m² to about 70mg/m². Additionally, the related anthracycline idarubicin, in one embodiment, is administered at from about 4mg/m² to about 25mg/m². In one embodiment, the high dose idarubicin is administered at about 10mg/m² to 20mg/m². In one embodiment, the intermediate dose idarubicin is administered at about 6mg/m² to about 10mg/m². In a particular embodiment, idarubicin is administered at a dose of about 8 mg/m² daily for five days. In another example, this intermediate dose is administered daily for 2-10 days.

[00158] In another aspect, the present disclosure is a method for preparing a personalized genomics profile for a patient with acute myeloid leukemia, comprising: subjecting

mononuclear cells extracted from a bone marrow aspirate or blood sample from the patient to gene mutational analysis; assaying the sample and detecting the presence of trisomy 8 and one or more mutations in a gene selected from the group consisting of *FLT3ITD*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL-PTD*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* in said cells; and generating a report of the data obtained by the gene mutation analysis, wherein the report comprises a prediction of the likelihood of survival of the patient or a response to therapy.

[00159] Methods of monitoring gene expression by monitoring RNA or protein levels are known in the art. RNA levels can be measured by any methods known to those of skill in the art such as, for example, differential screening, subtractive hybridization, differential display, and microarrays. A variety of protocols for detecting and measuring the expression of proteins, using either polyclonal or monoclonal antibodies specific for the proteins, are known in the art. Examples include Western blotting, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS).

[00160] **EXAMPLES**

[00161] The invention, having been generally described, may be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention in any way.

[00162] Each of the applications and patents cited in this text, as well as each document or reference cited in each of the applications and patents (“application cited documents”), and each of the PCT and foreign applications or patents corresponding to and/or

paragraphing priority from any of these applications and patents, and each of the documents cited or referenced in each of the application cited documents, are hereby expressly incorporated herein by reference. More generally, documents or references are cited in this text, either in a Reference List or in the text itself; and, each of these documents or references ("herein-cited references"), as well as each document or reference cited in each of the herein-cited references (including any manufacturer's specifications, instructions, *etc.*), is hereby expressly incorporated herein by reference.

[00163] Patients

[00164] Mutational analysis was performed on diagnostic patient samples from the ECOG E1900 trial in the test (n=398) and validation (n=104) cohorts. The test cohort comprised of all E1900 patients for whom viably frozen cells were available for DNA extraction and mutational profiling. The validation cohort comprised of a second set of patients for whom samples were banked in Trizol, which was used to extract DNA for mutational studies.

[00165] Clinical characteristics of the patients studied compared to the complete E1900 trial cohort are in **Table 1**. The median follow-up time of patients included for analysis was 47.4 months from induction randomization. Cytogenetic analysis, fluorescent *in situ* hybridization, and RT-PCR for recurrent cytogenetic lesions was performed as described initially by Slovak *et al.* and utilized previously with central review by the ECOG Cytogenetics Committee (see ref. 16 and 17).

[00166] Mutational Analysis

[00167] Source of the DNA was bone marrow for 55.2% (277/502) and peripheral blood for 44.8% (225/502) of the samples. Applicants sequenced the entire coding regions of

TET2, ASXL1, DNMT3A, CEBPA, PHF6, WT1, TP53, EZH2, RUNX1, and PTEN and the regions of previously described mutations for *FLT3, NPM1, HRAS, KRAS, NRAS, KIT, IDH1, and IDH2*.

[00168] The genomic coordinates and sequences of all primers utilized in the instant disclosure are provided for in **Table 2**. Paired remission DNA was available from 241 of the 398 samples in the initially analyzed cohort and 65 of the 104 in the validation cohort. Variants that could not be validated as bona fide somatic mutations due to unavailable remission DNA and their absence from the published literature of somatic mutations were censored with respect to mutational status for that specific gene. Further details of the sequencing methodology are provided *infra*.

[00169] Statistical Analysis

[00170] Mutual exclusivity of pairs of mutations was evaluated by fourfold contingency tables and Fisher's exact test. The association between mutations and cytogenetic risk classification was tested using the chi-square test. Hierarchical clustering was performed using the Lance-Williams dissimilarity formula and complete linkage.

[00171] Survival time was measured from date of randomization to date of death for those who died and date of last follow-up for those who were alive at the time of analysis. Survival probabilities were estimated using the Kaplan-Meier method and compared across mutant and wild-type patients using the log-rank test. Multivariate analyses were conducted using the Cox model with forward selection. Proportional hazards assumption was checked by testing for a non-zero slope in a regression of the scaled Schoenfeld residuals on functions of time (**Table 3**).

[00172] When necessary, such as the analyses performed in various subsets, results of the univariate analyses were used to select the variables to be included in the forward variable search. Final multivariate models informed the development of novel risk classification rules. When indicated, p-values were adjusted to control the family wise error rate (FWER) using the complete null distribution approximated by resampling obtained through PROC MULTTEST in SAS or the multtest library in R¹⁹. These adjustments were performed to adjust for the probability of making one or more false discoveries given that multiple pairwise tests were being performed. The only exception is adjustment for tests regarding effect of mutations on response to induction dose where a step-down Holm procedure was used to correct for multiple testing. All analyses were performed using SAS 9.2 (www.sas.com) and R 2.12 (www.r-project.org).

[00173] Supplementary Methods

[00174] Diagnostic Samples from ECOG 1900 Clinical Trial: DNA was isolated from pretreatment bone marrow samples of 398 patients enrolled in the ECOG E1900 trial; DNA was isolated from mononuclear cells after Ficoll purification. IRB approval was obtained at Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center. All genomic DNA samples were whole genome amplified using Ø29 polymerase. Remission DNA was available from 241 patients who achieved complete remission after induction chemotherapy. Cytogenetic, fluorescent *in situ* hybridization, and RT-PCR for recurrent cytogenetic lesions was performed as described previously (Bullinger et al., N Engl J Med 2004, 350, 1605-1616) with central review by the ECOG Cytogenetics Committee.

[00175] **Integrated Mutational Analysis:** Mutational analysis of the entire coding regions of *TET2*, *ASXL1*, *DNMT3A*, *PHF6*, *WT1*, *TP53*, *NPM1*, *CEBPA*, *EZH2*, *RUNX1*, and

PTEN and of coding exons of *FLT3*, *HRAS*, *KRAS*, *NRAS*, *KIT*, *IDH1*, and *IDH2* with known somatic mutations was performed using PCR amplification and bidirectional Sanger sequencing as previously described. 13 Primer sequences and PCR conditions are provided in **Table 1**.

[00176] Target regions in individual patient samples were PCR amplified using standard techniques and sequenced using conventional Sanger sequencing, yielding 93.3% of all trimmed reads with an average quality score of 20 or more. All traces were reviewed manually using Mutation Surveyor (SoftGenetics, State College, PA). All variants were validated by repeat PCR amplification and Sanger resequencing of unamplified diagnostic DNA. All mutations which were not previously reported to be either somatic or germline were analyzed in matched remission DNA, when available, to determine somatic status. All patients with variants whose somatic status could not be determined were censored with regard to mutational status for the specific gene.

[00177] ***NPM1/CEBPA* Next-Generation Sequencing Analysis:** A mononucleotide tract near the canonical frameshift mutations in *NPM1* and the high GC content of the *CEBPA* gene limited Applicants' ability to obtain sufficiently high quality Sanger sequence traces for primary mutation calling. Applicants therefore performed pooled amplicon resequencing of *NPM1* and *CEBPA* using the SOLiD 4 system. We performed PCR amplification followed by barcoding (20 pools each with 20 samples) and SOLiD sequencing. The data was processed through the Bioscope pipeline: all variants not present in reference sequence were manually inspected and validated by repeat PCR amplification and Sanger sequencing.

[00178] Mutational Cooperativity Matrix: Applicants adapted the Circos graphical algorithm to visualize co-occurring mutations in AML patients. The arc length corresponds to the proportion of patient with mutations in the first gene and the ribbon corresponds to the percentage of patients with a coincident mutation in the second gene. Pairwise cooccurrence of mutations is denoted only once, beginning with the first gene in the clockwise direction. Since only pairwise mutations are encoded for clarity, the arc length was adjusted to maintain the relative size of the arc and the correct proportion of patients with a single mutant allele is represented by the empty space within each mutational subset.

[00179] Statistical Analysis: Mutual exclusivity of pairs of mutations were evaluated by fourfold contingency tables and Fisher's exact test. The association between mutations and cytogenetic risk classification was tested using the chi-square test. Hierarchical clustering was performed using the Lance-Williams dissimilarity formula and complete linkage. Survival time was measured from date of randomization to date of death for those who died and date of last follow-up for those who were alive at the time of analysis. Survival probabilities were estimated using the Kaplan-Meier method and compared across mutant and wildtype patients using the log-rank test. Multivariate analyses were conducted using the Cox model. Proportional hazards assumption was checked by testing for a non-zero slope in a regression of the scaled Schoenfeld residuals on functions of time. Many of the statistical analyses conducted in this study use Cox regression which depends on the assumption of proportional hazards.

[00180] Table 3 shows the results of the checks which were conducted for each mutation to determine whether the resultant survival curves (one curve for mutant and one curve for wildtype for each mutation) satisfy this assumption. A significant p-value indicates a departure from the proposal hazard assumption. Out of the 27 mutations included in this

study, only a single one significantly deviated from proportional hazards (*MLL-PTD*, $p=0.04$). Considering the possible multiple testing problem, one would have expected 1-2 significances in this table by chance only hence Applicants conclude that it is acceptable to use the Cox regression model for all mutations. Forward model selection was employed. When necessary, such as the analyses performed in various subsets, results of the univariate analyses were used to select the variables to be included in the forward variable search. Final multivariate models informed the development of novel risk classification rules. All analyses were performed using SAS 9.2 (www.sas.com) and R 2.12 (www.r-project.org).

[00181] Frequency of genetic alterations in de novo AML. Somatic alterations were identified in 97.3% of patients. **Figures 1A-C** show the frequency of somatic mutations in the entire cohort and the interrelationships between the various mutations visually represented using a Circos plot. Data for all molecular subsets are provided in **Figures 6 and 7 and Tables 4 and 5**. In particular, mutational heterogeneity in patients with intermediate risk AML was higher than in patients with favorable or unfavorable risk AML ($p=0.01$; **Figure 7D**).

[00182] Mutational complementation groups in AML. Integrated mutational analysis allowed Applicants to identify frequently co-occurring mutations and mutations that were mutually exclusive in the E1900 patient cohort (**Table 6**). In addition to noting a frequent co-occurrence between *KIT* mutations and core-binding factor alterations $t(8;21)$ and $inv(16)/t(16;16)$ ($p<0.001$), Applicants found significant co-occurrence of *IDH1* or *IDH2* mutations with *NPM1* mutations ($p<0.001$), and *DNMT3A* mutations with *NPM1*, *FLT3*, and *IDH1* alleles ($p<0.001$ for all) (**Table 7**). Applicants previously reported *IDH1* and *IDH2* mutations were mutually exclusive with *TET2* mutations; detailed mutational analysis revealed that *IDH1/2* mutations were also exclusive with *WT1* mutations

($p < 0.001$; **Figure 8 and Table 8**). Applicants also observed that *DNMT3A* mutations and *MLL*-translocations were mutually exclusive ($p < 0.01$).

[00183] Molecular determinants of overall survival in AML. Univariate analysis revealed that *FLT3* internal tandem duplication (*FLT3*-ITD) ($p = 0.001$) and *MLL* partial tandem duplication (*MLL*-PTD) ($p = 0.009$) mutations were associated with adverse OS (**Table 9**), while *CEBPA* ($p = 0.05$) mutations and patients with core-binding factor alterations $t(8;21)$ and $inv(16)/t(16;16)$ ($p < 0.001$) were associated with improved OS.^{2,23} In addition, *PHF6* ($p = 0.006$) and *ASXL1* ($p = 0.05$) mutations were associated with reduced OS (**Figure 9**). *IDH2* mutations were associated with improved OS in the entire cohort (**Figure 10**) ($p = 0.01$; 3 year OS=66%). The favorable impact of *IDH2* mutations was exclusive to patients with *IDH2* R140Q mutations ($p = 0.009$; **Figure 10**). All findings in univariate analysis were also statistically significant in multivariate analysis (adjusted $p < 0.05$) (taking into account age, white blood cell count, transplantation and cytogenetics) (**Table 9**) with the exception of *MLL*-PTD, *PHF6* and *ASXL1* mutations. *KIT* mutations were associated with reduced OS in $t(8;21)$ -positive AML ($p = 0.006$) but not in patients with $inv(16)/t(16;16)$ ($p = 0.19$) (**Figure 11**).

[00184] Prognostic Value of Molecular Alterations in Intermediate-risk AML. Amongst patients with cytogenetically-defined intermediate-risk AML (**Table 10**), *FLT3*-ITD mutations were associated with reduced OS ($p = 0.008$). Similar to their effect on the entire cohort, *ASXL1* and *PHF6* mutations were associated with reduced survival and *IDH2* R140Q mutations were associated with improved survival (**Table 10**). In addition, Applicants found that *TET2* mutations were associated with reduced OS in patients with intermediate-risk AML ($p = 0.007$; **Figure 12**).

[00185] Multivariate statistical analysis revealed that *FLT3*-ITD mutations represented the primary predictor of outcome in patients with intermediate-risk AML (adjusted $p < 0.001$). Applicants then performed multivariate analysis to identify mutations that affected outcome in patients with *FLT3*-ITD wild-type and mutant intermediate-risk AML, respectively. In patients with *FLT3*-ITD wild-type intermediate-risk AML, *TET2*, *ASXL1*, *PHF6*, and *MLL*-PTD mutations were independently associated with adverse outcome. Importantly, patients with both *IDH1/IDH2* and *NPM1* mutations (3 year OS=89%) but not *NPM1*-mutant patients wild-type for both *IDH1* and *IDH2* (3 year OS=31%), had improved OS within this subset of patients ($p < 0.001$, **Figure 13**). We then classified patients with *FLT3*-ITD wild-type intermediate-risk AML into three categories with marked differences in OS (adjusted $p < 0.001$, **Figure 2A**): patients with *IDH1/IDH2* and *NPM1* mutations (3 year OS=89%), patients with either *TET2*, *ASXL1*, *PHF6*, or *MLL*-PTD mutations (3 year OS=6.3%), and patients wild-type for *TET2*, *ASXL1*, *PHF6*, and *MLL*-PTD without co-occurring *IDH/NPM1* mutations (3 year OS=46.2%). Similar results were obtained when analysis was restricted to patients with a normal karyotype (**Figure 14A**).

[00186] In patients with *FLT3*-ITD mutant, intermediate-risk AML, Applicants found that *CEBPA* mutations were associated with improved outcome and that trisomy 8 and *TET2*, *DNMT3A*, and *MLL*-PTD mutations were associated with adverse outcome. We used these data to classify patients with *FLT3*-ITD mutant intermediate-risk AML into three categories. The first category included patients with trisomy 8 or *TET2*, *DNMT3A*, or *MLL*-PTD mutations, which were associated with adverse outcome (3 year OS=14.5%) significantly worse than for patients wild-type for *CEBPA*, *TET2*, *DNMT3A*, and *MLL*-PTD (3 year OS=35.2%; $p < 0.001$) or for patients with *CEBPA* mutations (3 year

OS=42%; $p<0.001$, **Figure 2B**). The survival of patients with *FLT3-ITD* mutant intermediate-risk AML who were wild-type for *CEBPA*, *TET2*, *DNMT3A*, and *MLL-PTD* did not differ from patients with *CEBPA*-mutant/*FLT3-ITD* mutant AML ($p=0.34$), suggesting that the presence of poor risk mutations more precisely identifies *FLT3-ITD* mutant AML patients with adverse outcome than the absence of *CEBPA* mutations alone. These same three risk groups also had significant prognostic value in *FLT3-ITD* mutant, normal karyotype AML (**Figure 14B**).

[00187] Prognostic Schema Using Integrated Mutational and Cytogenetic Profiling. These results allowed us to develop a prognostic schema integrating our findings from comprehensive mutational analysis with cytogenetic data into 3 risk groups with favorable (median: not reached, 3-year: 64%), intermediate (25.4 months, 42%), and adverse risk (10.1 months, 12%) (**Figure 3A and 3B, Table 11**). The mutational prognostic schema predicted for outcome independent age, WBC count, induction dose, and transplantation status in multivariate analysis (adjusted $p<0.001$). Our classification held true regardless of post-remission therapy with autologous, allogeneic, or consolidation chemotherapy alone (**Figure 15**). Given the number of variables on our prognostic classification, we tested the reproducibility of this predictor in an independent cohort of 104 patients from the ECOG E1900 trial. Importantly, mutational analysis of the validation cohort confirmed the reproducibility of our prognostic schema to predict outcome in AML (adjusted $p<0.001$; **Figure 3C**). The mutational prognostic schema was independent of treatment-related mortality (death within 30 days) or lack of response to induction chemotherapy (inability to achieve complete remission) in the test cohort and in the combined test/validation cohorts (**Table 12**).

[00188] **Genetic predictors of response to induction chemotherapy.** Recent studies noted that *DNMT3A*-mutant AML is associated with adverse outcome. However, Applicants here found that *DNMT3A* mutations were not associated with adverse outcome in the ECOG 1900 cohort (**Figure 4A**; $p=0.15$). The ECOG 1900 trial randomized patients to induction therapy with cytarabine plus 45 or 90 mg/m² daunorubicin (Fernandez et al. N Eng J Med 2009, 361: 1249-1259). Applicants therefore conceived that high dose daunorubicin improved outcomes in AML patients with *DNMT3A* mutations. Indeed Applicants found that *DNMT3A* mutational status had a significant impact on the outcome with dose-intensive chemotherapy (**Figure 4B**; $p=0.02$).

[00189] Applicants then assessed the effects of *DNMT3A* mutational status on outcome according to treatment arm, and found that high-dose daunorubicin was associated with improved survival in *DNMT3A* mutant patients (**Figure 16A**; $p=0.04$) but not in patients wild-type for *DNMT3A* (**Figure 16B**; $p=0.15$). In addition to *DNMT3A* mutations, univariate analysis revealed that dose-intensified induction therapy improved outcome in AML patients with *MLL* translocations (**Figure 16C and 11D**; $p=0.01$; p -value adjusted for multiple-testing=0.06) and *NPM1* mutations (**Figure 16E and 11F**; $p=0.01$; p -value adjusted for multiple-testing=0.1; **Table 13**).

[00190] Applicants then separated the patients in our cohort into two groups: patients with mutations in *DNMT3A* or *NPM1* or *MLL* translocations, and patients wild-type for these 3 genetic abnormalities. Dose-intensive induction therapy was associated with a marked improvement in survival in *DNMT3A/NPM1/MLL* translocation-positive patients (**Figure 4C**; $p=0.001$) but not in patients wild-type for *DNMT3A*, *NPM1*, and *MLL* translocations (**Figure 4D**; $p=0.67$). This finding was independent of the clinical covariates of age, WBC count, transplantation status, treatment-related mortality, and

chemotherapy resistance (adjusted $p=0.008$ and $p=0.34$ for mutant and wild-type patients respectively), suggesting that high-dose anthracycline chemotherapy offers benefit to genetically defined AML subgroups.

[00191] All publications, patents, and patent applications mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control. While several aspects of the present invention have been described and depicted herein, alternative aspects may be effected by those skilled in the art to accomplish the same objectives. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Accordingly, it is intended by the appended claims to cover all such alternative aspects as fall within the true spirit and scope of the invention.

TABLE 1a

Variable		Test cohort (N = 398)	Validation cohort (N = 104)	Entire cohort (N=657)
Age	Group – no (%)			
	< 50yr	227 (57.0)	42 (40.8)	360 (54.8)
	≥ 50 yr	171 (43.0)	61 (59.2)	297 (45.2)
	Median-yr	46.5	53	48.0
	Range-yr	18-60	18-60	17-60
Sex – no. (%)	Male	207 (52.0)	51 (49.5)	335 (51.0)
	Female	191 (48.0)	52 (50.5)	322 (49.0)
Peripheral blood white-cell count				
Level- no. (%)	< 10,000/mm ³	123 (30.9)	84 (81.6)	306 (46.6)
	≥ 10,000/mm ³	275 (69.1)	18 (17.5)	350 (53.3)
	Missing data	0 (0)	1 (1)	1 (0.2)
Median-cells/mm ³ x 1000		19.9	2.5	12.3
Range - cells/mm ³ x 1000		1 – 213	1- 117	1 – 366
Hemoglobin				
Level – no. (%)	<10g/dl	276 (69.3)	77 (74.8)	464 (70.6)
	≥10g/dl	121 (30.4)	25 (24.3)	191 (29.1)
	Missing data	1 (0.3)	1 (1)	2 (0.3)
Median – g/dl		9.2	9.2	9.2
	Range – g/dl	5 - 30	5-14	5 – 30
Peripheral-blood platelet count				
Level – no. (%)	<50,000/mm ³	194 (48.7)	43 (41.7)	305 (46.4)
	≥50,000/mm ³	204 (51.3)	59 (57.3)	351 (53.4)
	Missing data	0 (0)	1 (1)	1 (0.2)
Median – g/dl		50.0	61	50.0
Range – g/dl		1 - 650	6-995	1 – 995
Blasts				
Peripheral blood				
	Median %	47.5	8	31
Bone Marrow	Range %	0-98	0-99	0-99
Median %		68.5	49	64.0
	Range %	3 - 100	17-100	3 - 100
Leukemia Classification – no (%)				
Not reviewed		0 (0)	0	21 (3.2)
AML Minimally Differentiated		20 (5.0)	5 (4.9)	29 (4.4)

TABLE 1b

AML w/o Maturation	96 (24.1)	22 (21.4)	155 (23.6)
AML w/ Maturation	61 (15.3)	27 (26.2)	112 (17.0)
Acute myelomonocytic Leukemia	52 (13.1)	7 (6.8)	63 (9.6)
Acute monocytic/monoblastic Leukemia	27 (6.8)	3 (2.9)	40 (6.1)
Acute erythroid Leukemia	8 (2.0)	6 (5.8)	29 (4.4)
Acute megakaryoblastic Leukemia	0 (0)	2 (1.9)	3 (0.5)
Cytogenetic profile – no. (%)			
Favorable	67 (16.8)	10 (9.7)	89 (13.5)
Indeterminate	85 (21.4)	22 (21.4)	176 (26.8)
Intermediate	180 (45.2)	42 (40.8)	267 (40.6)
Normal karyotype	163 (41.0)	42 (40.4)	244 (37.1)
Unfavorable	65 (16.3)	29 (28.2)	122 (18.6)
Patients with secondary AML	11/398 (2.8)	4 (3.9)	22/657 (3.3)
Survival (days)			
Median	535.2	650.9	621

TABLE 2
Genomic DNA primer sequences utilized for comprehensive genetic analysis.
All primer sequences are displayed with M13F2/M13R2 tags.

Gene	Genomic coordinates of target region	Forward Primer Sequence	SEQ ID NO.	Reverse Primer Sequence	SEQ ID NO.
ASXL 1	chr20:3041019-4-30410296	GTAAACGACGGCCAGTGGTCTGTCTCAGTCCCTCA	1	CAGGAAACAGCTATGACCTCTTAAAGGAAGATGGCCCC	166
	chr20:3041784-7-30417930	GTAAACGACGGCCAGTCCAGCGGTACCTCATAGCAT	2	CAGGAAACAGCTATGACCGCGTTAGGCACAATAGAGGC	167
	chr20:3042047-8-30420587	GTAAACGACGGCCAGTTGGATTTGGGTATCACATAA	3	CAGGAAACAGCTATGACCTCCAGaaatcaCTGCACCAA	168
	chr20:3047959-1-30479712	GTAAACGACGGCCAGTTCCCTCTTTTCAAAAGCATACA	4	CAGGAAACAGCTATGACCCACCCCATCCATTAAAGGGTCC	169
	chr20:3047978-8-30479886	GTAAACGACGGCCAGTTTGTCTCACAGAAGGATGC	5	CAGGAAACAGCTATGACCTGTTCATCATTCCTCCTCCA	170
	chr20:3048080-1-30480895	GTAAACGACGGCCAGTAATGATGCTTGGCACAGTGA	6	CAGGAAACAGCTATGACCCAGAGCCCCAGCACTAGAACCC	171
	chr20:3048136-4-30481517	GTAAACGACGGCCAGTGGTTCTAGTGTGGGCTCTG	7	CAGGAAACAGCTATGACCAAAATAGAGGGCCACCCCAAG	172
	chr20:3048278-4-30482948	GTAAACGACGGCCAGTGTCTTGTGGAGCCTGTTCTC	8	CAGGAAACAGCTATGACCAAGGATCAAGGGGGAAAA	173
	chr20:3048304-6-30483143	GTAAACGACGGCCAGTGTCAAATGAAGCGCAACAGA	9	CAGGAAACAGCTATGACCGGGAGACATGCAACACCCACAC	174
	chr20:3048434-3-30484449	GTAAACGACGGCCAGTCAAGGAGTTGCTTGGTCTCA	10	CAGGAAACAGCTATGACCCACGTTCTGTGCTGCAATGACT	175
	chr20:3048474-7-30485127	GTAAACGACGGCCAGTCGACAGGAAATGGAGAAGGA	11	CAGGAAACAGCTATGACCTTCTGATCCTTGGGTTCCCTG	176
	chr20:3048512-8-30485381	GTAAACGACGGCCAGTAAAGTGGCTTGTGTGTCCTC	12	CAGGAAACAGCTATGACCGGCTGTCTCAAGCAAAACCTC	177
	chr20:3048589-5-30486275	GTAAACGACGGCCAGTGAGGTTTGCTTGAGACAGCC	13	CAGGAAACAGCTATGACCGAAGGAGGCTCTCTCTCCT	178
	chr20:3048627-6-30486655	GTAAACGACGGCCAGTGGACCCCTCGACACATTAAA	14	CAGGAAACAGCTATGACCTGTCAGGGCAATCAGTC	179
	chr20:3048665-6-30487035	GTAAACGACGGCCAGTGTCCAGAGCTAGGAG	15	CAGGAAACAGCTATGACCTGGCACAGTCCAGAGTGAAG	180
	chr20:3048703-6-30487415	GTAAACGACGGCCAGTCTTGAAACCAAGGCTCTCG	16	CAGGAAACAGCTATGACCCACAAGTGGGTTAGTGGCCT	181
	chr20:3048741-6-30487795	GTAAACGACGGCCAGTCAAGGTGAATGTTGACATGC	17	CAGGAAACAGCTATGACCCCTGGATGGAGGGAGTCAAAA	182
	chr20:3048779-6-30488175	GTAAACGACGGCCAGTCTGAGTACCAGCCCAAGAGCC	18	CAGGAAACAGCTATGACCAAGTGACCCACCAGTTCCAG	183
	chr20:3048817-6-30488555	GTAAACGACGGCCAGTTTGTACTCCTCCATCCAG	19	CAGGAAACAGCTATGACCACACTGGAGCGAGATGCTTT	184
	chr20:3048855-6-30488935	GTAAACGACGGCCAGTCTGGAACCTGGTGGGTCACTT	20	CAGGAAACAGCTATGACCTATACCCAGGAAACCCCTCC	185

TABLE 2

CEBP: a	chr19:3848315 6-38483535	GTAAACGACGGCCAGTGCAAGTATCCGAGCAAAACC	21	CAGGAAACAGCTATGACCGAGGAGGGGAGAATTCTTGG	186
	chr19:3848315 6-38483535	GTAAACGACGGCCAGTCCGACGGAGAGTCTCATTTT	22	CAGGAAACAGCTATGACCCCTGCTATAGGCTGGGCTTC	187
	chr19:3848315 6-38483535	GTAAACGACGGCCAGTGGAGAGGCGTGGAAGTAGAG	23	CAGGAAACAGCTATGACCCCTTGGTGGCTCTAAGATGAGG	188
	chr19:3848353 6-38483915	GTAAACGACGGCCAGTTTCATAACTCCGGTCCCTCTG	24	CAGGAAACAGCTATGACCCCTGGAGCTGACCAGTGACAA	189
	chr19:3848391 6-38484295	GTAAACGACGGCCAGTCAATTTCCAAAGGCACAAGGTT	25	CAGGAAACAGCTATGACCTGGACAAGAACAGCAACGAG	190
	chr19:3848429 6-38484675	GTAAACGACGGCCAGTTTGTCAGTGGTCAGCTCCAG	26	CAGGAAACAGCTATGACCCCTTCAACGACGAGTTCCTG	191
	chr19:3848429 6-38484675	GTAAACGACGGCCAGTTTGTCAGTGGTCAGCTCCAG	27	CAGGAAACAGCTATGACCCACCTGCAGTTCACAGATCG	192
	chr19:3848429 6-38484675	GTAAACGACGGCCAGTCAAGTGCGATGGTGGTCTG	28	CAGGAAACAGCTATGACCATCGACATCAGCGCCTACAT	193
	chr19:3848467 6-38485055	GTAAACGACGGCCAGTCTCGTTGCTGTTCTTGTC	29	CAGGAAACAGCTATGACCCCGGAGAACTCTAACTCCCC	194
	chr19:3848467 6-38485055	GTAAACGACGGCCAGTCTCGTTGCTGTTCTTGTC	30	CAGGAAACAGCTATGACCCAGGCTGGAGCCCTGTA	195
	chr19:3848467 6-38485055	GTAAACGACGGCCAGTCTGCTGGCTTCATCCTCCTC	31	CAGGAAACAGCTATGACCTCGGCCGACCTTCTACGAG	196
	chr19:3848505 6-38485160	GTAAACGACGGCCAGTGTAGGCGCTGATGTCGAT	32	CAGGAAACAGCTATGACCCCGGAGAACTCTAACTCCCC	197

DNMT 3a	chr2:25310489-25310793	GTAAACGACGGCCAGTCCTCTCTCCACCTTTCCTC	33	CAGGAAACAGCTATGACCCCTGAGTGCCGGGTGTTTAT	198
	chr2:25312079-25312198	GTAAACGACGGCCAGTGGAAACAAGTCAGGTGGGA	34	CAGGAAACAGCTATGACCTGGATCTAAGATTGGCCAGG	199
	chr2:25313308-25313378	GTAAACGACGGCCAGTccacactagctggaagca	35	CAGGAAACAGCTATGACCggggctcttaccctgtgaac	200
	chr2:25315502-25315588	GTAAACGACGGCCAGTcaigggcagagcagctagica	36	CAGGAAACAGCTATGACCtgtgtggctctctgagagaga	201
	chr2:25316674-25316823	GTAAACGACGGCCAGTAATACCCAACCCACAGGAGTC	37	CAGGAAACAGCTATGACCCCTTCTGTCTGTGCTCTGTCC	202
	chr2:25317012-25317103	GTAAACGACGGCCAGTGAAGCCATTAGTGAGCTGGC	38	CAGGAAACAGCTATGACCCAACTTGGTCCCCTCTTGT	203
	chr2:25317934-25318080	GTAAACGACGGCCAGTTTGCCAAAAGTATTGGGAGG	39	CAGGAAACAGCTATGACCCCCAGTTGGATCCAGAAAGGA	204
	chr2:25320270-25320355	GTAAACGACGGCCAGTaaagctcccttgggataa	40	CAGGAAACAGCTATGACCcagggtgtgtgggtctagga	205
	chr2:25320527-25320711	GTAAACGACGGCCAGTAGGGTCCTAAGCAGTGAGCA	41	CAGGAAACAGCTATGACCCCGTCTTTCCATTCCAGGTA	206
	chr2:25320912-25321025	GTAAACGACGGCCAGT aggtgtgtctactggaatgg	42	CAGGAAACAGCTATGACCcagggtctaggtctgtgag	207
	chr2:25321625-25321705	GTAAACGACGGCCAGTATCTGGGGACTAAAATGGGG	43	CAGGAAACAGCTATGACCCCTGGACTCTTTTCTGGCTG	208
	chr2:25322392-25322437	GTAAACGACGGCCAGTAGCAAAAGGTGAAGGCTGAA	44	CAGGAAACAGCTATGACCAGCCCAAGGTCAAGGAGATT	209
	chr2:25322532-25322682	GTAAACGACGGCCAGTCCCAGGCCAACAACTTACC	45	CAGGAAACAGCTATGACCcgaacaaagtggagaccaggcc	210
	chr2:25322992-25323149	GTAAACGACGGCCAGTCTTCIGGAGGAGGAAAGCA	46	CAGGAAACAGCTATGACCCCTGTGCCACCCCTCACTACT	211
	chr2:25323423-25323531	GTAAACGACGGCCAGTAGTAGAGGGTGGCACAGG	47	CAGGAAACAGCTATGACCCCTCTCTTTGCATCGGGTAA	212
	chr2:25323983-25324122	GTAAACGACGGCCAGTCTTACACTTGC AAGCACCCA	48	CAGGAAACAGCTATGACCGCCTCGTGACCACTGTGTAA	213
	chr2:25324409-25324625	GTAAACGACGGCCAGTCAATCCACCACACACAATGC	49	CAGGAAACAGCTATGACCCCTGTCACTGTTCCGGGTTTT	214
	chr2:25326029-25326097	GTAAACGACGGCCAGTTCTTCTCCACAAATCCCGCTG	50	CAGGAAACAGCTATGACCAGGGCGCGTGTTCCTAGATT	215
	chr2:25328566-25328684	GTAAACGACGGCCAGTCACTCTTTTCAAAACCCGGAG	51	CAGGAAACAGCTATGACCggtcTAAATCTCTTCCAGAGC	216
	chr2:25351313-25351460	GTAAACGACGGCCAGTadtagggcccaicadcttg	52	CAGGAAACAGCTATGACCcattgtgtgagcgagtg	217
	chr2:25351872-25351916	GTAAACGACGGCCAGTCTTCCACAGAGGGATGTGT	53	CAGGAAACAGCTATGACCgaaCAGCTAAACGGCCAGAG	218
	chr2:25358585-25358964	GTAAACGACGGCCAGTTACAATCACCCAGCCCTCTC	54	CAGGAAACAGCTATGACCAGCGGTCAATGATCCAAAAC	219
	chr2:25358965-25359084	GTAAACGACGGCCAGTAGCCAAGTCCCTGACTCTCA	55	CAGGAAACAGCTATGACCAGCGGTCAATGATCCAAAAC	220
	chr2:25376511-25376616	GTAAACGACGGCCAGTTTGAAGAATGGGGTACCTGC	56	CAGGAAACAGCTATGACCGGTGGGGGCATATTACACAG	221
	chr2:25390285-25390534	GTAAACGACGGCCAGTtgggtgcaicgcaCTCAGTAT	57	CAGGAAACAGCTATGACCCGATCCTCTTCTCTCCCCCAC	222

TABLE 2

TABLE 2

EZH2	chr7:14813540 7-148135731	GTAAACGACGGCCAGTcttccacattaccaggcagt	58	CAGGAAACAGCTATGACCcttcagcaggtttgttg	223
	chr7:14813709 5-148137180	GTAAACGACGGCCAGTGGCGCATGATATGAGAAGGT	59	CAGGAAACAGCTATGACCCGCAAGGGTAACAAAAATTGG	224
	chr7:14813733 4-148137415	GTAAACGACGGCCAGTtgggtcagtgagcagaaga	60	CAGGAAACAGCTATGACCTtttagatttggggaagc	225
	chr7:14813835 7-148138439	GTAAACGACGGCCAGTCACAAGAGGTGAGGTGAGCA	61	CAGGAAACAGCTATGACCGTGACCCTTTTTTGTTGCGTT	226
	chr7:14813964 9-148139745	GTAAACGACGGCCAGTAGCATGCAAAATCCACAACA	62	CAGGAAACAGCTATGACCGGTGTCGCCAAATTACTGCCCT	227
	chr7:14814198 3-148142162	GTAAACGACGGCCAGTTTTGCCCCAGCTAAATCATC	63	CAGGAAACAGCTATGACCggtacagcccttgcacgtaT	228
	chr7:14814293 8-148143064	GTAAACGACGGCCAGTCTGCTCACACACACAGAC	64	CAGGAAACAGCTATGACCCTTGGGGGTGGGAGAGTATT	229
	chr7:14814353 0-148143571	GTAAACGACGGCCAGTCGGCTACATCTCAGTCCCAT	65	CAGGAAACAGCTATGACCATTGTAGCTTCCCGCAGAA	230
	chr7:14814470 8-148144803	GTAAACGACGGCCAGTCCAAACACAGCCCTTAGGAA	66	CAGGAAACAGCTATGACCCCCAGCATCTAGCAGTGTC	231
	chr7:14814524 6-148145416	GTAAACGACGGCCAGTTGACACTGCTAGATGCTGGG	67	CAGGAAACAGCTATGACCCGCCGATTGGATTGAGTTGT	232
	chr7:14814590 1-148146142	GTAAACGACGGCCAGTACAACCTCAAATCCAAATCGGC	68	CAGGAAACAGCTATGACCTGCCCTGATGTTGACATTTT	233
	chr7:14814762 0-148147712	GTAAACGACGGCCAGTGAGAGGGGCTTGGGATCTAC	69	CAGGAAACAGCTATGACCTGGGCATCAGTTTACTTGC	234
	chr7:14815447 8-148154657	GTAAACGACGGCCAGTTCAGAGCAATCCTCAAGCAA	70	CAGGAAACAGCTATGACCTTCTTGATAACACCATGCACAA	235
	chr7:14815518 8-148155291	GTAAACGACGGCCAGTAAAGTGTAGTGGCTCATCCGC	71	CAGGAAACAGCTATGACCtctctgtctccagtgctctT	236
	chr7:14815676 4-148156905	GTAAACGACGGCCAGTccacctaccctggccATAAT	72	CAGGAAACAGCTATGACCTGCTTCTTTGCCTAACACC	237
	chr7:14815775 2-148157873	GTAAACGACGGCCAGTGAGCCCTATATGCCACAGA	73	CAGGAAACAGCTATGACCTGCTTATTGGTGAGAGGGGT	238
	chr7:14816065 8-148160775	GTAAACGACGGCCAGTctgtgtgattcacttgacaat	74	CAGGAAACAGCTATGACCGggtacacagcttaaggttgcct	239
	chr7:14817449 4-148174623	GTAAACGACGGCCAGTGGTCAATGATTTCTCTCCCAA	75	CAGGAAACAGCTATGACCATGGCAATCGTTTCTCTGTTT	240
	chr7:14817520 6-148175330	CAGGAAACAGCTATGACCATGGCAATCGTTTCTCTGTTT	76	CAGGAAACAGCTATGACCgagcacaagaagagccct	241

TABLE 2

FLT3	chr13:2749060-3-27490726	GTAAACGACGGCCAGTCTCTGAAGCTGCAGAAAACG	77	CAGGAAACAGCTATGACCTGCGATCACCCTGACCTGCTCCTA	242
	chr13:2749060-3-27490726	GTAAACGACGGCCAGTGTGTGACACCCCAATCCACTC	78	CAGGAAACAGCTATGACCGTGAACGGGCTCCTCAGATAA	243
	chr13:2750621-8-27506351	GTAAACGACGGCCAGTTTCCAAAAGCACCTGATCC	79	CAGGAAACAGCTATGACCTCATTGTGTTTAAACCTGCG	244
HRAS	chr11:523765-523944	GTAAACGACGGCCAGTGTCTGCTCCCTGAGAGGTG	80	CAGGAAACAGCTATGACGAGGGCTGGCTGTGTGAACCT	245
	chr11:523765-523944	GTAAACGACGGCCAGTCTCCCTGGTACCTCTCATGC	81	CAGGAAACAGCTATGACCGTGGGTTTGGCCCTTCAGAT	246
IDH1	chr2:20882133-7-208821629	GTAAACGACGGCCAGTTGTGTGAGATGACACGCCTA	82	CAGGAAACAGCTATGACCGGTGTACTCAGAGCCTTCGC	247
IDH2	chr15:8843282-2-88432983	GTAAACGACGGCCAGTCTGCTCTTTGTGGCCTAAG	83	CAGGAAACAGCTATGACCATTTCTGGTTGAAAGATGGCG	248
JAK2	chr9:5063697-5063785	GTAAACGACGGCCAGTGGGTTTCTCAGAACGTTGA	84	CAGGAAACAGCTATGACCCCTGACACCTAGCTGTGATCCTG	249
KIT	chr4:55284506-55284621	GTAAACGACGGCCAGTTTCTGCCCCTTTGAACCTTGCT	85	CAGGAAACAGCTATGACCAAAGCCACATGGCTAGAAAAA	250
	chr4:55288338-55288465	GTAAACGACGGCCAGTCCACACCCCTGTTCACTCCTT	86	CAGGAAACAGCTATGACCTGGCAACCTATCAAAAGGG	251
KRas	chr4:55293992-55294115	GTAAACGACGGCCAGTTGTGAACATCATTTCAAGGCG	87	CAGGAAACAGCTATGACCTGTTCAGCATACCATGCAAA	252
	chr12:2527143-4-25271613	GTAAACGACGGCCAGTTGCATGGCATTAGCAAAAGAC	88	CAGGAAACAGCTATGACCGGTGCTTAGTGGCCCATTTGT	253
	chr12:2528947-4-25289596	GTAAACGACGGCCAGTCCAAAGGAAAGTAAAGTTCCCA	89	CAGGAAACAGCTATGACCCCGTCTGCAGTCAACTGGAAT	254
NPM1	chr5:17077013-5-170770493	GTAAACGACGGCCAGTCTCGGGAGATGAAGTTGGAA	90	CAGGAAACAGCTATGACCactccagcctaggggaaaaa	255
NRas	chr1:11505794-3-115058122	GTAAACGACGGCCAGTGTGGTAACCTCATTTCCCCA	91	CAGGAAACAGCTATGACCCGGGACAAACCCAGATAGGCAG	256
	chr1:11506019-3-115060321	GTAAACGACGGCCAGTCAGGTTTGTAGAAACCTCAGCAGC	92	CAGGAAACAGCTATGACCATTATCCGGTGTTTTTCGCG	257

TABLE 2

PHF6	chrX:13333926 7-133339451	GTAAACGACGGCCAGTgggctagaglggctaatt	93	CAGGAAACAGCTATGACCgtctctgtgtgctgcccgtat	258
	chrX:13333970 0-133339802	GTAAACGACGGCCAGTTCGAAAAACCAGAAGGTGGC	94	CAGGAAACAGCTATGACCCGGATTTTGCTGGCTCAGAGA	259
	chrX:13335519 6-133355330	GTAAACGACGGCCAGTACCAATTGTGTTTCCCTTGACAGA	95	CAGGAAACAGCTATGACCCCGGAGCAGTACACTTCACCCA	260
	chrX:13335560 4-133355648	GTAAACGACGGCCAGTACCACCTGTGCATTGCATGAT	96	CAGGAAACAGCTATGACCTGAAAAGTGGCTGAAACGTG	261
	chrX:13337518 3-133375353	GTAAACGACGGCCAGTCTGAACACATTGGGTGGCTTT	97	CAGGAAACAGCTATGACCTTGGGCTTTAGATCACAGGG	262
	chrX:13337551 8-133375662	GTAAACGACGGCCAGTATGAACATGAACCTGGAGCCC	98	CAGGAAACAGCTATGACCTTGGGCTTTAGATCACAGGG	263
	chrX:13337671 1-133376987	GTAAACGACGGCCAGTTTAATCTTGGCTCCACACTGG	99	CAGGAAACAGCTATGACCGCTTGCAAAATGCCCTTGAAT	264
	chrX:13337866 4-133379244	GTAAACGACGGCCAGTttctgaataacgggtacga	100	CAGGAAACAGCTATGACCCcgccagtgatgtagtt	265
	chrX:13338689 6-133387276	GTAAACGACGGCCAGTCCCATGTTTTAAATGGGCAC	101	CAGGAAACAGCTATGACCCATGATGCTTGAGGGGAACAC	266
	chr10:8961409 8-89614406	GTAAACGACGGCCAGTatcagctaccgccagttcc	102	CAGGAAACAGCTATGACCgcaacctgaccagggtlaaa	267
	chr10:8964376 1-89643846	GTAAACGACGGCCAGTCTCCAGCTATAGTGGGAAA	103	CAGGAAACAGCTATGACCCCTGTATCCCCCTGAAGTCCA	268
	chr10:8967524 9-89675294	GTAAACGACGGCCAGTCCATAGAAGGGGTATTTGTTGG	104	CAGGAAACAGCTATGACCTGCCAACAAATGTTTACCTCA	269
	chr10:8968078 2-89680826	GTAAACGACGGCCAGTAAAGATTTCAGGCAATGTTTGT	105	CAGGAAACAGCTATGACCTCTCACTCGATAATCTGGATGAC	270
	chr10:8968274 9-89682968	GTAAACGACGGCCAGTGGAAATCCAGTGTTCTTTAAATACC	106	CAGGAAACAGCTATGACCCGAAACCCCAAAATCTGTTTCCA	271
	chr10:8970185 4-89701996	GTAAACGACGGCCAGTGGCTACGACCCAGTTACCAT	107	CAGGAAACAGCTATGACCTAAAACCCCATGCTTTTGGC	272
	chr10:8970758 9-89707756	GTAAACGACGGCCAGTTGCTTGAGATCAAGATTGCAG	108	CAGGAAACAGCTATGACCGCCATAAGGCCCTTTTCCTTC	273
PTEN	chr10:8971063 0-89710855	GTAAACGACGGCCAGTGCACACAGATAAATCAGATTGCC	109	CAGGAAACAGCTATGACCTTTTGACGCTGTGTACATTGG	274
	chr10:8971502 3-89715403	GTAAACGACGGCCAGTTGTTTCATCTGCAAAATGGAAT	110	CAGGAAACAGCTATGACCTAAAACCGGGAAGTGCCATC	275

TABLE 2

RUNX 1	chr21:3508614 8-35086527	GTAAACGACGGCCAGTCTTCTGTTGCTTCCAGC	111	CAGGAAACAGCTATGACCCACGCGCTACCAACACCTAC	276
	chr21:3508652 8-35086777	GTAAACGACGGCCAGTACCACTCGCTCTGGTTC	112	CAGGAAACAGCTATGACCATCCTCGTCTCTTGGGAGT	277
	chr21:3509346 7-35093629	GTAAACGACGGCCAGTAAGAAATCAGTGCATGGGC	113	CAGGAAACAGCTATGACCAACCCTGGTACATAGGCCACA	278
	chr21:3511582 4-35115863	GTAAACGACGGCCAGTTGTACGACGGTTTGCAGAG	114	CAGGAAACAGCTATGACCGGAAGGGAATCTTG	279
	chr21:3512857 6-35128768	GTAAACGACGGCCAGTAGTTGGTCTGGGAAGTGTG	115	CAGGAAACAGCTATGACCGGAAGACAAGAAAGCCCC	280
	chr21:3515364 0-35153745	GTAAACGACGGCCAGTGCAACTTTTGGCTTTACGG	116	CAGGAAACAGCTATGACCGGTAACTTGTGCTGAAGGGC	281
	chr21:3517472 3-35174880	GTAAACGACGGCCAGTCCGAGTTCTAGGGATTCCA	117	CAGGAAACAGCTATGACCCATTGCTATTCTCTGCAACC	282
	chr21:3518100 9-35181389	GTAAACGACGGCCAGTAGAAAGCTGAGACGAGTGCC	118	CAGGAAACAGCTATGACCGCAGAACCAACGTTTCC	283
	chr21:3518709 1-35187130	GTAAACGACGGCCAGTGGAAATCAGCAGAAACAGCCT	119	CAGGAAACAGCTATGACCAACCACCGTGCATAAGGAACA	284
	chr21:3534300 8-35343388	GTAAACGACGGCCAGTGGTGAACAAGCTGCCATT	120	CAGGAAACAGCTATGACCTTTGGGCCTCATAACAACACC	285

TABLE 2

TET2	chr4:10637450 2-106374882	GTAAACGACGGCCAGTCACCCCTGTTCTCCATGACC	121	CAGGAAACAGCTATGACCTGGTTGACTGCTTTACCTG	286
	chr4:10637488 3-106375262	GTAAACGACGGCCAGTAAATGGAGACACCAAGTGGC	122	CAGGAAACAGCTATGACCGAGGTATGCGATGGGTGAGT	287
	chr4:10637526 3-106375642	GTAAACGACGGCCAGTATGAGCAGGAGGGGAAAGT	123	CAGGAAACAGCTATGACCTGGTGTGTAGTGGCAGAAA	288
	chr4:10637564 3-106376022	GTAAACGACGGCCAGTACTACCCCATCGCATACCTC	124	CAGGAAACAGCTATGACCAGATAGTGTGTGGGGG	289
	chr4:10637602 3-106376402	GTAAACGACGGCCAGTTTCCACAGGTTCCCTCAGCTT	125	CAGGAAACAGCTATGACCGAGAAAGTGCAACCTGGTGTGA	290
	chr4:10637678 3-106377162	GTAAACGACGGCCAGTAAGGCAAGCTTACACCCAGA	126	CAGGAAACAGCTATGACCGGTTCCACCTTAATTGGCCT	291
	chr4:10637716 3-106377542	GTAAACGACGGCCAGTAATGTCCAATGGGACTGGA	127	CAGGAAACAGCTATGACCAGTGGCCCTGACATTTCAAC	292
	chr4:10637754 3-106377922	GTAAACGACGGCCAGTCCCGAAGGACACTCAAAA	128	CAGGAAACAGCTATGACCCAAATTGCTGCCAGACTCAA	293
	chr4:10637792 3-106378302	GTAAACGACGGCCAGTACTTGATAGCCACACCCCCAG	129	CAGGAAACAGCTATGACCTTCCCCCAACTCATGAAGAC	294
	chr4:10638172 3-106382102	GTAAACGACGGCCAGTTgcacaaagtagaagtcaca	130	CAGGAAACAGCTATGAGCagtggaatttcacacaaca	295
	chr4:10638343 9-106383533	GTAAACGACGGCCAGTTTCCCATTTTCACCCACAT	131	CAGGAAACAGCTATGACCACCCAAATTCAGGGTACAGA	296
	chr4:10638417 5-106384384	GTAAACGACGGCCAGTAGGGTCAAAAGCCCACTTTT	132	CAGGAAACAGCTATGACCTGAGGGCCATGTGGTTACAGA	297
	chr4:10640022 4-106400375	GTAAACGACGGCCAGTGTGGTTATGCCACAGCTT	133	CAGGAAACAGCTATGACCCCAAGAGGAAGTTTGTGTC	298
	chr4:10640236 4-106402454	GTAAACGACGGCCAGTACCATACGGCTTAATTCCCC	134	CAGGAAACAGCTATGACCTGTTACAATTGCTGCCAATGA	299
	chr4:10641021 5-106410353	GTAAACGACGGCCAGTTGTCATTCATTTTGTCTGG	135	CAGGAAACAGCTATGACCCCTGCTAAGCTGTCTCAGCC	300
	chr4:10641316 9-106413524	GTAAACGACGGCCAGTTCTGGATCAACTAGGCCACC	136	CAGGAAACAGCTATGACCGGGGGCAAAACCAAAATAAT	301
	chr4:10641565 3-106416033	GTAAACGACGGCCAGTTCAAGCAGAGGCATGTTACG	137	CAGGAAACAGCTATGACCTATTTCCAAACCTTGGCTGG	302
	chr4:10641603 4-106416413	GTAAACGACGGCCAGTAATCCCATGAACCCTTACCC	138	CAGGAAACAGCTATGACCACCCAGACCTCATCGTTGTCC	303
	chr4:10641641 4-106416793	GTAAACGACGGCCAGTATCAGTGGACAACCTGCTCCC	139	CAGGAAACAGCTATGACCATGAAACGCGCAGGTAAGTGGG	304
	chr4:10641679 4-106417173	GTAAACGACGGCCAGTATTGGCACTAGTCCAGGGTG	140	CAGGAAACAGCTATGACCAGTGTGACCFTTCCCCCACTG	305

83

TP53	chr17:7505821-7506057	GTAAACACGACGGCCAGTCGGAACCTCCTGAGCTGAAAG	141	CAGGAAACAGCTATGACCGCAGGAGAGTTGCTTGAACC	306	
	chr17:7510128-7510287	GTAAACACGACGGCCAGTCGTGCTGTGCTGGATTAC	142	CAGGAAACAGCTATGACCGTGGCAGGAGCTGTTCTAGG	307	
	chr17:7513585-7513733	GTAAACACGACGGCCAGTCCACAACAAACACACCACTGC	143	CAGGAAACAGCTATGACCAAAAGCATTTGGTCAGGGAAAA	308	
	chr17:7514651-7514758	GTAAACACGACGGCCAGTTCACCCGGAGGAAGACTAAAAA	144	CAGGAAACAGCTATGACCATCAGCCAAAGATTGCACCAT	309	
	chr17:7517249-7517309	GTAAACACGACGGCCAGTAAGCAGGTAGGTAAGTatg	145	CAGGAAACAGCTATGACCaaaggaccagaccagcttica	310	
	chr17:7517577-7517651	GTAAACACGACGGCCAGTTGTCTTTGAGGCATCACTGC	146	CAGGAAACAGCTATGACCGCGCACAGAGGAAGAGAATC	311	
	chr17:7517743-7517880	GTAAACACGACGGCCAGTGTGGTTCTTCTTTGGCTGG	147	CAGGAAACAGCTATGACCCAAGGGTGGTTGGGAGTAGA	312	
	chr17:7518223-7518333	GTAAACACGACGGCCAGTTggaagaaalcggtaaagaglig	148	CAGGAAACAGCTATGACCCgtctgacacagggtccc	313	
	chr17:7518901-7519014	GTAAACACGACGGCCAGTTTGACATCTCATGGGGTTA	149	CAGGAAACAGCTATGACAGTCACAGCACATGACGGGAG	314	
	chr17:7519095-7519475	GTAAACACGACGGCCAGTTACCTGCAATTTGGGGCAATT	150	CAGGAAACAGCTATGACCGCAGGCTAGGCTAAGCTATGATG	315	
	chr17:7520036-7520315	GTAAACACGACGGCCAGTGCCAAAGGGTGAAAGAGGAAT	151	CAGGAAACAGCTATGACCGTAAAGGACAAGGGTTGGGCT	316	
	chr17:7520424-7520446	GTAAACACGACGGCCAGTTTCATCTGGACCTGGGTCTTC	152	CAGGAAACAGCTATGACCCCCCTCTGAGTCAGGAAACA	317	
	chr17:7520563-7520865	GTAAACACGACGGCCAGTAGCCCAACCCCTTGTCCTTAC	153	CAGGAAACAGCTATGACCCAGCCCATCTTTTCTCTGCTC	318	
	WT1	chr11:3236704-1-32367301	GTAAACACGACGGCCAGTGGGGACATGATCAGCTATGG	154	CAGGAAACAGCTATGACCTCCTTAAAGCCCCCAAGAGGT	319
		chr11:3237009-3-32370186	CAGGAAACAGCTATGACCGCCACGCACCTATTCCTTCTC	155	GTAAACACGACGGCCAGTGGGAAATCTAAGGGTGAGGC	320
		chr11:3237078-7-32370877	CAGGAAACAGCTATGACCTGTGGGGTGTTCCTTTTCT	156	GTAAACACGACGGCCAGTGTGGGATCATCTCTACCCCT	321
		chr11:3237437-8-32374529	CAGGAAACAGCTATGACCTAGCAGTGTGAGAGCCTGGA	157	GTAAACACGACGGCCAGTGGAGTGTGAATGGAGTGGT	322
		chr11:3237806-9-32378166	CAGGAAACAGCTATGACCTAAGGAACTAAAGGGGCCGGT	158	GTAAACACGACGGCCAGTCCCATCATTCCTCCTCTGATTG	323
		chr11:3239461-1-32394862	CAGGAAACAGCTATGACCGGAATAAGAGAGGTGGSSGC	159	GTAAACACGACGGCCAGTGGCTTTTCACTGGATCTGG	324
		chr11:3239569-8-32395776	CAGGAAACAGCTATGACCAACCACTAGGGGAAGGAGGA	160	GTAAACACGACGGCCAGTCTGTGCAGAGATCAGTGGGA	325
		chr11:3240607-7-32406180	GTAAACACGACGGCCAGTCAGAGACCAGGGAGATCAGC	161	GTAAACACGACGGCCAGTGACTGCTAGGGGAATGCAAA	326
		chr11:3240661-8-32406741	GTAAACACGACGGCCAGTTGCCATTGGGGTAATGATTT	162	CAGGAAACAGCTATGACCCAAGGTTCACATCCAGGGACT	327
		chr11:3240865-1-32408835	GTAAACACGACGGCCAGTAGTGAAGGCCGGAATTTCTGA	163	CAGGAAACAGCTATGACCTCCAAGGCCTGTACAAGGAG	328
		chr11:3241282-1-32413201	GTAAACACGACGGCCAGTGGTAAGAGCTGCGGGTCAAAA	164	CAGGAAACAGCTATGACCTTACGCCCTACAGCAGCCAGAGCAGC	329
chr11:3241320-2-32413581		GTAAACACGACGGCCAGTGGCTCTCTTTGATGAAGGA	165	CAGGAAACAGCTATGACCGTAAAGGAGTTCAAGGCAGCG	330	

TABLE 3

Gene	p-value
DNMT3A	0.17
IDH1	0.24
IDH2	0.59
IDH2R140Q	0.61
IDH2R172K	0.13
TET2	0.92
ASXL1	0.16
FLT3	0.6
NPM1	0.23
PHF6	0.09
KIT	0.24
CEBPA	0.23
WT1	0.68
KRas	0.45
NRas	0.49
P53	0.85
PTEN	0.95
RUNX1	0.09
CBF	0.67
Del(5q)	0.66
EVI	0.9
MLL-PTD	0.04
Split MLL	0.21
Monosomy 7	0.97
t(6;9)	0.36
Trisomy 8	0.89
AML1-ETO	0.08

TABLE 4

Gene	Overall Frequency (%)	Favorable Risk	Intermediate Risk	Unfavorable Risk
FLT3 (ITD, TKD) ¹	37 (30, 7)	8 (3, 5)	52 (42, 7)*	36 (35, 1)
NPM1	29	4	49*	12
DNMT3A	23	4	33*	15
NRAS	10	12	5	2
CEBPA	9	5	12	5
TET2	8	5	8	10
WT1	8	1	12*	5
IDH2	8	3	9	9
IDH1	7	3	9	3
KIT	6	28*	1	0
RUNX1	5	3	6	6
MLL-PTD ²	5	0	5	8
ASXL1	3	0	4	2
PHF6	3	1	2	3
KRAS	2	7	5	3
PTEN	2	1	2	1
TP53	2	0	1	6
HRAS	0	0	0	0
EZH2	0	0	0	0

1) ITD – internal tandem duplication; TKD – tyrosine kinase domain mutation.

2) PTD – partial tandem duplication.

* denotes mutations which were significantly enriched in a specific cytogenetic risk group compared to the entire cohort (p<0.01 for all).

TABLE 5a

	DNMT3a	IDH1	IDH2	TET2	ASXL1	FLT3	NPM1	CEBPA	WT1	KRas	NRas	PHF6
DNMT3a	3.3% (13/398)	1.5% (6/398)	1.5% (6/398)	1.5% (6/398)	0% (0/398)	13.3% (53/398)	14.3% (57/398)	1.75% (7/398)	0.75% (3/398)	0.75% (3/398)	2.5% (10/398)	0% (0/398)
IDH1	3.3% (13/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	1% (4/398)	1.5% (6/398)	0.25% (1/398)	0% (0/398)	0.25% (1/398)	0.75% (3/398)	0.5% (2/398)
IDH2	1.5% (6/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.5% (2/398)	2% (8/398)	2% (8/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.75% (3/398)	0% (0/398)
TET2	1.5% (6/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.75% (3/398)	3% (12/398)	1.5% (6/398)	0.5% (2/398)	0.5% (2/398)	0% (0/398)	1% (4/398)	0.25% (1/398)
ASXL1	0% (0/398)	0.25% (1/398)	0.5% (2/398)	0.75% (3/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0.5% (2/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0.25% (1/398)
FLT3	13.3% (53/398)	1% (4/398)	2% (8/398)	3% (12/398)	0% (0/398)	0% (0/398)	6.8% (27/398)	3.5% (14/398)	5% (20/398)	0.25% (1/398)	0.5% (2/398)	1% (4/398)
NPM1	14.3% (57/398)	1.5% (6/398)	2% (8/398)	1.5% (6/398)	0.25% (1/398)	6.8% (27/398)	0.5% (2/398)	0.5% (2/398)	0.25% (1/398)	0.5% (2/398)	1.3% (5/398)	0% (0/398)
CEBPA	1.75% (7/398)	0.25% (1/398)	0% (0/398)	0.5% (2/398)	0.5% (2/398)	3.5% (14/398)	0.5% (2/398)	0% (0/398)	1.3% (5/398)	0% (0/398)	0.5% (2/398)	0.5% (2/398)
WT1	0.75% (3/398)	0% (0/398)	0% (0/398)	0.5% (2/398)	0% (0/398)	5% (20/398)	0.25% (1/398)	1.3% (5/398)	0% (0/398)	0% (0/398)	0.75% (3/398)	0% (0/398)
KRas	0.75% (3/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0.5% (2/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
NRas	2.5% (10/398)	0.75% (3/398)	0.75% (3/398)	1% (4/398)	0.25% (1/398)	0.5% (2/398)	1.3% (5/398)	0.5% (2/398)	0.75% (3/398)	0% (0/398)	0% (0/398)	0% (0/398)
PHF6	0% (0/398)	0.5% (2/398)	0% (0/398)	0.25% (1/398)	0.25% (1/398)	1% (4/398)	0% (0/398)	0.5% (2/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
KIT	0.5% (2/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
TP53	0.25% (1/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0.25% (1/398)	0.25% (1/398)	0.5% (2/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0% (0/398)
PTEN	0.75% (3/398)	0.5% (2/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.5% (2/398)	0.5% (2/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.5% (2/398)	0% (0/398)
RUNX1	0.75% (3/398)	0.25% (1/398)	0.75% (3/398)	0.25% (1/398)	1% (4/398)	1.5% (6/398)	0.5% (2/398)	0% (0/398)	0.75% (3/398)	0.25% (1/398)	0.5% (2/398)	0% (0/398)
CBF	0.25% (1/398)	0.25% (1/398)	0% (0/398)	1.3% (5/398)	1.3% (5/398)	1.5% (6/398)	0% (0/398)	1% (4/398)	1% (4/398)	0.5% (2/398)	3% (12/398)	0.25% (1/398)
Del (5q)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)
EV11	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0.25% (1/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0.25% (1/398)
MLL-PTD	1% (4/398)	0.5% (2/398)	0.75% (3/398)	0% (0/398)	0.5% (2/398)	2.5% (10/398)	0% (0/398)	0.5% (2/398)	0.5% (2/398)	0% (0/398)	0% (0/398)	0.25% (1/398)
Split MLL	0.25% (1/398)	0.25% (1/398)	0.5% (2/398)	0% (0/398)	0.25% (1/398)	0.5% (2/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0.75% (3/398)	0% (0/398)
Monosomy (7/7q)	0.25% (1/398)	0.25% (1/398)	0.25% (1/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
t(6;9)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
Tn(8)	1.5% (6/398)	0.5% (2/398)	0% (0/398)	0.25% (1/398)	0.25% (1/398)	2.26% (9/398)	0.25% (1/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
AML1-ETO	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)

87

Kit	TP53	PTEN	RUNX1	GBF	Del (5q)	EV11	MLL- PTD	Split MLL	Monosomy (7/7q)	T(6;9)	T(1;8)	AML1- ETO
0.5% (2/398)	0.25% (1/398)	0.75% (3/398)	0.75% (3/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	1% (4/398)	0.25% (1/398)	0.25% (1/398)	0% (0/398)	1.5% (6/398)	0% (0/398)
0.25% (1/398)	0% (0/398)	0.5% (2/398)	0.25% (1/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0.5% (2/398)	0.25% (1/398)	0.25% (1/398)	0% (0/398)	0.5% (2/398)	0% (0/398)
0% (0/398)	0% (0/398)	0% (0/398)	0.75% (3/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.75% (3/398)	0.5% (2/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)
0% (0/398)	0.25% (1/398)	0% (0/398)	0.25% (1/398)	1.3% (5/398)	0.25% (1/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0.25% (1/398)	0% (0/398)
0% (0/398)	0% (0/398)	0% (0/398)	1% (4/398)	1.3% (5/398)	0% (0/398)	0.25% (1/398)	0.5% (2/398)	0.25% (1/398)	0% (0/398)	0.25% (1/398)	0.25% (1/398)	0% (0/398)
0% (0/398)	0.25% (1/398)	0.5% (2/398)	1.5% (6/398)	1.5% (6/398)	0.25% (1/398)	0.25% (1/398)	2.5% (10/398)	0.5% (2/398)	0% (0/398)	0.25% (1/398)	2.26% (9/398)	0% (0/398)
0.25% (1/398)	0% (0/398)	0.5% (2/398)	0.5% (2/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0% (0/398)
0.5% (2/398)	0% (0/398)	0% (0/398)	0% (0/398)	1% (4/398)	0% (0/398)	0% (0/398)	0.5% (2/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0.25% (1/398)	0% (0/398)
0% (0/398)	0% (0/398)	0% (0/398)	0.75% (3/398)	1% (4/398)	0% (0/398)	0% (0/398)	0.5% (2/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0% (0/398)
0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0.5% (2/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
0.25% (1/398)	0% (0/398)	0.5% (2/398)	0.5% (2/398)	3% (12/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0.75% (3/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0.25% (1/398)	0.25% (1/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	5.3% (21/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
0% (0/398)	0% (0/398)	0.25% (1/398)	0.25% (1/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
0% (0/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
5.3% (21/398)	0% (0/398)	0.25% (1/398)	0.5% (2/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)
0% (0/398)	0.25% (1/398)	0% (0/398)	0.75% (3/398)	0% (0/398)	0% (0/398)	0% (0/398)	1% (4/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)
0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0% (0/398)	0.25% (1/398)	0% (0/398)	0% (0/398)	0%

TABLE 6a

Abnormality #1		Abnormality #2	M/M ²	WT/M ³	M/M ⁴	WT/WT ⁵
1	DNMT3A	IDH1	19	32	70	262
2	DNMT3A	IDH1	13	9	76	286
3	DNMT3A	IDH2	6	23	83	272
4	DNMT3A	IDH2_R140Q	3	18	86	277
5	DNMT3A	IDH2_R172K	3	5	86	290
6	DNMT3A	TET2	6	26	83	266
7	DNMT3A	ASXL1	0	10	88	285
8	DNMT3A	FLT3	52	92	37	204
9	DNMT3A	NPM1	57	57	32	239
10	DNMT3A	PHF6	0	9	88	284
11	DNMT3A	KIT	2	21	87	275
12	DNMT3A	CEBPa	6	26	82	267
13	DNMT3A	WT1	3	26	86	264
14	DNMT3A	KRAS	2	6	87	288
15	DNMT3A	NRAS	10	28	79	267
16	DNMT3A	TP53	1	7	86	283
17	DNMT3A	PTEN	3	2	86	293
18	DNMT3A	RUNX1	3	16	85	267
19	DNMT3A	CBF	1	71	88	225
20	DNMT3A	del5q	1	5	88	291
21	DNMT3A	EV11pos	0	5	89	291
22	DNMT3A	MLLPTD or split MLLPTD	4	13	85	283
23	DNMT3A	splitMLLPTD or split MLL	1	21	88	275
24	DNMT3A	MLLPTD or split MLL	5	32	84	264
25	DNMT3A	Monosomy7	1	2	88	294
26	DNMT3A	t(6;9)	0	2	89	294
27	DNMT3A	trisomy 8	6	9	83	287
28	DNMT3A	AML1ETO	0	1	89	295
29	DNMT3A_R882	IDH1	13	38	50	282
30	DNMT3A_R882	IDH1	9	13	54	308
31	DNMT3A_R882	IDH2	4	25	59	296
32	DNMT3A_R882	IDH2_R140Q	2	19	61	302
33	DNMT3A_R882	IDH2_R172K	2	6	61	315
34	DNMT3A_R882	IDH1_IDH2_R172K	11	19	52	302
35	DNMT3A_R882	TET2	4	28	59	290
36	DNMT3A_R882	ASXL1	0	10	62	311
37	DNMT3A_R882	FLT3	41	103	22	219

TABLE 6b

38	DNMT3A_R882	NPM1	43	71	20	251
39	DNMT3A_R882	PHF6	0	9	62	310
40	DNMT3A_R882	KIT	2	21	61	301
41	DNMT3A_R882	CEBPa	4	28	58	291
42	DNMT3A_R882	WT1	0	29	63	287
43	DNMT3A_R882	KRAS	2	6	61	314
44	DNMT3A_R882	NRAS	5	33	58	288
45	DNMT3A_R882	TP53	1	7	60	309
46	DNMT3A_R882	PTEN	2	3	61	318
47	DNMT3A_R882	RUNX1	2	17	61	291
48	DNMT3A_R882	CBF	0	72	63	250
49	DNMT3A_R882	del5q	1	5	62	317
50	DNMT3A_R882	EVI1pos	0	5	63	317
51	DNMT3A_R882	MLLPTD or split MLLPTD	3	14	60	308
52	DNMT3A_R882	splitMLLPTD or split MLL	0	22	63	300
53	DNMT3A_R882	MLLPTD or split MLL	3	34	60	288
54	DNMT3A_R882	Monosomy7	0	3	63	319
55	DNMT3A_R882	t(6;9)	0	2	63	320
56	DNMT3A_R882	trisomy 8	5	10	58	312
57	DNMT3A_R882	AML1ETO	0	1	63	321
58	DNMT3A_other	IDH	6	45	22	310
59	DNMT3A_other	IDH1	4	18	24	338
60	DNMT3A_other	IDH2	2	27	26	329
61	DNMT3A_other	IDH2_R140Q	1	20	27	336
62	DNMT3A_other	IDH2_R172K	1	7	27	349
63	DNMT3A_other	IDH1_IDH2_R172K	5	25	23	331
64	DNMT3A_other	TET2	2	30	26	323
65	DNMT3A_other	ASXL1	0	10	28	345
66	DNMT3A_other	FLT3	12	132	16	225
67	DNMT3A_other	NPM1	15	99	13	258
68	DNMT3A_other	PHF6	0	9	28	344
69	DNMT3A_other	KIT	0	23	28	334
70	DNMT3A_other	CEBPa	2	30	26	323
71	DNMT3A_other	WT1	3	26	25	325
72	DNMT3A_other	KRAS	0	8	28	347
73	DNMT3A_other	NRAS	6	32	22	324
74	DNMT3A_other	TP53	0	8	28	341
75	DNMT3A_other	PTEN	1	4	27	352
76	DNMT3A_other	RUNX1	2	17	25	327

TABLE 6C

77	DNMT3A_other	CBF	1	71	27	286
78	DNMT3A_other	del5q	1	5	27	352
79	DNMT3A_other	EV1pos	0	5	28	352
80	DNMT3A_other	MLLPTD or split MLLPTD	1	16	27	341
81	DNMT3A_other	splitMLLPTD or split MLL	1	21	27	336
82	DNMT3A_other	MLLPTD or split MLL	2	35	26	322
83	DNMT3A_other	Monosomy7	1	2	27	355
84	DNMT3A_other	t(6;9)	0	2	28	355
85	DNMT3A_other	trisomy 8	1	14	27	343
86	DNMT3A_other	AML1ETO	0	1	28	356
87	IDH	TET2	0	33	56	301
88	IDH	ASXL1	3	7	54	329
89	IDH	FLT3	13	133	44	205
90	IDH	NPM1	31	87	26	251
91	IDH	PHF6	2	7	54	328
92	IDH	KIT	1	22	56	316
93	IDH	CEBPa	1	33	56	302
94	IDH	WT1	0	30	56	303
95	IDH	KRAS	1	7	56	329
96	IDH	NRAS	6	34	51	303
97	IDH	TP53	0	8	57	323
98	IDH	PTEN	2	4	55	333
99	IDH	RUNX1	4	16	52	308
100	IDH	CBF	1	71	56	267
101	IDH	del5q	0	6	57	332
102	IDH	EV1pos	0	5	57	333
103	IDH	MLLPTD or split MLLPTD	5	13	52	325
104	IDH	splitMLLPTD or split MLL	2	19	55	319
105	IDH	MLLPTD or split MLL	6	31	51	307
106	IDH	Monosomy7	2	2	55	336
107	IDH	t(6;9)	0	2	57	336
108	IDH	trisomy 8	2	13	55	325
109	IDH	AML1ETO	0	1	57	337
110	IDH1	IDH2	0	33	24	338
111	IDH1	IDH2_R140Q	0	24	24	347
112	IDH1	IDH2_R172K	0	9	24	362
113	IDH1	TET2	0	33	24	334

TABLE 6d

114	IDH1	ASXL1	1	9	23	361
115	IDH1	FLT3	4	142	20	230
116	IDH1	NPM1	14	104	10	268
117	IDH1	PHF6	2	7	21	362
118	IDH1	KIT	1	22	23	350
119	IDH1	CEBPa	1	33	23	336
120	IDH1	WT1	0	30	23	337
121	IDH1	KRAS	1	7	23	363
122	IDH1	NRAS	3	37	21	334
123	IDH1	TP53	0	8	24	356
124	IDH1	PTEN	2	4	22	367
125	IDH1	RUNX1	1	19	22	339
126	IDH1	CBF	1	71	23	301
127	IDH1	del5q	0	6	24	366
128	IDH1	EVI1pos	0	5	24	367
129	IDH1	MLLPTD or split MLLPTD	2	16	22	356
130	IDH1	splitMLLPTD or split MLL	0	21	24	351
131	IDH1	MLLPTD or split MLL	2	35	22	337
132	IDH1	Monosomy7	1	3	23	369
133	IDH1	t(6;9)	0	2	24	370
134	IDH1	trisomy 8	2	13	22	359
135	IDH1	AML1ETO	0	1	24	371
136	IDH2	ASXL1	2	8	31	353
137	IDH2	FLT3	9	138	24	225
138	IDH2	NPM1	17	101	16	262
139	IDH2	PHF6	0	9	33	350
140	IDH2	KIT	0	23	33	340
141	IDH2	CEBPa	0	34	33	325
142	IDH2	WT1	0	30	33	327
143	IDH2	KRAS	0	8	33	353
144	IDH2	NRAS	3	37	30	325
145	IDH2	TP53	0	8	33	348
146	IDH2	PTEN	0	6	33	356
147	IDH2	RUNX1	3	17	30	331
148	IDH2	CBF	0	72	33	291
149	IDH2	del5q	0	6	33	357
150	IDH2	EVI1pos	0	5	33	358
151	IDH2	MLLPTD or split MLLPTD	3	15	30	348
152	IDH2	splitMLLPTD or	2	20	31	343

TABLE 6e

		split MLL							
153	IDH2	MLLPTD or split MLL	4	34	29			329	
154	IDH2	Monosomy 7	1	3	32			360	
155	IDH2	t(6;9)	0	2	33			361	
156	IDH2	Trisomy 8	0	15	33			348	
157	IDH2	AML1ETO	0	1	33			362	
158	IDH2_R140Q	IDH2_R172K	0	9	24			363	
159	IDH2_R140Q	TET2	0	33	23			335	
160	IDH2_R140Q	ASXL1	1	9	23			361	
161	IDH2_R140Q	FLT3	8	139	16			233	
162	IDH2_R140Q	NPM1	16	102	8			270	
163	IDH2_R140Q	PHF6	0	9	24			359	
164	IDH2_R140Q	KIT	0	23	24			349	
165	IDH2_R140Q	CEBPa	0	34	24			334	
166	IDH2_R140Q	WT1	0	30	24			336	
167	IDH2_R140Q	KRAS	0	8	24			362	
168	IDH2_R140Q	NRAS	3	37	21			334	
169	IDH2_R140Q	TP53	0	8	24			357	
170	IDH2_R140Q	PTEN	0	6	24			365	
171	IDH2_R140Q	RUNX1	2	18	22			339	
172	IDH2_R140Q	CBF	0	72	24			300	
173	IDH2_R140Q	del5q	0	6	24			366	
174	IDH2_R140Q	EV11pos	0	5	24			367	
175	IDH2_R140Q	MLLPTD or split MLLPTD	1	17	23			355	
176	IDH2_R140Q	splitMLLPTD or split MLL	2	20	22			352	
177	IDH2_R140Q	MLLPTD or split MLL	2	36	22			336	
178	IDH2_R140Q	Monosomy 7	1	3	23			369	
179	IDH2_R140Q	t(6;9)	0	2	24			370	
180	IDH2_R140Q	trisomy 8	0	15	24			357	
181	IDH2_R140Q	AML1ETO	0	1	24			371	
182	IDH2_R172K	TET2	0	33	9			349	
183	IDH2_R172K	ASXL1	1	9	8			376	
184	IDH2_R172K	FLT3	1	146	8			241	
185	IDH2_R172K	NPM1	1	117	8			270	
186	IDH2_R172K	PHF6	0	9	9			374	
187	IDH2_R172K	KIT	0	23	9			364	
188	IDH2_R172K	CEBPa	0	34	9			349	
189	IDH2_R172K	WT1	0	30	9			351	
190	IDH2_R172K	KRAS	0	8	9			377	

TABLE 6f

191	IDH2_R172K	NRAS		0	40	9	346
192	IDH2_R172K	TP53		0	8	9	372
193	IDH2_R172K	PTEN		0	6	9	380
194	IDH2_R172K	RUNX1		1	19	8	353
195	IDH2_R172K	CBF		0	72	9	315
196	IDH2_R172K	del5q		0	6	9	381
197	IDH2_R172K	EVI1pos		0	5	9	382
198	IDH2_R172K	MLLPTD or split MLLPTD		2	16	7	371
199	IDH2_R172K	splitMLLPTD or split MLL		0	22	9	365
200	IDH2_R172K	MLLPTD or split MLL		2	36	7	351
201	IDH2_R172K	Monosomy7		0	4	9	383
202	IDH2_R172K	t(6;9)		0	2	9	385
203	IDH2_R172K	Trisomy 8		0	15	9	372
204	IDH2_R172K	AML1ETO		0	1	9	386
205	TET2	ASXL1		4	6	29	351
206	TET2	FLT3		12	134	21	225
207	TET2	NPM1		10	106	23	253
208	TET2	PHF6		2	7	31	348
209	TET2	KIT		1	22	32	337
210	TET2	CEBPa		2	31	30	325
211	TET2	WT1		3	27	30	326
212	TET2	KRAS		0	8	33	349
213	TET2	NRAS		4	34	29	325
214	TET2	TP53		1	7	32	344
215	TET2	PTEN		1	5	32	353
216	TET2	RUNX1		3	15	29	330
217	TET2	CBF		4	67	29	292
218	TET2	del5q		0	6	33	353
219	TET2	EVI1pos		1	4	32	355
220	TET2	MLLPTD or split MLLPTD		0	18	33	341
221	TET2	splitMLLPTD or split MLL		1	21	32	338
222	TET2	MLLPTD or split MLL		1	37	32	322
223	TET2	Monosomy7		1	2	32	357
224	TET2	t(6;9)		0	2	33	357
225	TET2	Trisomy 8		1	14	32	345
226	TET2	AML1ETO		0	1	33	358
227	ASXL1	FLT3		0	146	10	239

TABLE 6g

228	ASXL1		NPM1		1	117	9	268
229	ASXL1		PHF6		1	8	9	373
230	ASXL1		KIT		0	22	10	363
231	ASXL1		CEBPa		2	32	8	349
232	ASXL1		WT1		0	30	10	349
233	ASXL1		KRAS		0	8	10	375
234	ASXL1		NRAS		1	38	9	346
235	ASXL1		TP53		0	8	9	370
236	ASXL1		PTEN		0	6	10	378
237	ASXL1		RUNX1		5	15	4	356
238	ASXL1		CBF		0	71	10	314
239	ASXL1		del5q		0	6	10	379
240	ASXL1		EVI1pos		0	5	10	380
241	ASXL1		MLLPTD or split MLLPTD		0	17	10	368
242	ASXL1		splitMLLPTD or split MLL		0	22	10	363
243	ASXL1		MLLPTD or split MLL		0	37	10	348
244	ASXL1		Monosomy7		0	4	10	381
245	ASXL1		t(6;9)		0	2	10	383
246	ASXL1		Trisomy 8		0	15	10	370
247	ASXL1		AML1ETO		0	1	10	384
248	FLT3		NPM1		63	55	84	195
249	FLT3		PHF6		3	6	143	241
250	FLT3		KIT		0	23	147	227
251	FLT3		CEBPa		13	21	131	228
252	FLT3		WT1		18	12	127	234
253	FLT3		KRAS		1	7	146	241
254	FLT3		NRAS		3	37	144	212
255	FLT3		TP53		1	7	144	237
256	FLT3		PTEN		2	4	144	246
257	FLT3		RUNX1		6	14	139	223
258	FLT3		CBF		6	66	141	184
259	FLT3		del5q		1	5	146	245
260	FLT3		EVI1pos		1	4	146	246
261	FLT3		MLLPTD or split MLLPTD		10	8	137	242
262	FLT3		splitMLLPTD or split MLL		2	20	145	230
263	FLT3		MLLPTD or split MLL		11	27	136	223
264	FLT3		Monosomy7		0	4	147	246

TABLE 6h

265	FLT3	t(6;9)	1	1	146	249
266	FLT3	Trisomy 8	9	6	138	244
267	FLT3	AML1ETO	0	1	147	249
268	NPM1	PHF6	0	9	118	266
269	NPM1	KIT	2	21	116	258
270	NPM1	CEBPa	3	31	113	246
271	NPM1	WT1	6	24	111	250
272	NPM1	KRAS	3	5	115	272
273	NPM1	NRAS	14	26	103	253
274	NPM1	TP53	1	7	115	266
275	NPM1	PTEN	3	3	115	275
276	NPM1	RUNX1	4	16	114	248
277	NPM1	CBF	0	72	118	207
278	NPM1	del5q	0	6	118	273
279	NPM1	EVI1pos	0	5	118	274
280	NPM1	MLLPTD or split MLLPTD	0	18	118	261
281	NPM1	splitMLLPTD or split MLL	0	22	118	257
282	NPM1	MLLPTD or split MLL	0	38	118	241
283	NPM1	Monosomy7	0	4	118	275
284	NPM1	t(6;9)	0	2	118	277
285	NPM1	Trisomy 8	2	13	116	266
286	NPM1	AML1ETO	0	1	118	278
287	PHF6	KIT	0	23	9	361
288	PHF6	CEBPa	2	32	7	348
289	PHF6	WT1	0	30	9	348
290	PHF6	KRAS	0	8	9	374
291	PHF6	NRAS	0	39	9	344
292	PHF6	TP53	0	8	9	368
293	PHF6	PTEN	0	6	9	377
294	PHF6	RUNX1	1	19	8	350
295	PHF6	CBF	1	70	8	314
296	PHF6	del5q	1	5	8	379
297	PHF6	EVI1pos	1	4	8	380
298	PHF6	MLLPTD or split MLLPTD	1	17	8	367
299	PHF6	splitMLLPTD or split MLL	0	22	9	362
300	PHF6	MLLPTD or split MLL	1	37	8	347
301	PHF6	Monosomy7	0	4	9	380

TABLE 6i

302	PHF6	t(6;9)	0	2	9	382
303	PHF6	Trisomy 8	1	13	8	371
304	PHF6	AML1ETO	0	1	9	383
305	KIT	CEBPa	2	32	21	338
306	KIT	WT1	0	30	22	339
307	KIT	KRAS	0	8	22	365
308	KIT	NRAS	2	38	21	335
309	KIT	TP53	0	8	23	358
310	KIT	PTEN	0	6	23	367
311	KIT	RUNX1	0	20	22	340
312	KIT	CBF	21	51	2	323
313	KIT	del5q	0	6	23	368
314	KIT	EVI1pos	0	5	23	369
315	KIT	MLLPTD or split	0	18	23	356
316	KIT	MLLPTD or split	0	22	23	352
317	KIT	MLL	0	38	23	336
318	KIT	Monosomy7	0	4	23	370
319	KIT	t(6;9)	0	2	23	372
320	KIT	Trisomy 8	0	15	23	359
321	KIT	AML1ETO	0	1	23	373
322	CEBPa	WT1	4	26	28	329
323	CEBPa	KRAS	0	8	34	349
324	CEBPa	NRAS	2	38	32	320
325	CEBPa	TP53	0	8	34	343
326	CEBPa	PTEN	0	6	34	352
327	CEBPa	RUNX1	0	20	33	326
328	CEBPa	CBF	4	68	30	291
329	CEBPa	del5q	0	6	34	353
330	CEBPa	EVI1pos	1	4	33	355
331	CEBPa	MLLPTD or split	2	16	32	343
332	CEBPa	MLLPTD or split	0	21	34	338
333	CEBPa	MLL	2	35	32	324
334	CEBPa	Monosomy7	0	3	34	356
335	CEBPa	t(6;9)	0	2	34	357
336	CEBPa	Trisomy 8	1	14	33	345
337	CEBPa	AML1ETO	0	1	34	358
338	WT1	KRAS	0	8	30	351

TABLE 6j

339	WT1	NRAS	3	37	27	323
340	WT1	TP53	0	8	30	345
341	WT1	PTEN	0	6	30	354
342	WT1	RUNX1	3	17	26	330
343	WT1	CBF	1	69	29	292
344	WT1	del5q	0	6	30	355
345	WT1	EV11pos	0	4	30	357
346	WT1	MLLPTD or split MLLPTD	2	16	28	345
347	WT1	splitMLLPTD or split MLL	0	22	30	339
348	WT1	MLLPTD or split MLL	2	36	28	325
349	WT1	Monosomy7	0	4	30	357
350	WT1	t(6;9)	1	1	29	360
351	WT1	Trisomy 8	1	14	29	347
352	WT1	AML1ETO	0	1	30	360
353	KRAS	NRAS	0	40	8	346
354	KRAS	TP53	0	8	8	371
355	KRAS	PTEN	0	6	8	380
356	KRAS	RUNX1	1	19	7	353
357	KRAS	CBF	2	68	6	319
358	KRAS	del5q	0	6	8	381
359	KRAS	EV11pos	0	5	8	382
360	KRAS	MLLPTD or split MLLPTD	0	18	8	369
361	KRAS	splitMLLPTD or split MLL	1	21	7	366
362	KRAS	MLLPTD or split MLL	1	37	7	350
363	KRAS	Monosomy7	0	4	8	383
364	KRAS	t(6;9)	0	2	8	385
365	KRAS	Trisomy 8	0	15	8	372
366	KRAS	AML1ETO	0	1	8	386
367	NRAS	TP53	0	8	39	341
368	NRAS	PTEN	2	4	38	351
369	NRAS	RUNX1	2	18	35	326
370	NRAS	CBF	12	60	28	296
371	NRAS	del5q	0	6	40	350
372	NRAS	EV11pos	1	4	39	352
373	NRAS	MLLPTD or split MLLPTD	0	18	40	338
374	NRAS	splitMLLPTD or split MLL	2	20	38	336

TABLE 6k

375	NRAS	MLLPTD or split MLL	2	36	38	320
376	NRAS	Monosomy7	0	4	40	352
377	NRAS	t(6;9)	0	2	40	354
378	NRAS	Trisomy 8	0	15	40	341
379	NRAS	AML1ETO	0	1	40	355
380	PTEN	PTEN	1	5	7	375
381	TP53	RUNX1	1	19	7	348
382	TP53	CBF	0	72	8	309
383	TP53	del5q	1	5	7	376
384	TP53	EVI1pos	0	5	8	376
385	TP53	MLLPTD or split MLLPTD	0	17	8	364
386	TP53	splitMLLPTD or split MLL	0	22	8	359
387	TP53	MLLPTD or split MLL	0	37	8	344
388	TP53	Monosomy7	0	4	8	377
389	TP53	t(6;9)	0	2	8	379
390	TP53	trisomy 8	0	15	8	366
391	TP53	AML1ETO	0	1	8	380
392	PTEN	RUNX1	0	20	6	355
393	PTEN	CBF	1	71	5	319
394	PTEN	del5q	0	6	6	384
395	PTEN	EVI1pos	0	5	6	385
396	PTEN	MLLPTD or split MLLPTD	0	18	6	372
397	PTEN	splitMLLPTD or split MLL	0	22	6	368
398	PTEN	MLLPTD or split MLL	0	38	6	352
399	PTEN	Monosomy7	0	4	6	386
400	PTEN	t(6;9)	0	2	6	388
401	PTEN	trisomy 8	0	15	6	375
402	PTEN	AML1ETO	0	1	6	389
403	RUNX1	CBF	2	66	18	296
404	RUNX1	del5q	3	3	17	359
405	RUNX1	EVI1pos	0	4	20	358
406	RUNX1	MLLPTD or split MLLPTD	3	15	17	347
407	RUNX1	splitMLLPTD or split MLL	0	19	20	343
408	RUNX1	MLLPTD or split MLL	3	32	17	330
409	RUNX1	Monosomy7	1	2	19	360

TABLE 6I

410	RUNX1	t(6;9)	0	2	20	360
411	RUNX1	trisomy 8	0	14	20	348
412	RUNX1	AML1ETO	0	1	20	361
413	CBF	del5q	0	6	72	319
414	CBF	EVI1pos	0	5	72	320
415	CBF	MLLPTD or split MLLPTD	0	18	72	307
416	CBF	splitMLLPTD or split MLL	0	22	72	303
417	CBF	MLLPTD or split MLL	0	38	72	287
418	CBF	Monosomy7	0	4	72	321
419	CBF	t(6;9)	0	2	72	323
420	CBF	trisomy 8	0	15	72	310
421	CBF	AML1ETO	1	0	71	325
422	del5q	EVI1pos	0	5	6	386
423	del5q	MLLPTD or split MLLPTD	0	18	6	373
424	del5q	splitMLLPTD or split MLL	0	22	6	369
425	del5q	MLLPTD or split MLL	0	38	6	353
426	del5q	Monosomy7	0	4	6	387
427	del5q	t(6;9)	0	2	6	389
428	del5q	trisomy 8	0	15	6	376
429	del5q	AML1ETO	0	1	6	390
430	EVI1pos	MLLPTD or split MLLPTD	0	18	5	374
431	EVI1pos	splitMLLPTD or split MLL	0	22	5	370
432	EVI1pos	MLLPTD or split MLL	0	38	5	354
433	EVI1pos	Monosomy7	0	4	5	388
434	EVI1pos	t(6;9)	0	2	5	390
435	EVI1pos	trisomy 8	0	15	5	377
436	EVI1pos	AML1ETO	0	1	5	391
437	MLLPTD or split MLLPTD	Monosomy7	1	3	17	376
438	MLLPTD or split MLLPTD	t(6;9)	0	2	18	377
439	MLLPTD or split MLLPTD	trisomy 8	0	15	18	364
440	MLLPTD or split MLLPTD	AML1ETO	0	1	18	378
441	splitMLLPTD or split MLL	Monosomy7	0	4	22	371

TABLE 6m

442	splitMLLPTD or split MLL	t(6;9)		0	2	22	373
443	splitMLLPTD or split MLL	trisomy 8		0	15	22	360
444	splitMLLPTD or split MLL	AML1ETO		0	1	22	374
445	MLLPTD or split MLL	Monosomy7		1	3	37	356
446	MLLPTD or split MLL	t(6;9)		0	2	38	357
447	MLLPTD or split MLL	trisomy 8		0	15	38	344
448	MLLPTD or split MLL	AML1ETO		0	1	38	358
449	Monosomy7	t(6;9)		0	2	4	391
450	Monosomy7	trisomy 8		0	15	4	378
451	Monosomy7	AML1ETO		0	1	4	392
452	t(6;9)	trisomy 8		0	15	2	380
453	t(6;9)	AML1ETO		0	1	2	394
454	Trisomy 8	AML1ETO		0	1	15	381

- 1) Single nucleotide variants which could not be verified as bona fide somatic mutations were censored from analysis, therefore sample number does not add up to 398 in all instances.
- 2) Number of patients mutated for both gene #1 and gene #2.
- 3) Number of patients wildtype for gene #1 but mutant for gene #2.
- 4) Number of patients mutated for gene #1 and wildtype for gene #2.
- 5) Number of patients wildtype for both genes.

TABLE 7

Mutated Gene #1	Mutated Gene #2	M/M ²	WT/M ³	% M/M ⁴	M/WT ⁵	WT/WT ⁶	% M/WT ⁷	p-value ⁸	Adjusted p-value ⁹
ASXL1	RUNX1	5	15	25.0	4	356	1.1	<0.001	<0.001
DNMT3A	NPM1	57	57	50.0	32	239	11.8	<0.001	<0.001
DNMT3A	FLT3 ITD	52	92	36.1	37	204	15.4	<0.001	<0.001
DNMT3A	IDH1	13	9	59.1	76	286	21.0	<0.001	0.008
DNMT3A	IDH1 or IDH2	19	32	37.3	70	262	21.1	0.02	0.91
FLT3 ITD	NPM1	63	55	53.4	84	195	30.1	<0.001	<0.001
FLT3 ITD	WT1	18	12	60.0	127	234	35.2	0.01	0.94
IDH1 or IDH2	NPM1	31	87	26.3	26	251	9.4	<0.001	0.002
IDH1	NPM1	14	104	11.9	10	268	3.6	0.004	0.38
IDH1	PTEN	2	4	33.3	22	367	5.7	0.05	0.69
IDH2	NPM1	17	101	14.4	16	262	5.8	0.01	0.67
IDH2 R140Q	NPM1	16	102	13.6	8	270	2.9	<0.001	0.01
KIT	CBF	21	51	29.2	2	323	0.6	<0.001	<0.001
NRAS	CBF	12	60	16.7	28	296	8.6	0.05	0.1
RUNX1	Del 5q	3	3	50.0	17	359	4.5	0.002	1.0
TET2	ASXL1	4	6	40.0	29	351	7.6	0.006	0.03

- 1) Single nucleotide variants which could not be verified as bona fide somatic mutations were censored from analysis, therefore sample number does not sum up to 398 in all instances.
- 2) Number of patients mutated for both gene #1 and gene #2.
- 3) Number of patients wildtype for gene #1 but mutant for gene #2.
- 4) Percentage of patients mutant for gene #1 and gene #2 over all patients mutated for either gene.
- 5) Number of patients mutated for gene #1 and wildtype for gene #2.
- 6) Number of patients wildtype for both genes.
- 7) Percentage of patients mutant for either gene over all patients wildtype for either gene.
- 8) P-value by Fisher's exact test.
- 9) P-value adjusted for multiple comparisons.

TABLE 8

Mutated Gene #1	Mutated Gene #2	M/M ²	WT/M ³	% M/M ⁴	M/M ⁵	WT/WT ⁶	% M/WT ⁷	p-value ⁸	Adjusted p-value ⁹
ASXL1	FLT3	0	146	0	10	239	4.0	0.02	0.94
CBF	MLL abnormalities	0	38	0	72	287	20.1	<0.001	0.99
CBF	Split MLL	0	22	0	72	303	19.2	0.02	1.0
CBF	MLL PTD	0	18	0	72	307	19.0	0.05	1.0
DNMT3A	CBF	1	71	1.4	88	225	28.1	<0.001	0.11
DNMT3A	Split MLL	1	21	4.6	88	275	24.2	0.04	0.97
DNMT3A	WT1	0	29	0	63	287	18.0	0.01	0.92
R882									
FLT3	CBF	6	66	8.3	141	184	43.4	<0.001	0.02
FLT3	NRAS	3	37	7.5	144	212	40.5	<0.001	0.008
FLT3	KIT	0	23	0	147	227	39.3	<0.001	0.04
FLT3	Split MLL	2	20	9.1	145	230	38.7	0.005	0.39
IDH1 or IDH2	CBF	1	71	1.4	56	267	17.3	<0.001	0.63
IDH1 or IDH2	TET2	0	33	0	56	301	15.7	0.008	0.97
IDH1 or IDH2	WT1	0	30	0	56	303	15.6	0.01	0.98
IDH1 or IDH2	FLT3	13	133	8.9	44	205	17.7	0.02	1.0
IDH1 or IDH2	CEBPA	1	33	2.9	56	302	15.6	0.04	0.99
IDH1	FLT3	4	142	2.7	20	230	8.0	0.04	1.0
IDH2	CBF	0	72	0	33	291	10.2	0.002	0.99
NPM1	CBF	0	72	0	118	207	36.3	<0.001	0.001
NPM1	MLL abnormalities	0	38	0	118	241	32.9	<0.001	0.02
NPM1	Split MLL	0	22	0	118	257	31.5	<0.001	0.59
NPM1	MLL PTD	0	18	0	118	261	31.1	0.002	0.59
NPM1	CEBPA	3	31	8.2	113	246	31.5	0.005	0.34
NPM1	KIT	2	21	8.7	116	258	31.0	0.03	0.99
WT1	CBF	1	69	1.4	29	292	9.0	0.03	1.0

- 1) Single nucleotide variants which could not be verified as bona fide somatic mutations were censored from analysis, therefore sample number does not sum up to 398 in all instances.
- 2) Number of patients mutated for both gene #1 and gene #2
- 3) Number of patients wildtype for gene #1 but mutant for gene #2
- 4) Percentage of patients mutant for gene #1 and gene #2 over all patients mutated for either gene
- 5) Number of patients mutated for gene #1 and wildtype for gene #2
- 6) Number of patients wildtype for both genes
- 7) Percentage of patients mutant for either genes over all patients wildtype for either gene
- 8) P-value by Fisher's exact test.
- 9) P-value adjusted for multiple comparisons

TABLE 9a

Gene/Cytogenetic Abnormality	Mutational Status	Number of patients	Median Survival (months)	UV analysis p-value ²	MV analysis p-value ³
DNMT3A	Mutant	88	14.1	0.19	0.29
	Wildtype	296	21.3		
DNMT3A	R882 Mutant	63	14.1	0.14	0.26
	Wildtype	321	21.3		
DNMT3A	Non-R882 Mutant	27	18.2	0.90	0.91
	Wildtype	357	18.0		
IDH1/2	Mutant for IDH1 or IDH2	56	42.4	0.009	0.001
	Wildtype	358	16.2		
IDH1	Mutant	23	38.7	0.42	0.59
	Wildtype	372	17.0		
IDH2	Mutant	33	49.4	0.01	0.001
	Wildtype	362	16.3		
IDH2	R140Q Mutant	24	-	0.009	0.001
	Wildtype	371	16.6		
IDH2	R172K Mutant	9	41.3	0.58	0.46
	Wildtype	386	16.9		
TET2	Mutant	33	13.2	0.16	0.61
	Wildtype	358	18.0		
ASXL1	Mutant	10	10.3	0.05	0.22
	Wildtype	384	17.7		
FLT3	Mutant	148	13.8	0.006	0.003
	Wildtype	248	22.0		
NPM1	Mutant	118	22.3	0.07	0.005
	Wildtype	278	16.5		
PHF6	Mutant	9	4.3	0.006	0.08
	Wildtype	383	17.7		
KIT	Mutant	23	57.9	0.08	0.6
	Wildtype	373	16.6		
CEBPa	Mutant	34	31.7	0.05	0.03
	Wildtype	358	16.9		
WT1	Mutant	30	12.2	0.23	0.19
	Wildtype	360	17.7		
KRAS	Mutant	8	-	0.17	0.19
	Wildtype	386	16.9		
NRAS	Mutant	40	21.3	0.13	0.19
	Wildtype	355	16.9		

TABLE 9b

TP53	Mutant	8	12.4	0.14	0.83
	Wildtype	380	18.2		
PTEN	Mutant	6	15.2	0.68	0.68
	Wildtype	389	17.9		
RUNX1	Mutant	20	16.9	0.90	0.63
	Wildtype	361	16.9		
CBF translocations	Present	43	-	0.001	0.47
	Absent	353	16.2		
Del 5q	Present	12	7.0	0.001	0.46
	Absent	384	18.0		
EVI positive	Present	8	2.8	<0.001	0.02
	Absent	388	18.0		
MLL PTD	Present	19	12.6	0.009	0.19
	Absent	377	18.0		
Split MLL	Present	25	11.7	0.05	0.44
	Absent	371	18.2		
Any MLL abnormalities	Present	39	10.9	<0.001	0.33
	Absent	357	19.7		
Monosomy 7	Present	9	3.5	<0.001	0.18
	Absent	387	18.0		
t(6;9)	Present	2	15.8	0.42	0.81
	Absent	394	17.5		
Trisomy 8	Present	19	10.2	0.06	0.03
	Absent	377	18.0		
t(8;21)	Present	29	47.1	0.02	0.37
	Absent	367	16.5		

- 1) Absence of value under column for overall survival indicates that deaths were not observed.
- 2) Univariate (UV) analysis p-value (calculated by Log-rank test).
- 3) Multivariate (MV) analysis p-value taking into account WBC count, age, transplantation, and cytogenetics.

TABLE 10a

Gene/Cytogenetic Abnormality	Mutational Status	Number of patients	Median Survival (months)	p-value ²
DNMT3A	Mutant	75	14.08	0.17
	Wildtype	151	22.83	
DNMT3A	R882 Mutant	56	14.08	0.07
	Wildtype	170	22.83	
DNMT3A	Non-R882 Mutant	21	23.52	0.57
	Wildtype	205	17.96	
IDH1/2	Mutant for IDH1 or IDH2	46	-	0.001
	Wildtype	188	15.53	
IDH1	Mutant	21	38.65	0.49
	Wildtype	213	17.53	
IDH2	Mutant	25	-	0.001
	Wildtype	209	16.15	
IDH2	R140Q Mutant	18	-	0.001
	Wildtype	216	16.91	
IDH2	R172K Mutant	7	37.96	0.44
	Wildtype	227	16.94	
TET2	Mutant	17	8.82	0.008
	Wildtype	214	19.08	
ASXL1	Mutant	6	24.42	0.48
	Wildtype	227	17.66	
FLT3	Mutant	120	13.52	0.001
	Wildtype	114	34.31	
NPM1	Mutant	110	23.52	0.04
	Wildtype	124	16.15	
PHF6	Mutant	3	2.53	<0.0001
	Wildtype	229	17.96	
KIT	Mutant	2	-	0.98
	Wildtype	232	17.66	
CEBPa	Mutant	26	31.68	0.14
	Wildtype	207	16.91	
WT1	Mutant	26	10.94	0.12
	Wildtype	205	18.26	
KRAS	Mutant	5	-	0.09
	Wildtype	229	17.53	
NRAS	Mutant	20	-	0.10
	Wildtype	213	16.94	
TP53	Mutant	2	-	0.57
	Wildtype	229	17.89	

TABLE 10b

PTEN	Mutant	4	-	0.99
	Wildtype	229	17.89	
RUNX1	Mutant	13	16.91	0.54
	Wildtype	215	17.89	
EVI positive	Present	2	1.25	<0.0001
	Absent	232	17.89	
MLL PTD	Present	12	16.54	0.04
	Absent	222	18.26	
Split MLL	Present	7	21.71	0.96
	Absent	227	17.77	
Any MLL abnormality	Present	17	16.15	0.08
	Absent	217	18.95	
Trisomy 8	Present	19	10.16	0.04
	Absent	215	18.25	

1) Absence of value under column for overall survival indicates that deaths were not observed.
2) P-value calculated by Log-rank test.

TABLE 11a

Cytogenetic Classification	Mutations		Test cohort (% (N))	Validation cohort (% (N))	Overall Risk
Inversion (16), t(8;21)	Any		19.7% (71)	15.5% (13)	Favorable
Normal Karyotype or Intermediate Risk Cytogenetic Lesions	FLT3-ITD negative	NPM1 and IDH1/2 mutant	5.8% (21)	7.1% (6)	Intermediate
	FLT3-ITD negative	ASXL1, MLL-PTD, PHF6 and TET2-wildtype	35.5% (129)	27.4% (23)	
	FLT3-ITD negative or positive	CEBPA mutant			
	FLT3-ITD positive	MLL-PTD, TET2, and DNMT3A	20.9% (76)	21.4% (18)	Unfavorable
	FLT3-ITD negative	TET2, MLL-PTD, ASXL1, or PHF6 mutant			
	FLT3-ITD positive	TET2, MLL-PTD, DNMT3A mutant or trisomy 8			
Unfavorable	Any		18.2% (66)	28.6% (24)	

TABLE 12

Test cohort (n=398)			
	Hazard Ratio	Confidence Interval	p-value
Favorable	Reference		<0.001
Intermediate	1.88	1.15 – 3.05	
Unfavorable	6.16	3.83 – 9.88	
Entire cohort (n=502)			
	Hazard Ratio	Confidence Interval	p-value
Favorable	Reference		<0.001
Intermediate	1.83	1.18 – 2.85	
Unfavorable	5.76	3.76 – 8.82	

¹Treatment-related mortality defined as death within 30 days after beginning induction chemotherapy.
²Chemotherapy resistance defined as failure to enter complete remission despite not incurring treatment-related mortality, or relapse.

TABLE 13a

Gene/Cytogenetic Abnormality	Mutational Status	p-value ¹	Adjusted p-value ²
DNMT3A	Mutant	0.01	0.10
	Wildtype	0.14	0.28
IDH1	Mutant	0.62	-
	Wildtype	0.01	-
IDH2	Mutant	0.33	-
	Wildtype	0.05	-
IDH2 R140Q	R140Q Mutant	0.15	1.0
	Wildtype	0.05	0.22
IDH2 R172K	R172K Mutant	0.73	-
	Wildtype	0.02	-
TET2	Mutant	0.45	1.0
	Wildtype	0.006	0.04
ASXL1	Mutant	0.08	0.50
	Wildtype	0.009	0.05
FLT3	Mutant	0.14	0.71
	Wildtype	0.10	0.30
NPM1	Mutant	0.01	0.11
	Wildtype	0.20	0.20
PHF6	Mutant	0.19	0.77
	Wildtype	0.005	0.04
KIT	Mutant	0.12	-
	Wildtype	0.004	-
CEBPa	Mutant	0.56	0.56
	Wildtype	0.003	0.03
WT1	Mutant	0.2	-
	Wildtype	0.02	-
KRAS	Mutant	0.62	-
	Wildtype	0.01	-
NRAS	Mutant	0.15	-
	Wildtype	0.04	-
TP53	Mutant	0.75	-
	Wildtype	0.01	-
PTEN	Mutant	0.78	-
	Wildtype	0.02	-
RUNX1	Mutant	0.47	-
	Wildtype	0.01	-
EVI positive	Present	0.90	-
	Absent	0.03	-
MLL PTD	Present	0.27	-
	Absent	0.01	-

TABLE 13b

Split MLL	Present	0.007	0.07
	Absent	0.06	0.25

1) P-value calculated by Log-rank test.
2) P-value adjusted for multiple testing by a step-down Holm procedure (see Supplementary Methods). “-” indicates adjusted p-value not performed.

CLAIMS

1. A method of predicting survival of a patient with acute myeloid leukemia, said method comprising:

(a) analyzing a genetic sample isolated from the patient for the presence of cytogenetic abnormalities and a mutation in at least one of *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL-PTD*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* genes; and

(b) (i) predicting poor survival of the patient if a mutation is present in at least one of *FLT3*, *MLL-PTD*, *ASXL1* and *PHF6* genes, or (ii) predicting favorable survival of the patient if a mutation is present in *IDH2R140* and/or a mutation is present in *CEBPA*.

2. The method of claim 1, further comprising,

predicting intermediate survival of the patient with cytogenetically-defined intermediate risk AML if :

(i) no mutation is present in any of *FLT3-ITD*, *TET2*, *MLL-PTD*, *DNMT3A*, *ASXL1* or *PHF6* genes,

(ii) a mutation in *CEBPA* and the *FLT3-ITD* is present, or

(iii) a mutation is present in *FLT3-ITD* but trisomy 8 is absent.

3. The method of claim 1, further comprising:

predicting unfavorable survival of the patient with cytogenetically-defined intermediate-risk AML if

(i) a mutation in *TET2*, *ASXL1*, or *PHF6* or an *MLL-PTD* is present in a patient without the *FLT3-ITD* mutation, or

- (ii) the patient has a *FLT3*-ITD mutation a *DNMT3A*, *MLL*-PTD or trisomy 8.
4. The method of claim 2, wherein intermediate survival the patient is survival of about 18 months to about 30 months.
5. A method of predicting survival of a patient with acute myeloid leukemia, said method comprising:
- (a) assaying a genetic sample from the patient's blood or bone marrow for the presence of a mutation in at least one of genes *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL*-PTD, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* in said sample; and
 - (b) predicting a poor survival of the patient if a mutation is present in at least one of genes *FLT3*-ITD, *MLL*-PTD, *ASXL1*, *PHF6*; or predicting a favorable survival of the patient if a mutation is present in *CEBPA* or a mutation is present in *IDH2* at R140.
6. The method of claim 5, wherein amongst patients with cytogenetically-defined intermediate-risk acute myeloid leukemia who have *FLT3*-ITD mutation, at least one of the following: trisomy 8 or a mutation in *TET2*, *DNMT3A*, or the *MLL*-PTD are associated with an adverse outcome and poor overall survival of the patient.
7. The method of claim 5, wherein amongst patients with cytogenetically-defined intermediate-risk acute myeloid leukemia who have a mutation in *FLT3*-ITD gene, a mutation in *CEBPA* gene is associated with improved outcome and overall survival of the patient.

8. The method of claim 5, wherein in a cytogenetically AML patient with both *IDH1/IDH2* and *NPM1* mutations, the overall survival is improved compared to *NPM1*-mutant patients wild-type for both *IDH1* and *IDH2*.
9. The method of claim 5, wherein amongst patients with acute myeloid leukemia, *IDH2R140* mutations are associated with improved overall survival.
10. The method of any one of claims 1 to 9, wherein poor or unfavorable survival (adverse risk) of the patient is survival of less than or equal to about 10 months.
11. The method of any one of claims 1 to 9, wherein favorable survival of the patient is survival of about 32 months or more.
12. A method of predicting survival of a patient with acute myeloid leukemia, said method comprising:
 - (a) assaying a genetic sample from the patient's blood or bone marrow for the presence of a mutation in genes *ASXL1* and *WT1*; and
 - (b) determining the patient has or will develop primary refractory acute myeloid leukemia if mutated *ASXL1* and *WT1* genes are detected.
13. A method of determining responsiveness of a patient with acute myeloid leukemia to high dose therapy, said method comprising:
 - (a) analyzing a genetic sample isolated from the patient for the presence of a mutation in genes *DNMT3A*, and *NPM1*, and for the presence of a *MLL* translocation; and

- (b) (i) identifying the patient as one who
therapy if a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation
are present; or
- (ii) identifying the patient as one who will not respond to high dose
therapy in the absence of mutations in *DNMT3A* or *NPM1* or an
MLL translocation.

14. A method of predicting whether a patient suffering from acute myeloid leukemia will respond better to high dose chemotherapy than to standard dose chemotherapy, the method comprising:

- (a) obtaining a DNA sample obtained from the patient's blood or bone marrow;
- (b) determining the mutational status of genes *DNMT3A* and *NPM1*, and the presence of a *MLL* translocation; and
- (c) predicting that the subject will be more responsive to high dose chemotherapy than standard dose chemotherapy where the sample is positive for a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation; or predicting that the subject will be non-responsive to high dose chemotherapy compared to standard dose chemotherapy where the sample is wild type with no mutations in *DNMT3a* or *NPM1* genes and no translocation in *MLL*.

15. A method of screening a patient with acute myeloid leukemia for responsiveness to treatment with high dose of Daunorubicin or a pharmaceutically acceptable salt, solvate, or hydrate thereof, comprising: obtaining a genetic sample comprising an acute myeloid

leukemic cell from said individual; and assaying the sample for a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation; and correlating a finding of a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation, as compared to wild type controls where there is no mutation, with said acute myeloid leukemia patient being more sensitive to high dose treatment with Daunorubicin or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

16. The method of claim 15, wherein the method further comprises predicting the patient is at a lower risk of relapse of acute myeloid leukemia following chemotherapy if a mutation in *DNMT3A* or *NPM1* or an *MLL* translocation is detected.

17. A method of determining whether a human has an increased genetic risk for developing or developing a relapse of acute myeloid leukemia, comprising:

(a) analyzing a genetic sample isolated from the human's blood or bone marrow for the presence of a mutation in at least one gene from *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL-PTD*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2*; and

(b) determining the individual with cytogenetically-defined intermediate risk AML has an increased genetic risk for developing or developing a relapse of acute myeloid leukemia, relative to a control human with no such gene mutations in said genes, when: (i) a mutation in at least one of *TET2*, *MLL-PTD*, *ASXL1* and *PHF6* genes is detected when the patient has no *FLT3*-ITD mutation, or (ii) a mutation in at least one of *TET2*, *MLL-PTD*, and *DNMT3A* genes or trisomy 8 is detected when the patient has a *FLT3*-ITD mutation.

18. A method for preparing a personalized genomics profile for a patient with acute myeloid leukemia, comprising:

(a) subjecting mononuclear cells extracted from a bone marrow aspirate or blood sample from the patient to gene mutational analysis;

(b) assaying the sample and detecting the presence of a cytogenetic abnormality and one or more mutations in a gene selected from the group consisting of *FLT3*, *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *MLL-PTD*, *ASXL1*, *PHF6*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* in said cells; and

(c) generating a report of the data obtained by the gene mutation analysis, wherein the report comprises a prediction of the likelihood of survival of the patient or a response to therapy.

19. A kit for determining treatment of a patient with AML, the kit comprising means for detecting a mutation in at least one gene selected from the group consisting of *ASXL1*, *DNMT3A*, *NPM1*, *PHF6*, *WT1*, *TP53*, *EZH2*, *CEBPA*, *TET2*, *RUNX1*, *PTEN*, *FLT3*, *HRAS*, *KRAS*, *NRAS*, *KIT*, *IDH1*, and *IDH2*; and instructions for recommended treatment based on the presence of a mutation in one or more of said genes.

20. The kit of claim 31, wherein the instructions for recommended treatment for the patient based on the presence of a *DNMT3A* or *NPM1* mutation or *MLL* translocation indicate high-dose daunorubicin as the recommended treatment.

21. A method of treating, preventing or managing acute myeloid leukemia in a patient, comprising:

- (a) analyzing a genetic sample isolated from the a mutation in genes *DNMT3A*, and *NPM1*, and for the presence of a *MLL* translocation;
- (b) identifying the patient as one who will respond to high dose chemotherapy better than standard dose chemotherapy if a mutation in *DNMT3A* or *NPM1* or a *MLL* translocation are present; and
- (c) administering high dose therapy to the patient.

22. The method of claim 5, or claim 13, or claim 14, or claim 21, wherein the patient is characterized as intermediate-risk on the basis of cytogenetic analysis.

23. The method of claim 14, or claim 21, wherein the therapy comprises the administration of anthracycline.

24. The method of claim 14 or claim 21, wherein administering high dose therapy comprises administering one or more high dose anthracycline antibiotics selected from the group consisting of Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, and Adriamycin.

25. The method of claim 13 or claim 21, wherein the sample is DNA extracted from bone marrow or blood from the patient.

26. The method of claim 13 or claim 21, wherein the genetic sample is DNA isolated from mononuclear cells (MNC) from the patient.

27. The method of claim 21, wherein the high dose administration is Daunorubicin administered at from about 70mg/m² to about 140mg/m², or Idarubicin administered at from about 10mg/m² to about 20 mg/m².

28. A high dose chemotherapeutic agent for use in a method of managing acute myeloid leukemia in a patient, the method comprising:
- (a) analyzing a genetic sample isolated from the patient for the presence of a mutation in genes *DNMT3A*, and *NPM1*, and for the presence of a *MLL* translocation;
 - (b) identifying the patient as one who will respond to high dose chemotherapy better than standard dose chemotherapy if a mutation in *DNMT3A* or *NPM1* or a *MLL* translocation are present; and
 - (c) administering high dose therapy to the patient.
29. The agent for use of claim 28, wherein the patient is characterized as intermediate-risk on the basis of cytogenetic analysis.
30. The agent for use of claim 28 or claim 29, wherein the agent is an anthracycline antibiotic, optionally selected from the group consisting of Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mitoxantrone, and Adriamycin.
31. The agent for use of any one of claims 28 to 30, wherein the sample is DNA which has previously been extracted from bone marrow or blood from the patient.
32. The agent for use of any one of claims 28 to 30, wherein the genetic sample is DNA which has previously been isolated from mononuclear cells (MNC) from the patient.
33. The agent for use of any one of claims 28 to 32, wherein the high dose administration is Daunorubicin administered at from about 70mg/m² to about 140mg/m², or Idarubicin administered at from about 10mg/m² to about 20 mg/m².
34. A method of predicting survival of a patient with acute myeloid leukemia, comprising:

(a) analyzing a sample isolated from the patient for the 1

(i) a mutation in at least one of *FLT3*, *MLL-PTD*, *ASXL1*, and *PHF6* genes, plus optionally one or more of *NPM1*, *DNMT3A*, *NRAS*, *CEBPA*, *TET2*, *WT1*, *IDH1*, *IDH2*, *KIT*, *RUNX1*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* genes; or

(ii) a mutation in *IDH2* and/or *CEBPA* genes, plus optionally one or more of *FLT3*, *MLL-PTD*, *ASXL1*, *PHF6*, *NPM1*, *DNMT3A*, *NRAS*, *TET2*, *WT1*, *IDH1*, *KIT*, *RUNX1*, *KRAS*, *PTEN*, *P53*, *HRAS*, and *EZH2* genes; and

(b) (i) predicting poor survival of the patient if a mutation is present in at least one of *FLT3*, *MLL-PTD*, *ASXL1* and *PHF6* genes, or (ii) predicting favorable survival of the patient if a mutation is present in *IDH2R140* and/or a mutation is present in *CEBPA*.

35. The method of claim 34, further comprising analyzing the sample for the presence of cytogenetic abnormalities.

36. The method of claim 34, further comprising (ii) predicting favorable survival of the patient if the following mutation is present: *IDH2R140Q*.

FIG. 1a




FIG. 1b




FIG. 1c




FIG. 2a




FIG. 2b




FIG. 3a

Cytogenetic Classification		Mutations		Overall Risk
inv(16)/t(16;16) t(8;21)		Any		Favorable
		FLT3-ITD negative	NPM1 and IDH1/2 mutant	
Normal Karyotype or Intermediate-Risk Cytogenetic Lesions		FLT3-ITD negative	ASXL1, MLL-PTD, PHF6, and TET2 wildtype	Intermediate
		FLT3-ITD negative or positive	CEBPA mutant	
		FLT3-ITD positive	MLL-PTD, TET2, and DNMT3A wildtype, and trisomy 8 negative	
		FLT3-ITD negative	TET2, MLL-PTD, ASXL1 or PHF6 mutant	Unfavorable
		FLT3-ITD positive	TET2, MLL-PTD, DNMT3A mutant or trisomy 8	
Unfavorable				

FIG. 3b




FIG. 3c




FIG. 4a






FIG. 4b








FIG. 4d




FIG. 5a

FIG. 5b

	<i>DNMT3A</i> or <i>NPM1</i> mutant or <i>MLL</i> translocated		All other genotypes
	High Dose	3yr OS: 44%	3yr OS: 35%
Standard Dose	3yr OS: 25%	3yr OS: 39%	

FIG. 6a




FIG. 6b




FIG. 6c




FIG. 6d




FIG. 6e




FIG. 6f




FIG. 6g




FIG. 6h




FIG. 6i




FIG. 6j





FIG. 6k



65




FIG. 6m




FIG. 6n




FIG. 7a




FIG. 7b




FIG. 7c




FIG. 7d

Cytogenetic Risk Category	% of samples with ≥ 2 mutations
Favorable	15.5%
Intermediate	69.8%
Unfavorable	24.2%

FIG. 8a




FIG. 9a




FIG. 9b




FIG. 10a




FIG. 10b




FIG. 10c




FIG. 10d




FIG. 10e





FIG. 10f







FIG. 11a






FIG. 11c

FIG. 12a




FIG. 13a




FIG. 14a




FIG. 14b




FIG. 15a




FIG. 15b





FIG. 15c






FIG. 16a




FIG. 16b





FIG. 16c

FIG. 16d







FIG. 16e

FIG. 16f



Cytogenetic Classification	Mutations		Overall Risk
inv(16)/t(16;16) t(8;21)	Any		Favorable
Normal Karyotype or Intermediate-Risk Cytogenetic Lesions	<i>FLT3</i> -ITD negative	<i>NPM1</i> and <i>IDH1/2</i> mutant	Intermediate
	<i>FLT3</i> -ITD negative	<i>ASXL1</i> , <i>MLL</i> -PTD, <i>PHF6</i> , and <i>TET2</i> wildtype	
	<i>FLT3</i> -ITD negative or positive	<i>CEBPA</i> mutant	
	<i>FLT3</i> -ITD positive	<i>MLL</i> -PTD, <i>TET2</i> , and <i>DNMT3A</i> wildtype, and trisomy 8 negative	
	<i>FLT3</i> -ITD negative	<i>TET2</i> , <i>MLL</i> -PTD, <i>ASXL1</i> or <i>PHF6</i> mutant	Unfavorable
	<i>FLT3</i> -ITD positive	<i>TET2</i> , <i>MLL</i> -PTD, <i>DNMT3A</i> mutant or trisomy 8	
Unfavorable			

FIG. 3a